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The work presented in this dissertation focuses on investigating new and safe ways to use
radiation for enhancing cancer treatment via preclinical studies of Spatially Fractionated
Radiation Therapy (SFRT). SFRT is a very promising, yet poorly understood, cancer
radiotherapy approach that has recently gained traction due to its remarkable tissue
selectivity, eradicating tumors effectively with little treatment toxicity, as well as its easy
implementation on a wide range of clinical radiotherapy machines. Decades of clinical and
preclinical research have demonstrated that SFRT may be used as a safe and effective way
to shrink very large, bulky tumors in patients for whom other modern treatment approaches
have been ineffective. Despite its very high therapeutic ratio and potential to satisfy
several unmet needs in cancer treatment, SFRT remains largely an experimental approach,
and a lack of preclinical SFRT research leaves many important questions unanswered.
This body of work investigates the development of a novel SFRT-delivery system
and its implementation in a variety of preclinical SFRT research scenarios in the hopes
of shedding light on some of the unanswered questions that hinder clinical translation
of this promising treatment technology. In this work, systemic studies investigate key
unique SFRT dosimetric parameters and their correlations with treatment response, as
well as SFRT’s specific advantages over conventional radiotherapy, particularly those
enhancing multi-modality cancer therapy approaches such as anti-cancer immunotherapy
and nanoparticle chemotherapy drug-delivery to tumors. SFRT is a low-toxicity and
low-cost radiation therapy treatment that offers hope for many cancer patients, especially
iii
those failed by current cancer treatment technologies. The work presented here aims to
improve the understanding of this treatment approach and contribute to the effective and
accessible treatment of cancer.
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CHAPTER 1: CANCER AND THE ROLE OF RADIATION THERAPY
1.1 Cancer- What Is It?
Loosely defined, cancer refers to a group of cells that have lost their inherent ability to
perform normal functions or form normal tissues, and these cells even gain new functions
including the ability to grow uncontrollably, invade, and metastasize. These cells often
create a small body of cells, a tumor, but though a tumor is made from cancerous cells,
the environment is far from homogenous. A distinct microenvironment exists within a
tumor, including different cell types and vasculature, and this microenvironment is still
not fully understood. Because each instance of cancer is unique and highly dependent on
the environment, mutation, and other factors, the most effectual treatment methods for
cancer still remain mysterious.
New discoveries are made every year that help shed light on some of these mysteries
and the very definition of “cancer” and what are considered to be its distinguishing
features are still evolving [1]. A vast amount of molecular cancer research has embraced
the notion that the key to curing cancer lies in finding and decoding the common cancer
genes responsible for the majority of cancers [1]. The gene mutation theory of cancer
indicates that the genetic differences between cancer types determine how aggressively any
individual type of cancer grows and affects its host environment. Numerous studies have
created molecular and genetic profiles of cancer and their different subtypes. With huge
amounts of emerging genetic molecular data of cancer. In 2000 Hannan and Weinberg
classified these large number of diverse gene mutations into simplified molecular principles,
known as the Hallmarks of Cancer [2].
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1.2 Radiobiology- The Hallmarks of Cancer
Hannan and Weinberg organized the framework for the Hallmarks of Cancer into
6 major pathways which cancer alters to develop: insensitivity to anti-growth signals,
self-sufficient oncogenes, evasion of apoptosis, sustained angiogenesis, metastasis, and
limitless replicative potential[2]. Each leg of this framework offers a method through
which cancer develops, grows, and develops a distinct microenvironment and are briefly
summarized, below.
1. Cancers cells are insensitive to anti-growth signals, circumventing the cell’s natural
tumor suppressor genes through mutations that prevent anti-growth signals from
binding to a receptor, or alternatively, phosphorylation, etc.
2. Cancer cells develop self-sufficiency in growth signals, locking a cell’s oncogenes into
an ON state so normal sources for growth signals are not needed.
3. Cancers evade cell death, apoptosis, through mutations in tumor suppressor signals,
such as the p-53 tumor suppressor protein, which allow tumor cells to survive where
they otherwise would not, potentially bypassing replicative senescence, a natural
stop to cell division after appropriate population doublings.
4. Cancers have sustained angiogenesis, development of new vasculature. This present
a unique challenge as tumors may become resistant to angiogenesis inhibitor drugs,
such as VEGF-pathway inhibitors, by seeking alternative signaling pathways for
recruiting vasculature into the tumor [3].
5. Cancers have an increased ability to both invade surrounding normal tissues and also
metastasize, wherein tumor cells breach the tumor basement membrane and move
after proliferation and angiogenesis of the primary tumor. In addition, metastatic
cells may detach themselves from the primary tumor and invade the circulatory
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system, adhere to a vessel wall, extravasate, establish a microenvironment in a
micrometastases and then further proliferate. However, this metastatic cascade is
extremely inefficient and very few cells manage to generate macroscopic metastases.
6. Cancers have limitless replicative potential, where disruption of the pathway that
limits cell replication allows tumor cells to become immortalized. Benign tumor
cells that have undergone the first five major pathway mutations discussed so far
cannot yet divide with infinite replicative potential. However, these cells finally
become immortalized due to the overexpression of telomerase, an enzyme cells use
to synthesize DNA, after the erosion of the cell’s telomeres.
The gene mutation theory of cancer underlying the hallmarks that Hannahan and
Weinberg organized into a blueprint for understanding carcinogenesis have served as a
driver of cancer biology research. By organizing the cellular properties of carcinogenesis
into a framework of six pathways they provided a guideline for cancer treatments. The
majority of modern cancer treatments attempt to target and disrupt at least one of these
major pathways to halt cancer progression [4], [5]. Cancer therapies with drugs that target
one or more of these pathways are an area of very active investigation; thousands of drugs
are in development [6].
Notably, a decade after their initial publication, Hannahan and Weinberg updated
Hallmarks of Cancer framework to include four additional pathways: reprogramming
energy metabolism, evading the immune response, and the enabling traits of genome
instability/mutation, and tumor promoting inflammation [7]. “Hallmarks II” also mentions
the emerging importance of the Tumor Microenvironment and its numerous modifiers.
Many investigators have noted that the majority of research on cancer to date has
focused on the parenchyma of the tumor and the associated normal tissues [5], where the
parenchyma is the part (s) of the tissue that performs biological functions and in a tumor
refers to the tumor cells themselves. However, in the last decade there has been emerging
3
evidence of the importance of the tumor microenvironment, including the tumor stroma,
tissues that support the function of the parenchymal cells such as the basement membrane,
extracellular matrix, immune cells, and vasculature etc. [8], [9]. The seed and soil theory,
in which cells will only grow in microenvironments that are correct for them [10], [11],
invites cancer therapies to target the tumor microenvironment and many treatments have
been developed to do so [3], [8], [12]. One such treatment includes altering the tumor
microvasculature, a component that plays a key role in the tumor’s ability to grow [5], [13].
These and other modifiers within the tumor microenvironment play a role in the health
and persistence of the tumor, and along with targeting the pathways described in the
Hallmarks of Cancer, research can be guided toward effective and appropriate treatment
[1].
One common treatment for cancer, Radiation Therapy (RT), is used in about half of
all cases of cancer within the U.S. [14], [15]. The primary target of Radiation Therapy
is to cause ionization events within the tissue, resulting in damage to DNA base-pairs,
single strand breaks (SSBs), and double-strand breaks (DSBs) [16], [17]. In each of these,
a pathway to tumor growth is potentially disrupted and researchers have linked these
pathways to the original Hallmarks [4], [5]. In principle, highly energetic, ionizing radiation
penetrates tissues and deposits energy to the cells that it passes through, destroying them
or inducing genetic changes that result in eventual cell death [17]. Radiation does not
distinguish between normal cells and cancer cells and is equally damaging to both; however,
all cells do not respond to radiation in the same way. Normal cells generally have vastly
improved repair mechanisms compared to cancer cells and can recover from radiation
damage more quickly [16], [18]. Radiation therapy may be used to exploit these differences
in cellular repair mechanisms to kill cancer cells, while minimizing exposure to normal
cells [16].
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1.3 Background and History of Radiotherapy
The start of Radiation Therapy can be traced to the discovery of x-rays by Wilhelm
Rontgen in 1895, natural radioactivity by Henry Becquerel in 1896, and radium by Pierre
and Marie Curie in 1898. The biological and physiological effects of x-ray radiation
immediately caught the interest of researchers and physicians around the world, and
only two months later, Austrian radiologists Freund and Schiff proposed their potential
therapeutic use [19], [20]. This discovery was quickly followed by the first experimental,
but ultimately fatal, treatment with x-rays. French physician Victor Despeignes attempted
to use x-rays to treat a case of stomach cancer in 1896, and though ultimately fatal, a
year later Radiation Therapy resulted in the successful treatment of lupus by Schiff in
1897 [19], [20]. The recognized therapeutic benefits of ionizing radiation for the use in
treatments of cancers and other malignancies quickly ushered in an era of rapid technology
development and a radical change in how cancer treatment was approached. Since the
turn of the 20th century, radiation therapy treatments have undergone several massive
changes, which have greatly enhanced therapeutic indices for patients as well as improved
survival and quality of life [16].
Among these changes is the development of the modern linear accelerator (LINAC)
machine, which has the ability to precisely deliver highly energetic x-ray radiation to target
patient tumors in any site of the body and destroy them. These machines use advanced
technology to shape the x-rays as they exit the machine to conform to the specific shape
of a tumor, while avoiding some of the surrounding critical organs. This modern linear
accelerator has revolutionized the way cancer is treated and over a century after the initial
discover of radiation, radiation therapy is still routinely used around the world as a means
for treating cancer and a multitude of other ailments. Today, radiation therapy is used in
approximately 50% of cancer treatments in the U S. [14].
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1.4 Overview of Modern Radiotherapy Treatments
The benefits of Radiation Therapy have advanced with technology and research, though
the ultimate goal has long remained: to eradicate the malignancy while minimizing the
effects on normal tissue, especially those tissues that are critical to patient survival
and quality of life. Modern radiation therapy technologies and techniques have been
specifically developed to enhance the Therapeutic Index (TI) of cancer treatment, that is,
the ability to eradicate tumors, while maximally sparing surrounding critical structures
and normal tissues in the body. In the last two decades, highly sophisticated and
complex radiation therapy and imaging technologies have been developed that result
in high precision and conformal radiation targeting of tumors. When combined with
advanced radiobiological understanding of tissue responses, these developments have led to
significant improvements in patient outcomes [21]. These developments include radiation
therapy techniques used both separately and in tandem to allow clinicians to strive toward
eradication of malignancy but preservation of normal tissue. Some of these techniques
include Multi-fractionated Therapy, Image-Guided Radiation Therapy (IGRT), Intensity
Modulated Radiation Therapy (IMRT), Stereotactic Radiosurgery (SRS) and Stereotactic
Body Radiation Therapy (SBRT), Proton Therapy, among others.
1.4.1 Multi-fractionated RT
The dose required to kill a tumor is often very high, and when delivered as a single
treatment may result in severe normal tissue toxicities [22]. These toxicities may cause
undue pain and stress to the patient and result in decreased quality of life. One technique
for limiting the damage to normal tissues involves dividing the tumor killing dose into
a number of smaller dose fractions, delivered over time, known as multi-fractionated
radiation therapy (MFRT). This technique effectively exploits differences between tumor
and normal tissue radiobiological repair mechanisms to guide treatment, effectively sparing
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normal tissues while increasing damage to the tumor [16].
1.4.2 3D Conformal RT, Intensity Modulated RT, and Image-Guided RT
Further sparing of normal tissue is achieved by conforming the 2-dimensional radiation
beam to fit the shape of the tumor volume and deliver a customized, irregular radiation
field shape to fit the tumor for each treatment angle used. Individually controlled miniature
radiation shields, called multi-leaf collimators (MLCs), create beamlets that when combined
with advances in CT imaging technology allow for this 3-dimensional conformal radiation
field shaping, called 3-dimensional Conformal Radiation Therapy (3DCRT) [23]. By
optimizing beam placement and shielding, 3DCRT has an enhanced ability to localize
treatment to the target volume and avoid nearby critical structures, known as organs at
risk (OAR), compared to conventional 2D radiotherapy that used rectangular-shaped fields
[24]. Intensity modulated radiation therapy (IMRT) improves on the 3DCRT technique
via advancements in treatment planning software [25]. The software user delineates
the treatment targets and OARs, defines the minimum and maximum dose limits and
number of beam angles to use, then the inverse planning software algorithm calculates the
optimal intensity for each individual beamlet. Computer-controlled MLCs are then used
to modulate each beamlet intensity for each angle which enables enhanced OAR sparing,
even for complex concave radiation field shapes [26].
As these advanced highly conformal 3D IMRT techniques allow users to create much
narrower treatment margins and higher dose gradients than ever before, there is also
enhanced risk of setup error and inadvertent radiation to nearby OARs [25]. The
development of advanced image-guided radiotherapy (IGRT), such as cone-beam CT
scans acquired before each treatment, allow for more accurate positioning to avoid nearby
misses. IGRT’s anatomical tracking allows for changes in daily treatment repositioning, as
well as computing the total volumetric dose from the entire treatment course [25]. These
advances in modern image-guidance procedures, as well as highly advanced treatment
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planning techniques and computer-controlled MLC technology, have helped make IMRT
possible.
The primary patient and physician concern is to control or eradicate cancers in the
immediate future; however, the biggest drawback of advanced radiotherapy techniques
like 3DCRT, IMRT, and IGRT is the increased total dose delivered to the patient’s body,
which is correlated with secondary malignancies later in life [27]. While the dose to critical
organs is minimized, the use of smaller beamlets of radiation through more angles in the
body leads to longer treatment times and, hence, increased radiation leakage through the
collimator leaves. The increased leakage is especially enhanced in patients with larger
tumor sizes or patients with recurring or more aggressive tumors types that require higher
total dose to eradicate. However, this radiation leakage contributes only a few percent of
the total dose to the body, where the total dose is largely determined by the prescription
dose and treatment tumor volume. In addition to being time-consuming and complex,
these advanced radiotherapy techniques require very expensive, sophisticated equipment
and well-trained staff to implement [26]. IMRT in particular remains very sensitive to
setup error and treatment misses near the setup margins [25].
1.4.3 Stereotactic Body RT
Advances in both IGRT, IMRT, as well as specialized treatment planning methods
have helped resulted in high targeting accuracy and step dose gradients beyond the target
volume [28], [29]. In conjunction with anatomy tracking, they have additionally enabled
the development of stereotactic body radiation therapy (SBRT), which precisely delivers
high, tumor-killing doses of radiation as a single treatment session, or a limited number
of time-fractionated session to cranial or extracranial targets anywhere within the body
[30]. These treatments have shown remarkable success in the treatment of extracranial
oligometastases less than 3cm [30] and limited success for all solid tumors less than 5cm
[31]; however, it is not recommended for tumors 5cm or larger due to high risk of fatal
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normal tissue toxicity complications [32].
1.4.4 Proton RT
Radiation therapy may also be carried out with energetic charged particles such as
protons. In x-ray radiotherapy, as well as electron radiotherapy, the x-rays deposit their
maximum energy at or near the tissue entrance and then continue depositing dose along
their entire trajectory until they come out the other side of the patient, killing cancer as
well as damaging normal cells in the process. However, protons in radiotherapy have a very
low dose at the tissue entrance which then increases with increasing depth until they reach
a sudden peak, maximum dose at the tumor and then falls off very rapidly, with no exit
dose [33]. In principle, protons are much less damaging to normal tissue cells compared to
modern x-ray radiotherapy for similar rates of tumor killing [34], [35]; however it is also
more sensitive to organ motion as well as anatomy changes within the path of the beam than
x-ray radiotherapy [34].. The distinct radiobiological advantages inherent to proton therapy
make a very promising treatment approach that has been used on thousands of patients
already, but it comes at a very steep cost and is considered a highly controversial treatment.
A single treatment room may be up to an order of magnitude higher than for even the most
high-end photon radiotherapy unit, requiring costly cyclotrons or synchrotron facilities
to produce and uses the most advanced beam shaping collimators, image-guidance, and
treatment planning techniques [33], [36]. In addition, several physicians and researchers
have raised concerns over its lack of cost-effectiveness as there is little convincing evidence
that proton therapy is superior to x-ray radiotherapy in terms of clinical outcomes [35],
[37]. Proton therapy is still considered a largely experimental, evolving approach and




Combination therapies are designed to exploit complementary cancer treatment
strategies to disrupt the pathways for malignancies. Though radiation therapy is the most
successful treatment type, the addition of other therapies may dramatically enhance the
effects of radiation therapy [39], [40]. Research shows a relationship between radiation
therapy and the immune response, complementary to immunotherapy [21], [41] as well as
chemotherapy [42]. Hannan and Weinberg’s Hallmarks of Cancer have been hugely
influential in driving the new molecular cancer and genetic research, which has identified
several new targets for anti-cancer drug development and revolutionized the field of
immunotherapy research citeahmadClinicalDevelopmentNovel2019. Currently, cancer
research that targets specific parts of the tumor’s genetic pathways to disrupt progression
is being explored [43]–[45]. There is evidence, albeit limited, that combining radiation
with immunotherapy may help augment the biological effects of treatment and induce a
greater tumor response and several immunomodulatory agents in development for this
purpose [46]–[49]. In 2016, the CTRad working group within the UK National Cancer
Research Institute (NCRI), published a consensus statement that called for identifying
barriers and solutions to increase the number of clinical trials in drug-radiotherapy
combinations as well as a list of recommendation and guidelines for future work in this
area [21]. In this call to action, the UK NCRI acknowledged many challenges to
widespread clinical implementation, and has shifted focus away from exclusive use of
Radiation Therapy alone.
1.5 The Case for Additional Treatment Technologies
Modern day radiotherapy treatments have undoubtedly benefited millions of patients
across the US and the world. These advancements include geometric precision and targeting
abilities and allow for some differentiation between the treatment target (tumor) and other
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sensitive tissues to control cancers and improve clinical outcomes [28], [29], [50]. However,
the benefit of these advanced technologies come with a high price tag. Several researchers
have argued that the development of these state-of-the-art technologies have significantly
contributed to the high rise in treatment costs [29], [50], [51], general healthcare costs
[52], [53], and places additional financial barriers to quality cancer care on medically
underserved communities [38], [49]. In addition, many of these treatment technologies are
still largely inaccessible for developing countries, where the majority of the world’s cancer
population resides [54], [55].
Beyond the need for cost-effective treatments, leaps made in this technological revolution
have not led to improvements in clinical outcome near the same order of magnitude. Today,
many experts believe that further geometric and dosimetric improvements have had a
diminishing return in clinical utility of radiation therapy. There remain a host of patients
with cancers that do not respond to conventional treatment approaches or for whom these
approaches are extremely dangerous. These patient populations include pediatric and
geriatric patients [29], [55], [56], patients whose critical organs have already received the
maximum tolerance dose [57], [58], patients with chemoresistant and radioresistant cancers
[59]–[62], and patients with recurring or metastatic disease [62]. Further, by 2040, the
global number of newly diagnosed cancers is expected to increase drastically to nearly
28 million, an increase of almost 40% from 2018 as a result of population growth and an
aging population [63], [64].
Therefore, there is a need to look beyond the physics and engineering approaches
for cancer therapy advancement and towards very different and innovative,
radiobiologically-driven, approaches that have the potential to significantly increase the
treatment therapeutic ratio compared to the current conventional standards, especially for
those patients for whom modern treatment approaches remain ineffective or are not an
option [65]. In addition, a closer look at alternative, cost-effective approaches may make
effective cancer treatment more widely accessible to all radiation therapy clinics [66]–[68].
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A treatment approach that may meet some of these clinical needs and has gained
traction in recent years is spatially fractionated radiation therapy (SFRT). Spatially
fractionated radiation therapy is an experimental treatment approach that may offer new
hope for these cancer patients. Modern radiotherapy treatment approaches generally fall
under the umbrella of classical radiobiology, wherein the entire tumor volume, including
margins, must receive a high curative radiation dose to achieve tumor control and any
unirradiated volume may eventually lead to local treatment failure in the form of disease
progression or recurrence. However, recent SFRT research has shown that local tumor
control may still be achieved even with multiple “cold”, unirradiated spots present within
the tumor [69]–[71]. In fact, numerous preclinical and limited clinical studies have supported
the hypothesis that this unique treatment is more effective in tumor control with less
treatment toxicity [72]. Additionally, compared to conventional radiotherapy, this spatially
inhomogeneous dose distribution may induce vastly different microenvironmental effects in
tumors and may even play an important role in multimodal treatment approaches such as
chemotherapy and immunotherapy [73]. Despite the potential for SFRT to satisfy several
unmet needs in cancer treatment, this approach has historically been difficult to accept
by most clinicians and researchers. Further, a general lack of preclinical SFRT research
leaves many important questions unanswered and the underlying working mechanism of
this treatment is still poorly understood, hindering the broad clinical translation of this
promising cancer treatment technology.
1.6 The Scope of This Work
This body of research discusses the development of a novel SFRT-delivery system and
its implementation in a variety of SFRT preclinical research scenarios in the hopes of
shedding light on some of the unanswered questions that hinder clinical translation of
SFRT treatment technology. Systemic studies demonstrating SFRT’s ability to control
tumors while sparing normal tissue as well as on potential methods to optimize treatment
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are performed. However, no research is completed in isolation and the work described in
this dissertation is no exception. The development, validation, and implementation of
this novel SFRT-delivery system for use in a variety of preclinical studies has required
extensive multi-disciplinary collaborations with a variety of researchers at three major
universities and may be broken down into three major parts:
1. Development of a novel pre-clinical SFRT-delivery system for cancer treatment in
Chapter 3, including all relevant design, construction, testing, methodologies, and
results. This work was dosimetrically validated with the help of the Duke University
Dosimetry Laboratory and Department of Medical Physics.
2. Application of the SFRT-delivery system for use in an investigation of unique SFRT
dosimetric parameters and their correlations with treatment outcomes in Chapter 4.
This work was completed in collaboration with Dr. Paul Dayton and the Dayton
Lab in the department of Biomedical Engineering at UNC-Chapel Hill and NC State
University.
3. Investigations of the specific advantages of SFRT over conventional radiation therapy
in multi-modality cancer therapy approaches, including
• An investigation of potential methods for immunotherapy enhancement using
spatially fractionated radiation therapy in Chapter 5. This work was completed
in collaboration with Dr. Palmer and the Palmer Lab at the Duke University
Dept. of Radiation Oncology.
• An investigation of potential methods for anti-cancer drug delivery enhancement
via SFRT-induced changes to the tumor microenvironment in Chapter 6. This
work was completed in collaboration with Dr. Zamboni, the Zamboni Lab, and
the UNC Animal Studies Core at UNC-Chapel Hill.
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In addition, Chapter 2 provides a literature review of the current state of SFRT,
including its historical background and modern-day clinical treatment outcomes, preclinical
SFRT research, as well as the current major challenges facing it’s broad-clinical translation.
Lastly, Chapter 7 offers a more global perspective on the potential impacts of SFRT
treatment technology and its promising future prospects.
SFRT is a new low toxicity and low-cost radiation therapy treatment that offers hope for
many cancer patients, especially those failed by the current cancer treatment technologies.
The work presented hopes to improve our understanding of this treatment approach and
in small part, contribute to the effective and accessible treatment of cancer.
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CHAPTER 2: SPATIALLY FRACTIONATED RADIATION THERAPY
BACKGROUND
2.1 Introduction
Spatially fractionated radiation therapy (SFRT) is a very promising experimental cancer
treatment approach that has recently gain traction due in part to its high therapeutic
ratio and relatively easy implementation on a wide range of clinical machines. SFRT
has remarkable tissue selectivity, eradicating tumors effectively with little treatment
toxicity. Decades of clinical studies have demonstrated that SFRT may be used as a
safe and effective way to shrink very large, bulky tumors in patients for whom other
modern treatment approaches have been ineffective. In direct contrast to conventional
radiotherapy, which demands treating the entire tumor volume with a high, uniform dose,
SFRT directly irradiates only small sub-regions within the treatment volume with very high
doses of radiation, and so the broad clinical translation of this promising cancer treatment
technology has both been historically difficult to accept and achieve. A general lack of
preclinical SFRT research has left many important questions unanswered, notably including
optimal spatial fractionation pattern and dose. Furthermore, the working mechanisms
behind this technique are not yet understood, but some theories include systemic immune
stimulation effects, radiation-induced bystander (abscopal) effects, altered cell signaling
that induces indirect cell death, and even changes to the tumor micro-vasculature or
micro- environment. This chapter provides a general overview of SFRT, a review of some
prominent clinical and preclinical studies, brief explanation of some of SFRT’s potential
working mechanisms, and a discussion of some of the critical barriers to widespread clinical
translation of the approach.
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2.2 Unique Dosimetric Characteristics of SFRT
Both clinical and preclinical SFRT share the same characteristic trait with very few
exceptions; a single, high dose, spatially inhomogeneous radiotherapy treatment is delivered
to the target. While the specific dose distributions and dosimetric parameters in preclinical
and clinical SFRT are vastly different, they may be described using largely the same
nomenclature. Common terms include the peak dose, valley dose, peak-to-valley dose
ratio (PVDR), peak width, valley width, peak-to-peak distance, as well as the percentage
% of target directly irradiated (also known as the ratio of open-to-shielded area). Figure
1 visually describes some of the characteristic properties that are common to all SFRT
treatments.
Figure 1: The unique beam profiles of SFRT may be dosimetrically characterized, in
part, by the high dose in the ”peak” region, the low dose in the ”valley” region between
consecutive peaks, the ratio of the peak to the valley dose, the peak widths and the
distance between them, as well as the valley widths.
2.2.1 Peak dose, valley dose, and peak-to-valley dose ratio
The peak dose is the maximum dose measured in the unshielded “peak” region of the
collimator opening located along the central axis of the SFRT field and at a depth at
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which dose for specific-energy photons are at maximum, Dmax. Ideally, the peak dose is
the same for each of the SFRT beams in the field. Peak dose is critically important to
the effectiveness of SFRT treatments and must be carefully considered in the selection or
design of a collimator and GRID pattern. Another critical factor in SFRT treatments is the
valley dose, defined as the minimum dose measured in the shielded “valley” region, located
between two adjacent collimator openings, at the same depth, Dmax. The peak-to-valley
dose ratio (PVDR) is a numerical description of the difference in dose intensity between
the dose delivered to an unshielded area, the peak dose, and the dose delivered under
a shielded area, the valley dose, at Dmax [74]. Ideally, the valley dose would be zero;
however, in practice the PVDR is maximized for a given peak dose, in order to deliver the
lowest possible dose to the shielded areas of the GRID pattern. High PVDR is presumed
to maximally spare the negative effects of radiation on skin cells below the shielded regions
and enable the repopulation of skin cells in the unshielded regions of the GRID collimator
and decrease the severity of possible skin reactions to the treatment and normal tissue
toxicities [74]. Decreased time to heal and reduced severity of reactions is a distinct benefit
of SFRT therapy, therefore peak dose, valley dose, and PVDR must be designed, measured,
and calibrated for effective treatment.
2.2.2 Peak width, valley width, and peak-to-peak distance
Peak width, valley width, and peak-to-peak distance are factors that rely heavily on
the design of a collimator/GRID pattern. The peak width is the measured
full-width-at-half-maximum (FWHM) of the central SFRT peak located along the central
axis of the SFRT field. The peak-to-peak distance is the measured distance between the
central SFRT peak and the next nearest peak. In practice, the measured peak-to-peak
distance may vary along different axes of the SFRT field depending on the specific
geometry of the collimator. For example, in an ideal hexagonally-shaped, or
honeycomb-shaped, lattice GRID collimator [75], the peak-to-peak distance between the
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central peak and its nearest neighbor along one axis is geometrically calculated to be
exactly
√
3 times larger than the peak-to-peak distance between the central peak and its
nearest neighbor along the other, orthogonal axis. The valley width describes the overall
width of the valley regions of the SFRT collimator and may be calculated as the
peak-to-peak distance measurement minus the peak width measurement.
2.2.3 Collimator (or GRID) output factor
The collimator output factor (alternatively known as the GRID output factor) may
be described as the ratio of the dose with the SFRT/GRID collimator to the dose absent
the collimator at the linear accelerator calibration condition, measured at a given field
size. The collimator output factor is a function of field size and photon energy and is an
important tool for determining the treatment exposure time for a specific dose prescription.
An example output factor calculation for a clinical-type SFRT (GRID) collimator is shown
in Figure 2 [74].
Figure 2: The measured GRID factor as a function of field size, in cm2, at isocenter, d=
Dmax, for 6MV and 10MV photons on Novalis Varian accelerator using a brass GRID
collimator. For a given field size, the GRID treatment dose is calculated using the GRID
output factor curve [76].
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2.3 The Evolution of SFRT
2.3.1 A brief history of SFRT
Spatially Fractionated Radiation Therapy is an old radiotherapy treatment modality
that has been around for over a century, with varying degrees of use throughout that time.
Soon after x-rays were introduced for the treatment of malignancies, a growing number of
patients began experiencing severe radiation-induced normal tissue toxicities such as skin
ulcerations. The low, orthovoltage energy x-rays were heavily irradiating and subsequently
damaging the radiosensitive, superficial skin tissues on their path to the tumor [77]–[79].
In addition, the risk for developing a refractory, un-healing skin ulcer was increased when
delivering the tumoricidal doses needed to treat very large and very deeply seated tumors.
In 1909 Alban Kohler invented a sieve-like iron mesh to partially shield patient skin from
the radiation with remarkable success [77], [80]. The skin cells lying directly beneath the
iron “sieve” were protected from the high doses of radiation, and this protection promoted
skin healing in the unprotected regions [77]–[79], [81]. By the 1930s, this early form of
SFRT, known at the time as “sieve therapy” or “GRID therapy”, became a commonly
used method for limiting skin tissue toxicities while delivering a high dose of radiation to
tumors, and a variety of different types of collimator shapes and materials such as steel,
lead, and lead-rubber were utilized [69]. The technique remained in use through the 1950s
until the advent of the megavoltage, clinical linear accelerator (LINAC). The LINAC
completely revolutionized the way that radiation is delivered, allowing for greater tissue
penetration with improved surface skin sparing capabilities than ever before. By the late
1960s, GRID therapy as a treatment modality became largely phased out, and eventually
abandoned until a group of physicians and researchers at Thomas Jefferson University
Hospital revived the technique in the late 1980s [69], [82].
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2.3.2 The modern resurgence of SFRT
The development of clinical linear accelerators undoubtedly benefited hundreds of
thousands of patients across the US and the world; however, there remain a host of patients
with cancers that do not respond to conventional treatment approaches or for whom these
approaches are extremely dangerous. The search for innovative cancer treatment approaches
with the potential to significantly increase the treatment therapeutic ratio has sparked
renewed interest in SFRT. Physicians and researchers have asked how precise delivery
and exact dosimetry in SFRT affect survival, as well as what is needed to significantly
improve patient outcomes. Significant resources have been dedicated to these questions,
and while specific answers may vary, it is becoming increasingly clear that an improved
understanding of radiobiology is necessary to understand the impact of physics on clinical
outcomes. Though it has century-old roots, SFRT is a radically different, very promising,
and unique treatment approach, which makes studying the radiobiological mechanism
behind it very attractive.
2.4 Clinical SFRT
2.4.1 GRID Therapy
In late 1980s, Mohiuddin et al. at Jefferson University Hospital were the first group
to revive orthovoltage-style “sieve” therapy and adapt it for megavoltage accelerators for
the treatment of very large, deeply seated tumors [82], [83]. They accomplished this by
creating a large, square array grid of cylindrical apertures with a 1:1 open-to-closed area
made from a combination of stainless-steel tubing and lead alloy[74], [83]. The new “GRID
compensator” collimator was then mounted onto a fixed tray in the blocking tray-holder of
a LINAC head, and single fields of approximately 10-20Gy dose to Dmax were delivered to
patient tumors. Figure 3 shows an example of SFRT dose profiles created using a similar
type of GRID-compensator fitted onto a LINAC.
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Figure 3: On the left, Gafchromic RTQA-2 film is irradiated, top, and then, bottom.
The film density is converted to dose using a film density calibration curve based on ion
chamber data. Blue, horizontal, and Green, vertical, lines on film to indicate the location
of beam profiles measured. On the right, the GRID horizontal, top, and vertical, bottom,
dose profiles are measured at Dmax for 6MV and/or 10MV beams using 25x24cm field
size, 100cm SSD and either 1.5cm or 2cm buildup.
Despite these very high single doses of radiation, results using this GRID-compensator
type of megavoltage SFRT, now named “GRID radiotherapy”, have demonstrated high rates
of pain relief (in up to 91% of patients) with few to no associated normal tissue morbidities
[73], [82], [84]–[88], as well as reductions in bleeding [73], [82], and partially-controlled
shortness of breath [82]. In addition, reductions in tumor volume were observed in both
palliative and definitive treatment settings. In fact, complete tumor control responses were
observed when GRID radiotherapy was used as neoadjuvant to conventional radiotherapy,
chemotherapy, surgery, or immunotherapy [49], [73], [82], [86]. This improved tumor control
is not limited to SFRT; several non-SFRT studies have suggested that high “induction”
doses of uniform radiation prior to a conventional course of radiotherapy may result in
even better tumor suppression outcomes, though not without significant side effects [89].
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This GRID therapy technique has been used for treatment in a variety of sites and
specifically for bulky disease, larger than 8cm. Some treatment sites include (but are not
limited to) tumors in the extremities [73], [82], [84], the abdomen and pelvis in the case of
gynecological, gastrointestinal, and liver cancers [73], [82], [84], the thorax in the case of
breast and lung cancers [73], [85]–[87], and notably, in the rapidly proliferating tumor cells
common in head and neck cancers [49], [52], [73], [84], [90], [91]. These treatments have all
reported good oncological outcomes and few to none reported complications in the short or
long term, including to the CNS [73]. Importantly, the GRID therapy treatments targeted
advanced, very large disease that has historically been very difficult to treat, especially
for patients with recurring tumors, or patients that had already reached the maximum
chemotherapy or radiotherapy tolerance dose [82]. Massive, recurring tumors not only
have unfavorable tumor histology with limited chemotherapy options, but are also highly
vascularized, precluding treatment with surgery due to the risk of uncontrolled blood loss
during excision. In addition, traditional radiotherapy has limited impact on radio-resistant
tumors and tumoricidal doses do little to spare normal tissues with unacceptably high
risks for tissue morbidity [92]. The large size of bulky tumors also makes them unsuitable
candidates for treatment with specialized stereotactic radiosurgery [93], [94].
The amazing treatment outcomes reported by Mohiuddin et al in the 1990s sparked
a renewed interest in this radically different radiotherapy treatment modality, especially
for its potential as an additional tool in the radiation oncologist’s toolbox for treating
patients that have exhausted all other treatment options. The overall design principles
used in creating the compensator-based GRID therapy have not changed significantly over
the last 3 decades. GRID compensators may now be purchased commercially and are
customizable to fit a variety of LINAC models for use in clinical SFRT [76], [95].
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2.4.2 Advanced clinical SFRT techniques
Beyond customizable commercial collimators, in the last decade researchers have
developed additional methods for delivering spatially fractionated radiation patterns to
targets. MLC-based GRID therapy uses the multi-leaf collimators (MLCs) that come
pre-installed in modern LINAC treatment heads to create spatially modulated beam
patterns. This technique was developed in response to the impracticalities of repeatedly
installing and removing the heavy (up to 50lbs) GRID-compensator for treatment as
well as the fact that SFRT treatments are not optimized, employing a wide range of
SFRT pattern geometries [96]–[98]. MLCs allow for greater flexibility in creating different
geometric GRID patterns and ease in treatment planning since the dosimetry can more
readily be determined within the treatment planning system. However, major drawbacks
to MLCs include the limited ability for the large collimator leaves to generate small beam
sizes comparable to the pencil-beams generated with GRID-compensators [96]. In addition,
MLC-based GRID therapy produces up to 2 rows of spatial modulation at a time, requiring
a longer treatment time, which results in a higher surface dose as result of leakage through
the MLCs [99].
Both GRID-compensator and MLC-GRID-based SFRT share many of the same
dosimetric features, particularly that each delivers a single, high-dose fractionated pattern
to tumors, as well as normal tissues, using one (and sometimes two) field(s). To minimize the
dose delivered to normal tissues, especially for deeply seated tumors, Helical Tomotherapy
or Volumetric Arc Therapy techniques may be applied to simulate a virtual GRID collimator
and deliver SFRT to tumors with the advantage of sharp dose fall-offs just outside the
tumor treatment volume, avoiding critical structures [100].
The “traditional” GRID-compensator-based radiation dose distribution is fractionated
only in the plane perpendicular to the radiation pencil beams (x- and y- axes) and is not
fractionated in the direction parallel to the beams (z-axis), where the dose distributions
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for each beamlet may be approximated as 2-dimensional gaussians at any given depth in
(z), (an example of a 2-D gaussian model shown in Figure 4) [101]. Three-dimensional
Lattice Radiotherapy (3DLRT) is a novel spatial fractionation technique which expands
the 2-dimensional traditional dose distribution and applies it in 3-dimensions, spatially
fractionating the dose distribution throughout the entire 3-dimensional target volume.
This technique results in multiple spherical “hot spots” of high doses within the tumor
[102]. To date this technique has safely been used in treating large, bulky tumors without
observed normal tissue toxicities at doses of up to 18Gy [86]–[88]. The advanced SFRT
treatment techniques described above offer additional, potentially life-saving treatments
for patients, achieving more normal tissue sparing than ever before with high rates of
tumor eradication. However, these advancements would not have been possible without
the vast number of preclinical SFRT studies that helped elucidate some of the working
mechanisms of the promising treatment approach.
Figure 4: The dose distribution from a GRID-compensator with a “square lattice” pencil
beam geometry may be modeled as an array matrix of 2-dimensional gaussians at any
given depth in tissue. Image modeled in Matlab [103].
24
2.5 Preclinical SFRT
2.5.1 Microbeam Radiation Therapy
Spatially micro-fractionated radiation therapy (MRT) is an experimental, preclinical
form of SFRT consisting of very high (peak) and very low (valley) doses that are alternated
at a high spatial frequency over the treatment volume. Like SFRT, these spatially
modulated doses are usually, though not always, delivered as a single field to the treatment
volume. However, MRT is distinctly different from SFRT in several ways. MRT typically
consists of very narrow, highly collimated planes of radiation, each approximately 20-700
microns wide (FWHM) and between 100 to 4000 microns apart (peak-to-peak distance)
[104], [105]. The unique geometry of these micro-planar arrays allows for the delivery of
well-tolerated peak doses up to 2000Gy (or higher) for the smallest beam widths [105]–[107].
One example of a multi-slit MRT collimator is shown in Figure 3.
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Figure 5: The SFRT Minibeam dose profile measurement, top, is calculated along the
direction perpendicular to the beams. For this specific collimator, the minibeam PVDR
was 5.11 with peak width = 0.69mm and peak-to-peak distance = 1.87mm. At the bottom,
an irradiated EBT-3 film is shown with the dotted line on the film indicate location of
Beam Profile. Measurement specifications include 160kVp, 25mA, 0.254mmCu added
filtration, 37cm SSD, at 1cm depth.
To achieve these astounding dosimetric values, MRT is typically conducted at
synchrotron light source facilities, which are capable of producing brilliant, nearly parallel
x-rays, 50-600 keV, with minimal beam divergence and at ultra-high dose rates, 8-16
kGy/second [105]. Placing a multi-slit collimator in the path of the beam results in highly
collimated planes of light with very high dose gradients, peak-to-valley dose ratios of up
to 56 [104], [106], [107], and that are well-preserved even at depths of 15cm [108].
2.5.2 Radiobiological studies in MRT
Decades of preclinical research have demonstrated that SFRT has the ability to eradicate
tumors while simultaneously sparing normal tissues and functions, even when these are
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exposed to the same tumor-killing radiation. Preclinical MRT research from the last
three decades has demonstrated that these incredibly high doses are very well tolerated
for the given beam geometries. Early dose escalation studies investigated heavy cosmic
radiation exposure delivered by 25um-wide MRT beams with peak skin entrance doses of
up to 10,000Gy to live rodent cerebellums and reported maximum tissue tolerance doses
of 5000Gy at the skin entrance, with no apparent histological brain damage reported for
doses ¡=5000Gy [109]–[111]. In addition, this tolerance dose is several orders of magnitude
higher than conventional uniform or even millimeters-wide beams [109], [112] and the
tissue-sparing effect increases with increasing distance between beams [109].
These very promising early studies have sparked significant interest in advancing
understanding of SFRT through preclinical research. Since then, other preclinical studies
have validated the remarkably high tissue sparing effect of SFRT. Studies of CNS tissues
irradiated with MRT, between 50-600Gy, have demonstrated extremely high dose tolerances
with no long-term observable effects to tissue function or developmental behavior, including
in immature embryonic duck brain tissues [113], brains of suckling rat pups [114], weaning
piglet brains [115], and rat spinal cords observed without paralysis for over a year [116].
Most recently, highly sensitive testes organ germ cells were irradiated with MRT and
showed preserved spermatogenesis [117], [118].
MRT also preferentially kills tumors over normal tissues when exposed to the same
radiation doses and with high efficacy. This tumoricidal effect has been demonstrated in
a vast number of preclinical small animal studies, with nearly all demonstrating either
effective growth suppression or complete tumor eradication in several tumor models [119];
examples include tumorcidal results in very advanced stage rat 9L gliosarcomas [120]–[125],
in mouseEMT-6.5 mammary carcinomas [126], in human glioma xenografts in nude mice
[127], in mouse 4T1 mammary carcinomas [128], among others. In addition, these studies
have been repeated for highly radioresistant tumors such as squamous cell carcinoma
VII [129] and radioresistant B16-F10 melanomas in mice [130]. This preferential tissue
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sparing effect combined with the high tumor killing efficacy has led to much longer-term
survival outcomes compared to conventional, uniform radiation fields at significantly lower
doses [121], [122], [131], [132] . Additionally, similar studies examined the effects of
interlacing MRT beams for tumor killing and added tissue sparing [133], and then applied
this interlacing pattern to suppress seizures [134] as a potential treatment for epilepsy
[135].
2.6 Potential Working Mechanisms of SFRT
Radiation does more than just kill cells; it can affect biological processes throughout
the body. The radiobiological mechanisms behind the SFRT preferential normal tissue
sparing and tumor ablative effects, especially in relation to conventional radiation therapy,
are not well understood. Several theories and studies have been developed to help explain
some of these mysteries, such as the bystander and system immune effects, the tumor
reoxygenation effect, and differential microvascular tissue responses. However, these effects
are very complex and are likely inter-related, so studies have had difficulty isolating and
determining cause.
2.6.1 Bystander effect
The most interesting mystery in SFRT radiobiology is that although a large portion of
the tumor lies within the spared tumor fraction, which is not directly irradiated, tumor
growth suppression or outright eradication still occurs in the low dose non-cytotoxic “valley”
region, which means cells in the spared tumor fraction are being indirectly killed. This
indirect cell killing has been observed in numerous SFRT preclinical and clinical studies
and may be attributed to the Bystander Effect, the indirect killing of cells as a result of
radiation damage to other, adjacent cells [91], [136]–[138]. In theory, the high amount
of direct cell killing within the tumor causes this indirect cell killing response, which
may trigger other radiobiological observations, including the induction of cell signaling
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pathways and systemic immune (abscopal) effects [139], [140]. Many of these effects
may fall under the category of radiation bystander effects and these extended effects are
theorized to stimulate physical changes to tumor vasculature, which have been directly
observed [141]–[143]. Subsequently, some combination of these effects are likely responsible
for changes in tumor volume and eventual eradication.
Some of the potentially important cell signaling pathways that have been induced
after SFRT treatment include bystander factors such as TNF-alpha (protein), TRAIL
(protein), and Ceramide (lipid). TNF-alpha, TRAIL and Ceramide have all been identified
as potential mediators of or participants in the cell killing response (cellular apoptosis)
after exposure to high doses of radiation [144]–[146], including high-dose SBRT [147]. In
studies of serum samples taken from patients before and after SFRT treatment, TNF-alpha
[144], [145], TRAIL [144], and Ceramide [146] induction in the high-dose, unshielded
areas of the radiation beam was strongly correlated with increased incidences of partial or
complete tumor therapeutic response to the SFRT treatment, and induced pathways may
even have played a part in the improved 2-year survival of these patients [145]. Conversely,
activity levels for these bystander factors were not elevated in patients whose tumors were
unresponsive to the treatment [145], [146]. These observed bystander-type effects have not
been limited to the localized, primary tumor treatment. Distant, or “abscopal” systemic,
bystander effects have been reported as well, wherein completely unirradiated tumors,
distant from the irradiated volume, partially or completely respond to the radiotherapy
treatment [49], [91], [136], even in the case of advanced metastatic disease [49], [91].
Further, Tubin et al. reported progression-free disease at least 9 months post treatment
with SFRT in 87% of patients [136]. The role of SFRT in tumor oxygenation and, relatedly,
the bystander/abscopal effect is under active investigation; however, some of the effects
observed include increased oxygenation levels in radioresistant, hypoxic tumors within 2
weeks following treatment with SFRT [128]. This re-oxygenation effect may not be directly
involved in tumor-cell killing; however, it may still have therapeutic benefits.
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2.6.2 Reoxygenation effect
The interactions between high dose radiotherapy and tumor oxygenation are not
well understood. Although tumor oxygenation effects may not directly be involved in
tumor cell killing, some clinical outcomes show tumor reoxygenation following SFRT [89]
may be exploited as a radio-sensitizing agent, where the addition of oxygen to hypoxic
tumors increases the effectiveness of radiation therapy. In addition, targeting only the
radioresistant, hypoxic regions of tumors with high doses of radiation similar to SFRT
may successfully induce bystander and abscopal immune responses in clinical patients
with advanced metastatic disease [136]. In theory, these enhanced bystander/abscopal
responses may be due to the combined effect of the very high dose of radiation used [148]
and the observed significant increases in bystander and abscopal responses in cases when
radiation is targeted to hypoxic tumor cells [149]. However, these effects may depend in
part on the initial hypoxic fraction, the % of tumor volume directly irradiated, as well as
dose [89].
2.6.3 Differntial microvasculature and microenvironmental effects
SFRT also modifies the tumor microenvironment differently than uniform radiation by
preferentially damaging or reorganizing the tumor and tumor rim vascular architecture
[128], [150], [151], a theory which is supported by increased endothelial apoptosis in tumors
[146], [152]; however, these effects may depend on the state of vascular maturation [151],
differences in HIF-1 expression, a pro-angiogenic factor and participant in the bystander
effect, and which specific tumor model is studied [153]. For example, SFRT has also shown
increased tumoral angiogenesis [150], increased tumoral vascular density in radioresistant
tumors [150], and upregulated expression of HIF-1 and VEGF, a pro-angiogenic factor
[154], [155]. Generally, HIF-1 and VEGF are both associated with tumor progression,
tumor angiogenesis [156], [157], and promoting oxygen delivery to tumors [158], [159],
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though over-expression of HIF-1 may correlate with treatment failure and increased patient
mortality [153]. In MRT, hypoxia is associated with increased HIF-1 and VEGF expression
, and may lead to tumor cell protection from apoptosis and tumor radio-resistance [155].
Conversely, VEGF inhibition may decrease tumor blood vessel density and increase tumor
hypoxia following high-dose radiation [160].
2.6.4 Dose-volume effect
An additional potential working mechanism that may help to explain the tissue sparing
effect of SFRT is the dose-volume effect. The dose-volume effect in tissues is where the
tolerance dose of a given tissue is strongly correlated with the irradiated volume of that
tissue. In SFRT this may play a role to partially explain the treatment effects. For
example, in an MRT study researchers varied the spacing between radiation beams, from
50 to 100µm, delivered to intracranial rodent tumors to determine peak-to-peak distance
impact on survival. The resulting medial survival for all rodents in the larger beam
spacing was more than double that of the smaller width used [113]. This indicates that
increasing the distance between beams not only allows for improved animal survival, but
also allows for higher tumor peak doses while minimizing the skin dose and improving
the skin sparing effect. This dose-volume effect may help partially explain the normal
tissue sparing effects seen in SFRT treatments; however, there overall working mechanisms
behind the radiobiological outcomes of SFRT largely remain unclear.
This discussion presented several examples of some of the potential working mechanisms
behind SFRT and demonstrated their complex interconnectedness. Although each of these
individual radiobiological effects may potentially impact the tumor response, it is unlikely
that they act independently. In fact, these radiobiological effects are not unique to SFRT.
However, SFRT uniquely combines multiple radiobiological mechanisms, and it is the
complimentary nature of these effects, each working in unison to induce the observed
tumor control and tissue sparing, that makes SFRT exceptional.
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2.7 Challenges to Clinical Translation
There are many challenges impeding the widespread clinical translation of SFRT.
Although SFRT treatment technology has been around for decades, it remains relatively
poorly understood, and a lack of preclinical SFRT research on varied animal models and
cancer types remains a serious obstacle. A review of MRT preclinical research showed
that while nearly a hundred experimental animal studies have been completed, nearly 60%
are in a single rat model of 9L gliosarcoma and about 33% are in other murine models of
only a handful other types of cancer [119]. The use of so few severely limits our ability to
characterize the effects of SFRT treatment, so more and different types of animal and cancer
models desperately need be studied in preclinical SFRT. In addition, the pace of research
output, as measured by the number of MRT-specific papers published, is exceedingly slow,
peaking at 11 publications at one year, but usually only about 5 per year [119]. Furthermore,
the working mechanisms behind this technique need further investigation, including SFRT’s
systemic immune stimulation effects, radiation-induced bystander (abscopal) effects, altered
cell signaling that induces indirect cell death, and changes to the tumor micro-vasculature
or micro- environment. In addition, some SFRT studies have shown synergy or success
with other treatments, such as anti-cancer immunotherapy and chemotherapy, which both
deserve further investigation with neoadjuvant SFRT.
Solving some of the dosimetric challenges faced in SFRT may improve the pace of
preclinical research. MRT dosimetry in particular is challenging due to due to the high
dose gradients, sub-millimeter sized widths of the microbeams, and a lack of dosimeters
available with the spatial resolution necessary to measure them [161]–[164]. A number
of dosimeters have been developed or tested for application in MRT with these specific
dosimetry needs in mind, including novel Ge-doped silica fibers for thermoluminescence
measurements of dose [165], MOSFETs [108], [166], thermoluminescent dosimeters [164],
radiochromic film [167], [168], and related advancements in Monte Carlo dose simulations
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[108], though their success has varied. Beyond dosimetry, accurately positioning tumors
and organs under the MRT beams is often challenging and has led to developments in
image guidance [169] techniques and optical CT [170], [171], as well as the use of g-H2AX
as a marker for dose deposition in rodent brains for post-vivo analysis of treatment and
positioning accuracy [172].
One of the potential keys to unlocking our understanding of SFRT may involve
large-scale studies examining clinical treatment outcomes as a function of specific SFRT
parameters, fractionation patterns, dose prescriptions, etc. . . SFRT is not a
well-characterized and all researchers and clinicians apply it differently. Very few studies
have looked at SFRT pattern optimization, which can vary based on desired outcome
(destroy tumor, induce inflammatory response, etc) [98]. However, even if such a study
was attempted, understanding how to interpret the impacts would be a difficult
undertaking as human patients are highly variable; different ethnic and socioeconomic
backgrounds, ages, gender, and other relevant factors in human patients may play a role
in treatment outcome and should be considered in data collection methods. As with any
new or not well-understood treatment, there is a fear of potentially inducing negative
short- or long-term effects in patients. This fear is rightly justified. More conventional
radiotherapy temporally fractionates high doses, delivering only very small doses daily
over several weeks and at multiple entrance sites, while SFRT is characteristically
delivered as a single, very high dose to the treatment volume, intentionally irradiating
normal tissues lying directly in the beam path along the way. Any miscalculation or setup
error could lead to unintended, potentially disastrous effects to the patient such as
accidently delivering a very high single dose to an at-risk organ or other critical structure.
However, with the advent of the novel 3D Lattice therapy that delivers a high, spatially
fractionated dose within the tumor only and at multiple angles around the patient’s body,
hesitance to use SFRT may soon change as recent studies using these techniques have
resulted in very positive patient outcomes [86]–[88], [173] [xxx].
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With a century-old history of treating tumors, and a resurgence of interest from modern
research, Spatially Fractionated Radiation Therapy (SFRT) has potential cost-reducing
benefits as well as the potential to serve patients who are not eligible for conventional
cancer treatments. SFRT also has several unique benefits from multiple complementary
radiobiological effects, including a network of bystander factors, distinct vasculature
response, and re-oxygenation of hypoxic tumors. Though SFRT researchers face many
technical and general challenges, including a lack of preclinical research on varied models
in the literature, the next chapter will address the specific difficulties faced in this research
through applied engineering, physics, and unavoidable trial-and-error.
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CHAPTER 3: DEVELOPMENT OF PRECLINICAL SFRT DELIVERY
SYSTEM
3.1 Introduction and Motivation
Decades-long research in SFRT has demonstrated the ability to eradicate tumors while
sparing normal organs exposed to the same radiation. However, SFRT remains relatively
poorly understood and many challenges impede its widespread clinical translation. One
of the potential keys to unlocking a better understanding of SFRT technology may lie in
the small-scale, preclinical research designed to examine the new radiobiology observed in
SFRT. However, there is currently no commercially available microbeam radiation therapy
(MRT) treatment system and, as such, the pace of preclinical research progress is slow.
Hence, there is a need to develop SFRT-tech using existing small animal RT irradiators.
3.1.1 Synchrotron-based MRT
To this end, Microbeam Radiation Therapy (MRT) technology is a novel form of SFRT
consisting of very narrow, highly collimated microplanar arrays of radiation, approximately
20 – 700 µm wide, delivering alternating high and low radiation doses at a high spatial
frequency over the treatment volume [104], [174]. The majority of MRT research is
conducted in synchrotron facilities, particle accelerators that use very high-energy electrons
travelling at or nearly the speed of light in a large closed-loop that is approximately a
kilometer in circumference [105], [175]. The unique physics intrinsic to a synchrotron light
source results in a very intense and highly brilliant biomedical radiation beamline capable
of ultra-high dose-rates on the order of hundreds of Gray per second [105]. These ultra-high
dose-rates result in radiotherapy treatment times of fractions of seconds [105]. Furthermore,
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synchrotron-MRT involves a unique geometry where the synchrotron light source is a
very large relative distance (approximately 40 meters) from the MRT collimator, thus
closely mimicking an ideal point source. This results in highly collimated, nearly perfectly
parallel set of micro-planar arrays of radiation with very sharp edges [174][xxx] that may
be adjusted to be anywhere between just a few microns in width up to several-hundred
microns width [107].
This highly specialized treatment technology has opened new doors to understanding
SFRT; however, these magnificent, extremely small and non-divergent beamlets of radiation
delivered at ultra-high dose rates come with several inherent limitations and achieving a
successful MRT treatment at any of these facilities is no small feat. The unique physics
and geometry of synchrotron-based MRT require complex dosimetric techniques and
unique technologies to achieve that are not readily available to a majority of researchers
[176]. Investigations involving synchrotron-MRT are extremely expensive[177]; each of
these facilities may cost many millions of dollars to build and significant manpower to
operate [178]. In addition, since there are only a handful of synchrotron facilities around
the world equipped to perform MRT research, synchrotron-MRT investigations are also
geographically inaccessible to a majority of investigators.
3.1.2 Non-Synchrotron-based MRT using compact irradiators
To help combat the technological and monetary barrier to preclinical MRT research,
there has been a recent move to develop low-cost MRT-treatment machines that are much
more compact and therefore, more easily accessible for preclinical studies and patients [176],
[179]–[181]. There is currently no commercially available microbeam radiation therapy
(MRT) treatment system. To help increase the pace of this exciting research, a handful of
investigators, including ourselves, have taken to developing our own non-synchrotron-based,
low-cost MRT-treatment technologies.
One such research group at UNC-Chapel Hill has developed the first MRT-system
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made up of miniature x-ray tubes using a unique carbon nanotube (CNT) design.
Researchers Zhou and Chang at UNC-Chapel Hill developed and patented a novel compact
MRT-treatment delivery system with built-in CT imaging that used this CNT field emission
technology to produce highly collimated micro-beamlets of radiation[179], [182]. This
system utilizes an array of CNTs as the “cold” cathode to emit electrons under a bias
electrical field at room temperature [179]. This technology has successfully been used
to image and then treat hundreds of small animals with remarkable tissue sparing and
imaging results [176], [183], [184]. A handful of other researchers have developed desktop
SFRT research irradiators by modifying existing small animal research irradiators and
demonstrated their feasibility for conducting preclinical MRT research [180], [181], [185],
[186]. By placing a multi-slit collimator in the beam path between the source and the
animal, then aligning the target (tumor or other animal part) very close to the collimator
exit, they have been able to produce beam arrays with peak and valley beam widths
sufficiently collimated for MRT research and have achieved geometries on the order of
hundreds of microns, known as Minibeam radiotherapy (MBRT).
Several major limitations are associated with non-synchrotron-based MBRT research
including inherently low dose-rates and long treatment exposure times compared to
synchrotron-based MRT [179]. When combined with the animal anesthesia exposure
time limitations, the low dose-rate of non-synchrotron MBRT place an upper limit to
the achievable peak dose that may be delivered. Further, the long exposure times may
result in radiation off-target effects, where peak “broadening” (or blurring) occurs due
to respiratory and cardiac motion [104]. While the beams used in MBRT are slightly
larger than for synchrotron-MRT, dosimetry remains a challenge. While none of these
research irradiators can reproduce the distinct geometry and dosimetry possible using
synchrotron technology, these alternative methods for producing SFRT-beams provide
additional, unique, low-cost opportunities for furthering SFRT preclinical research [186].
The widespread availability and far-reduced cost of small animal irradiators makes them
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a very attractive resource. Using a conventional research irradiator and modifying it
to produce preclinical SFRT-treatment capable beams, we create a low-cost, accessible
alternative to investigating SFRT in a variety of radiobiological applications and scenarios.
In this chapter, I will focus largely on SFRT technology development using a
commercial research irradiator as well as on resolving some of the dosimetric challenges
that require novel approaches for measuring dose. Further, I will address some of the
unique considerations and challenges in designing spatially fractionated radiation fields
and will validate their experimental treatment accuracy and uncertainty. In this
dissertation work, I do not intend to replicate the superior synchrotron-specific dosimetry,
but rather, show that the SFRT beams generated using commercial research irradiators
may achieve similar radiobiological responses in tumor and normal tissues as their
synchrotron-generated counterparts. Therefore, by developing our own SFRT-treatment
system, we take a crucial first step towards investigating the effects of spatial
fractionation in living systems and, hopefully, advance preclinical research in the process.
3.2 SFRT Treatment Delivery System and Design
3.2.1 Overview
The primary goal in this chapter is to develop a novel small animal treatment
system capable of delivering a variety of unique spatial dose distribution profiles from
sub-millimeter-sized beamlets of radiation to seamless conventional radiotherapy patterns,
intended for delivery to solid tumors in small animals. These fractionation patterns are
carefully designed such that a specific peak/integral dose, valley dose, peak and valley
width, dose-rate, dose-profile, and percentage of tumor coverage are achieved for the
intended radiobiological outcome studied. I solve the unique physics and dosimetric
challenges for measuring dose in each of my SFRT collimators using novel approaches.
Finally, I will address the unique considerations and challenges to designing spatially
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fractionated radiation fields, and then will validate the experimental treatment accuracy
and uncertainty for these challenges.
I will modify a commercially available XRad-320 research irradiator [Precision XRay,
Inc., North Branford, CT] to accommodate the specialized the SFRT-treatment system for
small animals. This involves many unique inter-related design considerations, including
physics, geometry, and animal design-related issues, each of which present a unique
set of challenges. For example, beam spreading is one of the major challenges in
SFRT-treatment design with three major causes: geometry, radiation physics, and animal
motion. Throughout this chapter I will address each challenge or limitation as I come
across them and describe solutions developed to overcome them.
3.2.2 Physics considerations- energy and filtration
Physics considerations are an important component of the SFRT-delivery system design.
For example, the tube potential, the electrical potential difference, or voltage, applied
between the anode and cathode components of the x-ray tube, used during treatment
has a downstream effect on resulting beam dosimetric profiles and on the patient normal
tissues and organs at risk, such as the skin. In any x-ray tube, electrons are accelerated
from the cathode through a vacuum up to a high energy, then strike a target material,
the anode, wherein the production of x-ray photons occurs [187]. The tube potential
essentially defines the energy of the x-rays produced. Inherently, this process produces
photons in a range of energies and types, rather than photons with uniform parameters.
Bremsstrahlung photons, for example, are emitted from the x-ray tube and consist of
a broad, continuous energy spectrum, up to the maximum accelerated electron energy
used. Furthermore, a unique set of target material-dependent characteristic x-rays with
specifically defined energies are produced. Any material placed in the path of the photons
between source and detector will attenuate photons to a degree, which is dependent on
the material composition and thickness. However, lower energy photons are preferentially
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attenuated due to their higher interaction probabilities with in-path materials. On the
other hand, higher energy photons have significantly lower interaction probabilities for
these same materials. In practice, skin is a nearly unavoidable in-path material, which can
lead to skin toxicity damage.
To enhance skin sparing during treatment, physics photon attenuation principles may
be exploited by preferentially filtering lower energy photons that would otherwise deposit
their energy at the immediate skin surface, or at 0cm depth. Known as beam hardening,
specific materials and thickness, such as those shown in Figure 6, are chosen to filter
these lower energy photons to maximize the photons that are directly contributing to the
dose delivered to the target, while simultaneously minimizing the energy deposited at the
skin surface. These factors must be taken into careful consideration during the treatment
design.
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Figure 6: The x-ray transmission spectra through different filtration materials is shown,
above. The table, below, show the specific properties for 3 different types of filters used
with the X-Rad 320 Irradiator . Each filter attenuates x-rays differently, allowing for
varying degrees of photon transmission through the filtration material. These unique,
material-specific properties may be exploited to maximize tissue sparing in small animal
studies and are taken into consideration in the SFRT system design. Mass attenuation
coefficients from NIST Database [188].
Figure 6 shows a few properties of different filters that are useful for the range of energy
photons produced by the x-ray tube and that may be used in the SFRT-delivery system.
Among these properties are the type of filter material used, the filter thickness, the mass
attenuation coefficients (a measure of the ability for the material to attenuate radiation) of
each filter, the specific fraction of the incident x-ray beam intensity that is attenuated for
each filter, as well as the approximate average photon energy of the resulting transmitted
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x-rays. Compared to the filter-free measurement, each of the different filters produce vastly
different degrees of photon attenuation. The right-shifted spectra following the addition of
the different filters shows the preferential attenuation of the lower energy photons, photons
that would otherwise play no role in the overall dose deposited to the treatment target. In
addition, these resulting average spectral energies have an important role in approximating
the amount of dose that is absorbed by the target tissue and is discussed in detail in the
Dosimetry Section 3.3.
3.2.3 Physics considerations- radiation shielding
From a radiation safety design perspective, we want to shield everything that is not the
intended target of treatment, such as the animal’s healthy tissues or sensitive electronics,
to minimize unnecessary exposure to the electromagnetic radiation. All materials placed
between the source and detector attenuate radiation differently. Less attenuative materials
require additional thickness, often several orders of magnitude thicker than others, to
achieve the same total attenuation. Since the probability that a photon travelling a set
distance will undergo any scattering or absorption interaction in a medium is directly
correlated to its initial energy, more energetic photons require additional shielding (or
denser radiation absorbers) to achieve the same overall exposure underneath the shield.
In our studies we largely attenuate radiation with Cerrobend (Bolton Metal Products
Co., Inc, PA, USA) (Tin 13.3%, Bismuth 50%, Lead 26.7%, Cadmium 10%) due to its
high attenuation coefficient and ease of use (see Figure 7). Comparable to lead, Cerrobend
attenuates photons well and is convenient in radiotherapy treatment applications as it can
be used to make custom-shaped apertures and blocks. A eutectic alloy, Cerrobend has a
low melting point, below that of water, and is firmer than lead at standard temperature
and pressure. However, even in solid form it is easily prone to damage.
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Figure 7: At the top, a table of several specifications are shown for the three different
shielding materials used to block the 320kVp photons in our SFRT delivery system. Each
material is weighted against the other in terms of its ability to attenuate photons effectively,
its ease of use for creating custom shapes, and its ability to withstand repeated use without
deformation. The figure below shows the mass attenuation coefficents for each of the
shields across a wide range of energies, calculated using XMuDat Photon Attenuation
software [189].
In terms of collimator aperture design, we use shielding materials that maximize photon
attenuation while allowing the flexibility to create specific collimator shapes. In most cases
our collimator apertures are made of either Cerrobend or lead. However, in the case of our
smallest slit collimators for creating submillimeter sized beams, we use Tungsten due its
combined high attenuation coefficient and material strength to withstand daily, repeated
use without risk of aperture deformation.
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3.2.4 Geometric considerations
A variety of different SFRT and seamless broadbeam collimators are carefully designed
to meet specific SFRT characteristics for each of our radiobiological studies. Such
characteristics include peak dose, dose-rate, dose-profile, overall tumor coverage,
peak-to-peak (P-P) distances, the peak width (full-width-at-half-maximum or FWHM) for
the SFRT collimator peaks, and their valley widths and doses. Several physics and
geometric factors play an important role in SFRT collimator design. One design element
includes creating radiation beams with very high dose-gradients at the edge of the
radiation beam field, called penumbra. Since the beam penumbra contributes to valley
dose (dose located directly under the collimator) as well as the peak width (the FWHM of
the beam), sharpening the beam penumbra is a very important. In an ideal point source
(where the source-to-skin distance is significantly greater than the source width), the
radiation beams would be nearly step-wise, with very narrow penumbra. However, given
that the radiation source in the XRad irradiator is 8mm-wide and effectively not a point
source, collimating the radiation field results in wide geometric penumbra.
Figure 8, on the left, shows a point source of radiation compared to a wide source and
the resulting wide penumbra S1. The geometric penumbra width increases with distance
between the collimator and the detector (or skin); therefore, we minimize this penumbra
and sharpen the beam edges by decreasing the collimator-to-skin distance (CSD) and
positioning the detector (or skin) as close to the collimator exit as possible (shown by
position S2). In addition, reducing the CSD in position S2 of Figure 8 also increases the
dose-rate of the beam, a side-effect of reducing the photons’ geometric attenuation (by
decreasing the overall source-to-detector distance) (see Footnote1). However, the beam
1Supposing we draw a straight line from the source through a slab of material with attenuation coefficient
(µ) of thickness (t) to the radiation detector, the total number of photons that reach the detector without
interaction make up the uncollided dose Do(r) = SpR(E)4πr2 × e
−µ(E)t, where the total material attenuation
is e−µ(E)t, the geometric attenuation of the photons radiating outward from the point source is 14πr2 ,
and R is the dose air-to-tissue conversion coefficient for the detector [190].
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penumbra width is also inversely proportional to the source-to-collimator distance (SCD);
therefore, increasing the SCD as much as possible will decrease the geometric penumbra
width as well as the dose-rate. As discussed previously, the number of photons that
penetrate the attenuating medium (collimator in this case) is a function of the attenuator
thickness. Figure 8, on the right, shows that photons that are not completed attenuated
by the collimator, known as transmission penumbra, may also contribute to the beam
penumbra and the valley dose. Increasing the collimator thickness reduces the number of
photons directly underneath the collimator, both in the sharpened geometric penumbra
and the reduced number of transmission photons and therefore minimizes the valley dose.
As can also be seen in Figure 8, reducing the collimator separation as well as increasing
the collimator width will also help minimize the number of photons that contribute to the
valley dose. Although intended to reduce valley dose, this effect has a distinct disadvantage;
both reducing the collimator separation and increasing the collimator thickness also lower
the peak dose rate of the resulting beams.
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Figure 8: This schematic drawing illustrates the effects of SFRT collimator design on the
resulting geometric penumbra, on the left, and the transmission penumbra, on the right,
of the resulting SFRT beams. Geometric penumbra may be minimized by maximizing
the source-to-skin distance while minimizing the collimator-to-skin distance, shown in the
figure as positions S1 and S2. The transmission penumbra may be minimized by increasing
the collimator thickness as well as the collimator width.
To maintain peak dose rates and other SFRT-treatment requirements, other geometric
design factors must be considered, including solid angle and source-to-collimator distance
(SCD). Increasing the collimator thickness and decreasing collimator separation has the
intended effect of attenuating photons that travel at an oblique angle from the source to
the detector (or skin). The solid angle subtended by the span of the collimators from the
source is dependent on the source-to-collimator distance (SCD). At large solid angles,
this geometry may limit the span of the beams (the total number of beams) that may be
generated. Since treatment areas may be as wide as 2cm in diameter, significantly larger
than the x-ray source, it is very important to increase the span of the beams as much as
possible to achieve complete target coverage. Increasing the distance between the source
and collimator (SCD) is an effective way to decrease the solid angle subtended by the span
of the collimators and therefore increase the overall span of the SFRT beams. However, this
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has the unintended effect of also reducing the dose-rate of the SFRT beams via geometric
attenuation (see Footnote1.) Therefore, SFRT collimators need to be positioned such that
they are optimally situated between the radiation source (focal spot of the x-ray tube)
and the target through a combination of careful collimator positioning, trial and error,
and testing.
SFRT collimators are carefully designed in the hope of yielding specific treatment
outcomes. To this effect, achieving specific SFRT characteristic dosimetric parameters
requires a thoughtful balance of collimator aperture width, thickness, and separation,
among other parameters. Figure 9 shows an example SFRT collimator configuration that
was rigorously designed to achieve specific peak dose and width, valley dose and width,
peak-to-valley dose ratio, percentage of tumor directly irradiated, and other parameters
that are discussed in great detail in Chapter . This collimator was created by pouring
heated liquid Cerrobend into a 20x20x1cm mold and then manually drilling aperture slits
and a circular 1cm diameter cross-section hole to fit an endoscopic camera.
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Figure 9: The schematic above illustrates an example of a SFRT-Minibeam style collimator
that was carefully designed with all physics and geometric considerations mind. In
addition, a 1cm bore hole was drilled into the collimator at a steep, 63-degree angle for
insertion of a PC-linked camera. The steep, 63-degree camera viewing angle allows for
collimator-to-target alignment, discussed in detail in Section 3.2.5.
3.2.5 Animal considerations
Animal welfare must be carefully considered as an essential part of any radiotherapy
treatment design. Using live animals in radiobiological studies adds several additional
requirements, both institutional and practical, that must be made before performing any
radiotherapy treatments. As such, all protocols are approved by Institutional Animal
Concerns and Use Committee (IACUC) and all recommended NIH guidelines are strictly
followed to ensure that animal welfare remains a top priority in all studies.
The dose to surrounding non-targeted normal tissues should always be minimized
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for any given radiotherapy treatment; however, preventing radiation toxicity-triggered
euthanasia is especially vital in longitudinal studies where the long-term survival of the
animal is critically important to completing the study. The sub-millimeter geometry of
the SFRT beamlets not only makes them very difficult to align with the treatment target
(usually a tumor), but it also makes minimizing the dose delivered to surrounding normal
tissues in the region increasingly challenging. To overcome these positioning challenges, we
created a treatment system that includes two cameras as well as an animal/target height-
and angle-positioning platform, shown in Figure 10.
Figure 10: The SFRT delivery system includes two cameras, one for animal monitoring
during treatment, and the other for beam-to-animal alignment aided by the rotatable,
height-adjustable platform. Large cerrobend blocks shield the animal and electronics
from unintended irradiation. The cerrobend shields, collimators, electronics, and other
equipment are supported by a 1cm thick acrylic shelf that is cut to fit the length of the
irradiator and that has a large square hole drilled through the center for photons to travel
unimpeded from the collimator to the animal. In addition, the shelf is reinforced lengthwise
with two anodized aluminum 80/20 T-slot bars [80/20 Inc, Columbia, IN, USA], a type of
high strength(yield strength 35,000 psi), light-weight metal [191].
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During animal treatments, the animal platform is positioned downstream from the
stationary collimator and shielding blocks, and the position of the SFRT collimator with
respect to the x-ray source is determined via the built-in light field of the XRad irradiator.
A small hole through the Cerrobend shield near the collimator exit is fitted with a PC-linked
endoscopic camera. The resulting live video feed provides a beams’-eye-view of the target
during alignment with the radiation light-field. In addition, each animal is fixed to a
height-adjustable rotatable platform and angled with the radiation light field in such a
way that normal tissues lie beneath the Cerrobend shielding and are maximally spared.
The small beam widths of the SFRT collimators makes the resulting beams especially
prone to beam spreading due to motion blur; therefore, animals are rendered immobile and
fixed to the rotatable platform throughout treatments. To minimize stress to the animal
during the procedure as well as to reduce animal motion, all irradiations are performed under
anesthesia, typically continuously-delivered vaporized isoflurane. Delivering anesthesia
safely requires continual animal monitoring as prolonged exposure to isoflurane anesthesia
may result in respiratory and cardiac depression as well as hypothermia and hypoglycemia
[192]. Shown in Figure 10, the SFRT treatment setup includes a second camera for
post-alignment monitoring of the animal’s respiration, since change in respiration may
be an early indicator of potential problems during treatment. For example, animal
respiratory rate and depth may be determined by observing chest wall motion, where
10-40 breaths per minute is the expected normal range when the animal is exposed to the
recommended isoflurane anesthesia flow rate of 1.5 liters/min oxygen mixed with 1.5%
isoflurane [193]. As the depth of anesthesia increases, the respiratory rate and volume will
decrease; however, abnormally low respiratory rate (< 8− 10 breaths per minute) may
indicate that the anesthetic level is too high and needs to be reduced [193]. Conversely,
an elevated respiratory rate is the first sign of animal arousal from anesthesia, which may
impact radiotherapy treatment delivery due to motion.
The low dose-rates of the SFRT beams may result in relatively long radiation exposure
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times which translate into long periods under anesthesia for the animals. For animal
anesthesia exposures lasting longer than 10 minutes, animals are susceptible to body
temperature depression. Temperature depression is mitigated via a heat source placed
underneath the animal, such as an externally controlled, electronic heated platform. For any
radiotherapy treatment involving the use of vaporized isoflurane, an anesthesia scavenger
should be included in the anesthesia setup to remove the vented gas from the irradiation
chamber. In addition, longer exposure times may result in exhaled anesthetic gas or
anesthesia rodent nose cone leakage buildup in the irradiation chamber during course of
treatment. For irradiations lasting longer than 20 minutes, an active (electric) scavenger
is highly recommended as it is the most effective method for removal of anesthetic waste
gas. Figure 11 shows the electronics components of an electronic heated platform that
maintains the animal body temperature at a constant 38.2 degrees Celsius, as well as an
active scavenging unit that suctions airflow from waste anesthetic gas and then passes it
through an activated charcoal canister to adsorb the toxins before discharging the cleaned
air back into the room. These precautions are especially important to maintain animal
welfare during and after treatment, as well as ensure the effectiveness of said treatment.
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Figure 11: The animal body temperature is maintained via an externally-controlled electric
heating pad, external electrical component shown, and an anesthesia active scavenger is
used to draw anesthetic waste gas from the irradiation chamber.
3.3 Machine Specific Dosimetry
3.3.1 Equipment for measurements of exposure
The radiation output and quality of x-rays in a given machine may be highly susceptible
to minute changes in the x-ray tube. Ensuring the stability and reliability of the machine
x-ray output under standard operating conditions are critical in our SFRT experiments
to ensure that the treatment dose is delivered to the target as intended. Therefore, we
perform a series of extensive machine output measurements for quality assurance testing
as a standard practice and first step prior to adding an SFRT collimator for small animal
dosimetry.
The radiation output of the machine may be measured in terms of exposure, or the
amount of ionization the radiation produces in a volume of air. Under charged particle
equilibrium conditions (see footnote1), an ion chamber may be used to measure radiation
exposure, where a voltage potential, applied between two electrodes in the ion chamber
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with an incremental volume of air, measures the total charge (C) generated by the ion
pairs that are liberated and completed stopped in air, per unit mass of air (kg) (or
2.58x10−4C/kg) [190]. These exposure measurements may also then be used to calculate
absolute dose, discussed in Section 3.3.2.
We used several different ion chambers throughout our studies; however, the calibration
for each may be traced to a national Accredited Dosimetry Calibration Laboratory (ADCL)
traceable to the National Institutes of Standards and Technology (NIST), as recommended
[194], [195]. Furthermore, each measurement was verified with a second, independent source
whenever possible for enhanced measurement confidence. When measuring the XRad
machine output, we used an ion chamber from Duke University’s Radiation Dosimetry
Laboratory and cross-calibrated it against an ion chamber in the Department of Radiation
Oncology at UNC Chapel Hill. In addition, all measurements are corrected for differences
between ion chamber calibration conditions at the ADCL and any changes in measurement
conditions. The fully-corrected ion chamber reading, M , then is calculated as follows:
M = Mraw × PTP × Pion × Ppol × Pelec
, where Mraw corresponds to the Raw, uncorrected ion chamber reading, chamber
corrections for temperature and pressure (PTP ), ion recombination (Pion), polarity effects
(Ppol), and electrometer accuracy (Pelec) [194].
Prior to measuring machine output, we take a measure of the ion chamber dark current
(the residual current in the device without the presence of ionizing radiation), to ensure the
ion chamber itself does not affect reading results. Shown in Figure 12, measurements of
the ion chamber dark current are on the order of tens of milliRoentgen (mR), a negligible
amount as the machine output readings expected are on the order of hundreds of R.
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Figure 12: The ion chamber dark current, residual internal noise, may indicate potential
measurement issues. For this ion chamber, the dark current is negligible. In addition, the
ion chamber should be used for the dose ranges at which it was calibrated, shown in the
table.
3.3.2 Dose calculation
While measurements of exposure are informative for determining how much radiation
is present in air (air ionization), a more useful measure is how much energy that radiation
deposits to a specific medium, called the absorbed dose, which is linked to how much
radiation damage will occur in that medium. Absorbed dose is equal to the radiation
exposure multiplied by the ionization energy of that radiation in the medium ionized in J/kg
(and 1J/kg = 1Gy = 100rad). For example, an exposure of 1 Roentgen (2.58×10−4C/Kg)
yields a dose of 0.00876J/Kg in air (or 0.876Gyor0.876rad), where the ionization energy
of dry air is 33.97J/C at normal temperature and pressure conditions.
For the radiotherapy and radiobiology study applications outlined in this dissertation,
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the absorbed dose to tissue is of special interest. Therefore, we follow the American
Association of Physicists in Medicine (AAPM) guidelines set by the Radiation Therapy
Committee Task Group 61(TG− 61) for low (superficial) to medium (orthovoltage) energy
x-rays, 40 – 300kV [194]. The protocols outlined in TG-61 yield absorbed dose in water
and tissue at the point of measurement absent the ion chamber. For all of our small animal
radiotherapy experiments, doses need only be calculated at depths <= 2cm, and at points
on or near the surface of the skin (with measurement reference depth zref = 0); therefore,
the “in air” method described in TG-61 is the preferred method for calibration of our x-ray












is the mean mass energy-absorption coefficient ratio of water to air, Nk is the
ion chamber correction factor for the x-ray beam quality used, Pstem,air is the ion chamber
correction factor that accounts for any changes in field size as compared to the initial
calibration conditions that result in differences in measured charge in the ion chamber
stem, and Bw is the photon backscatter correction factor.
3.3.3 Beam quality
For calculating dose to tissue, the mass energy-absorption coefficient ratio of water to
air needs to be determined from the beam quality of the x-rays (320kV tube potential).
The x-rays half-value layer (HVL) and the tube potential are both used to characterize
the beam quality, where HVL is the thickness of material (usually Aluminum or Copper)
required to attenuate the beam intensity down to half of its original value. Shown in
Figure13, SpekCalc software is used to generate the x-ray emission spectra, on the left,
and is used to calculate their corresponding mean and effective (equivalent monoenergetic
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photon) energies and HVLs [196], [197]. In addition, Figure 13 shows the various photon
interaction coefficients for Dry Air and Soft Tissue (ICRU-44), calculated using XMuDat
software (InternationalAtomicEnergyAgency−NuclearDataSection, V ienna,Austria)
[189] . The table in Figure 14 summarizes the resulting dose calculation coefficients needed
for determining absorbed dose in tissue, including calculations for HVL, mean and effective
energy, and their corresponding mass-energy absorption coefficients [194].
Figure 13: The f-factors in Figure 14 were calculated from energy spectra generated with
Spekcalc, shown on the left [196], [197], which were used to determine the the mass-energy
absorption coefficients in XMuDat, shown on the right [189]. The resulting f-factor
calculations are used for converting converting the ion chamber in-air measurements of
exposure to dose in water [194].
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Figure 14: Dose calculation coefficients for converting the ion chamber in-air measurements
of exposure to dose in water. [188]. The f-factors were calculated from energy spectra
generated with Spekcalc [196], [197], which were used to determine the the mass-energy
absorption coefficients in XMuDat [189].
3.3.4 Irradiator linearity of current output
Absorbed dose is linearly related to the machine tube current; hence we perform
linearity of output measurements to verify the linear relationship between machine output
and current. Measurements were performed on the X-RAD 320 X-Ray Irradiator located
in Marsico B121 and under normal operating conditions on November 16, 2016. For all the
following measurements, the ion chamber was placed on 1cm of acrylic and measurements
were taken at the approximate open field isocenter at 37cm from the source. The plots in
Figure 15 show the machine output plotted as a function of the tube current at a constant
250kVp tube potential and 0.254mm Cu filtration. There is a linear relationship between
the exposure rate and current (R2 = 0.9841), where the exposure doubles as the current
is doubled, as expected. This linearity response is confirmed with measurements from
a second ion chamber (0.18cc farmer chamber). The small deviations in the linearity
measurements may be accounted for by the end effect, the amount of time that is not
accounted for by the internal machine timing mechanism during the exposures.
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Figure 15: The current-time product, in milliAmpere-seconds (mAs), is varied for different
time and current combinations and then plotted against the measured ion chamber,
in-air exposures. The linearity of output R2 value indicates the machine current output is
relatively stable. Linearity of output measurement conditions included 250kVp, 0.254mmCu
added filtration, at 38cm SSD.
3.3.5 Irradiator energy response and kVp check
Figure 16 details the energy response of the machine output. The top panel is a plot
of the machine exposure as a function of peak tube voltage (kVp). In general, the energy
response of the x-ray tube output is expected to be a quadratic function and approximately
a square of the tube voltage, where, depending on the filtration used, doubling the energy
will quadruple the measured output. For a copper filter 0.254mm thick, the measured
machine response is consistent with a fitted quadratic curve (R2 = 0.9995) and doubling
the energy from 160kVp (60.4R) to 320kVp (234.55R) yields an output 3.89 times the
initial output, just 2.9% short of the expected 4× output. The bottom panel in Figure 16
is a table of the XRad-320 X-Ray Irradiator kVp accuracy test measurements for selected
kVp tube potentials within a range of 50 to 150kVp and a fixed tube current of 1mA. All
nine measurements were within the recommended accuracy limit +/− 5% for all selected
tube potentials with a mean kVp accuracy of 2% [198].
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Figure 16: (Top) The machine energy exposure response was measured by varying the tube
potential while maintaining the current constant. (Bottom) A kVp check of the XRad-320
Irradiator was performed to verify the accuracy of the selected kVp against actual kVp
measurements.
3.3.6 Radiation field uniformity- flatness and symmetry
Looking at the wide field uniformity, namely via calculations of the field flatness and
symmetry, will help determine the optimal SFRT collimator positions for achieving the
most uniform beams possible. Point measurements along the x- and y-axis were made
to determine the cross-beam profiles of the generated x-rays for an open, 18cm x 18cm
field (with the large collimator in the fully open position) at 38cm axial distance from the
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source. Shown in Figure 17, the ion chamber was positioned at several points within the
irradiation chamber along the x- and y-axis, approximately 2cm apart.
Figure 17: The large-field radiation beam profiles were measured through the central
beam axis along the vertical, y-axis (back-to-front) and horizontal, x-axis (left-to-right)
directions and subsequently plotted. Each ion chamber measurement lasted 20seconds and
was completed under standard conditions (320kVp, 12.5mA, Cu0.254m added filtration).
For our study, the reference region of flatness is defined as the region extending from
the central axis outward up to 2cm from the field edges to exclude penumbral effects of
the outer beam [187]. In Figure 17, the reference region for calculating beam flatness is
defined in light blue. Along the x-axis (as measured from left-to-right within the chamber)
the flatness differed from measurements at the central axis of the field by as much as
+3.76% (at -6cm from the central axis, 38cm from the source.) Similarly, along the y-axis
(as measured from the back wall to the front chamber door) the flatness differed as much
as 3.5% (at -6cm from the central axis, 38cm from source.) Though this is not perfect field
flatness, the variation is significantly decreased nearer the central axis of the field, less
than 0.7% difference within 2cm from the central axis in all directions. To determine field
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symmetry, the x- and y-axis profiles are folded at the field center and the two halves are
compared. The field symmetry varies from the central ray as much as 3.3% for the x-axis
and 2.6% for the y-axis at the outer edges of the radiation field. Again, the field symmetry
increases closer to the central axis, and at 2cm is only 1.1% different from the isocenter.
3.4 Relative Dosimetry
Measurements of absolute exposure (or dose) via ion chamber are the gold standard in
radiation therapy due to their low energy dependence, real-time measurement capabilities,
and reliability for use in repeated measurements. However, while extremely valuable
tools for large field clinical dosimetry, when it comes to their use in preclinical SFRT
dosimetry, ion chambers are severely limited in their ability to measure regions of
high-gradient fields. Even the smallest ion chambers lack the high spatial resolution
necessary to measure sub-millimeter beam widths of our preclinical SFRT collimators in
real-time while maintaining charged particle equilibrium [187]. Among the many challenges
impeding the widespread clinical translation of SFRT technology is the lack of a suitable
radiation detector and overcoming this barrier is instrumental to advancing preclinical
SFRT research. Other types of radiation detectors for performing relative dosimetry
include semiconductors, thermoluminescent dosimeters (TLDs), radiographic film, and
the novel NanoFOD fiber-optic detector; however, each come with their own limitations,
including accuracy and precision, energy response, dose or dose-rate dependence, directional
dependence, spatial resolution, and real-time (or timely) dose read-out, among others.
In these next sections, I will describe these alternative measurement methods, and their
benefits and flaws in relation to this body of work.
3.4.1 Relative dosimetry using film
Gafchromic film is one of only a select few radiation detector types that are readily
available and meet some of the requirements for use in SFRT dosimetry. With a very
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high spatial resolution (25µm or less [199]) and low energy dependence of < 5% in the
100keV – 18MeV photon range [199], it is the most commonly used relative dosimeter
type in preclinical SFRT research [181]. Gafchromic film dosimeters contain a layer of
“photo-monomer molecules” in the form of a gel that undergoes self-polymerization chemical
changes when exposed to high energy photons such as those in ionization radiation [199],
[200]. Gafchromic EBT-3 film consists of a thin active layer of the polymerizable gel, 28µm
thick that is sandwiched between two layers of a clear polyester base, 125µm thick [199].
In addition, the gel polymers are largely insensitive to low-energy radiation such as visible
light and develop without post-exposure treatment since they do not require any special
wet chemical processing. However, EBT-3 Gafchromic film requires a lengthy development
time that may take anywhere between 4hrs – 48 hours [199] . This lack of timely dose
readout makes it less than ideal for fast-paced, practical SFRT dosimetry and research.
Nevertheless, the high spatial resolution capabilities of film dosimeters make using them a
practical method for SFRT dosimetry.
3.4.2 EBT-3 film calibration
Accurate EBT-3 film dosimetry first requires the film to be calibrated against an
ion chamber to establish a film-dose response curve. The film is cross-calibrated with
the ion chamber in large-field conditions, without any SFRT collimators in place, and
the irradiator is operated under identical conditions as those used during treatment, (at
full power using 320kVp anode voltage, 12.5mA current, and with 0.254mm Cu copper
added filtration). A sheet of film is cut into rectangular pieces, approximately 3cm x 2cm
area, using a precision paper cutter to minimize damage to the outer edges of the film
(since frayed film edges are known to result in erroneous measurements.) In addition, the
film orientation is recorded and maintained (relative to the original uncut sheet) for all
exposures, handling, and film readout as any changes in the film orientation may result in
measurement error [199].
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Film calibration setup is shown in Figure 18, a film piece is carefully placed on top of
water-equivalent bolus material and directly beside the ion chamber, at a height matching
the approximate center of the ion chamber’s sensitive volume such that ion chamber
readings would very closely correspond to the film results. In addition, these are all
placed onto a metal z-axis stage for adjusting the height of the detectors for specific
source-to-detector-distances, with a 1cm-thick acrylic slab placed between the detectors
and stage to minimize backscatter from the metal. The film is then irradiated for a
pre-determined length of time, the ion chamber reading is recorded, and the film piece is
removed and stored in the dark for readout later, taking care not to disturb the exposure
setup. This procedure is identically repeated for each new piece of unirradiated film,
varying only the exposure time, for accurate and reproducible film dosimetry. We limit
film exposures to the optimal dynamic range of the EBT-3 film, between 0.2Gy – 10Gy
[199], [200].
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Figure 18: Different components of the EBT-3 film and nanoFOD detectors setup for
cross-calibration with ion chamber (IC). The EBT-3 film (1) and nanoFOD scintillator
tip (2) are both placed on top of water equivalent bolus material (3) and directly next to
the ion chamber (cross-sections of each are visible) (4). In addition, these are all placed
onto a metal z-axis stage for height adjustment with a 1cm-thick acrylic slab (5) placed
in between for limiting the photon backscatter from the metal stage. The figure insert
shows a piece of film (sitting above a piece of water-equivalent bolus) placed next to the
ion chamber, as viewed from above.
For film readout we adhere to scanner and EBT-3 Gafchromic film manufacturer
recommendations [199]. Film is read out using a 48-bit RGB flatbed photo scanner
(such an Epson 10000XL or similar model with transparency adapter) and takes place
approximately 24hrs post-exposure (exact time post-exposure is recorded). The film are
handled with gloves and any smudges on the film are gently removed using alcohol wipes
prior to scanning. After the scanner has been warmed up, according to manufacturer
instructions, the film are placed in the center of the sensitive area of the scanner and then
scanned with all image and color correction features turned off using 72dpi resolution and
48-bit color settings. The scanned film images are saved as TIFF files due to their lossless
“deep color” formatting, retaining the 16-bit RGB color components need for triple channel
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dosimetry.
Figure 19, bottom, shows a complete film calibration set. The calibration regions of
interest are shown as blue dotted rectangles are shown below the calibration curve. Figure
regions of interest are selected near the center of the film, with a 2mm margin from the
edge of the film where the dose is most uniform. The digitized film transmission values
for each 16-bit color channel (red, green, and blue) are averaged within the regions of
interest using ImageJ (NIH public domain, MD, USA) and plotted against their respective
ion-chamber-derived dose values to create the three separate film dose response curves,
shown in Figure 19. The dose measurement points are fitted to an interpolating polynomial
to create a continuous curve. A Matlab [103] script was written to perform automatic dose
conversion calculations from film transmission value input. The film calibration is valid at
a specific point in time and requires re-calibration at minimum every 6 months or sooner
based on film storage conditions or machine changes. The red channel is used for dose
calculations up to 10Gy due to its high sensitivity to changes in dose (This determination
is based on the red channel’s observable steep dose response curve).
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Figure 19: (Bottom) EBT-3 film pieces are calibrated against an ion chamber and scanned.
The dotted blue lines indicate regions with 2mm margins in the center of each film that
are used for computing the average film-response for a given energy. (Top) The resulting
film dose-response curves are plotted and used for converting film readings to dose.
3.4.3 Film limitations
Given the limited dynamic range of the film, we are limited to exposures within
0.2Gy =< x >= 10Gy. These values are simultaneously greater than the minimum/valley
dose of some of our SFRT treatments (at the lower end of the film dynamic range) as
well as less than the peak dose of the SFRT treatments (at the higher end of the dynamic
range.) Therefore, overcoming this film limitation requires careful dose-rate calculation
and extrapolation to determine the peak and valley doses of our SFRT treatments. To
determine the valley dose in the 300µum SFRT collimator, film is intentionally over-exposed
in the peak region so as to bring the valley dose film regions up to within the dynamic
range of the film, ideally somewhere along the steepest portion of the calibration curve.
After scanning the resulting film, the measured dose in the valley region is divided by
the recorded total exposure time to determine the valley dose-rate. Similarly, to measure
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the dose in the peak regions of the SFRT beams, the film is intentionally under-exposed
in the peak region so as to lower the peak dose to within the dynamic range of the film.
After scanning the resulting film, the measured dose in the peak region is divided by the
recorded total exposure time to determine the peak dose-rate. These two measurements
of peak- and valley- dose rate combined help determine the peak and valley doses for a
treatment with a given exposure time.
3.4.4 Film dosimetry for SFRT
After positioning the SFRT collimators, 3cm × 4cm rectangles of ETB-3 film are
irradiated under the area defined by the collimated beams. Of specific interest are
measurements of the SFRT beam profiles, the profile of irradiation perpendicular to the
radiation beams, and their percentage dose distribution in depth, the profile of irradiation
parallel to the radiation beams. Shown in Figure 20, this is achieved by tightly sandwiching
a piece of film between two identical 3cm× 3cm× 4cm solid rectangular acrylic prisms
that act as phantom for the percentage depth dose film measurement. For this depth
dose measurement, the film is positioned edgewise, both parallel to the collimated rays
and centered along the lateral profile of the beams. Additionally, a second piece of film
is fixed to the top of the acrylic phantom (acrylic-film-sandwich), placed perpendicular
to collimated rays and centered over the percentage depth dose film. In the figure, the
approximate location of the percentage depth dose film underneath the beam profile film
is indicated by the red line. The film setup is then aligned with the collimator and source,
then irradiated. The process described above for measuring SFRT beam profiles and
PDDs is repeated for all collimators as needed for beam profile or percentage depth dose
measurement.
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Figure 20: The SFRT beam profile is taken perpendicular to the lateral direction of the
SFRT beams. The SFRT PDD measurements are calculated for up to 2cm depth along
the direction of the beam. RED drawings on film indicate location of Beam Profile and
PDD measurements. Similar measurement procedure is followed for all other SFRT beam
patterns.
3.4.5 Relative dosimetry using the NanoFOD
In addition to using film, we use a second, efficient dose measurement technique for SFRT
using a new technology based on nano-scintillator fiber-optic detector (nanoFOD), created
in conjunction with Duke University Department of Medical Physics. The nanoFOD system
successfully achieves real-time dosimetry measurements by simultaneously employing an
integrated positioning stage and automatic dose-rate integration script. In addition, the
nanoFOD is a portable, low-cost, real-time high-resolution dosimeter, which is particularly
useful for research labs such as our own. In addition, the 20-um-sized detector tip makes
it especially suitable for measurements of the peak dose of our smallest SFRT beams and
the beam profile [201].
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Shown in Figure 21, this device uses inorganic nano-crystalline (Y1.9O3, Eu0.1, Li0.16)
powder that is compressed into an 20µm-sized pellet and attached to one terminal of a
60µm UV/Vis Optical Fiber (LEONI Fiber Optics, Inc) [202]. The scintillating pellet
consists of highly sensitive photon absorbers in the x-ray range, with emission spectra that
peak at 611nm, well within the visible light part of the electromagnetic spectrum. The
emission photons travel down the fiberoptic cable, which is coupled to a S150C compact
silicone photodiode power sensor, selected for fiber-based optical power measurements
in the wavelength range 350-1100nm and optical power range 50nW-5mW, for photon
detection [201], [202]. The output is then read out by a PM100USB Power and Energy
Meter Interface which is operated and powered via PC [201], [202]. A standard laptop is
used for all data collection and display. In addition, the optical fiber is coated with black
paint to attenuate signals from ambient light.
Figure 21: A (2) 20µm-wide, inorganic, nanocrystalline, scintillating pellet is attached to
(1) the tip of an ultraviolet/visible wavelength optical fiber (Leoni Fiber Optics). The
signal travels through the (1) fiber and is detected by a (3) S150C silicone photo-diode
and PM100USB photo-diode laser power meter (Thorlabs) and then read out using a (4)
standard laptop for data collection and display. Photo adapted from Belley et al. [201]
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3.4.6 NanoFOD calibration
With proper calibration, the nanoFOD may be used to calculate the amount of radiation
incident on the nanoparticle scintillator (measured in Gy) based on the scintillation energy
of the photo-diode (measured in Joules). Both film and nanoFOD dosimeters are calibrated
together using the ion chamber for large-field geometry as recommended by TG-61, using
the setup shown previously in Figure 18. The nanoFOD scintillation tip is placed into a
fixed position next to the ion chamber and irradiated for a predetermined length of time.
Figure 22 shows resulting nanoFOD signal after a 30 second exposure, with background
signal (from ambient light and internal component noise, shown in red) subtracted. The
area under the signal-time curve (in green) is integrated to determine the Integral Net
output value. This procedure is repeated for multiple different exposures and all resulting
integrated output values are plotted against their respective ion chamber measurements
to create the NanoFOD Response Curve, shown in Figure 22 in the panel on the right.
The linear slope of this curve corresponds to the nanoFOD calibration factor (CF (E)),
as a function of energy, and is used for converting the nanoFOD light output (L) to a
measurement of Dose (D) at a given energy using equation,
D = L× CF (E)
.
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Figure 22: The nanoFOD calibration factor, CF, is used for converting the nanoFOD light
output measurement under the radiation to Absorbed Dose in tissue (or Exposure). Once
the scintillation tip is in a fixed position, ready for measurement, the light output (J/s)
of the NanoFOD is linear with Dose (D) at a given energy. To calibrate the nanoFOD,
background signal is collected and then the beam is turned on. After subtracting the
background signal (red dotted line) the area under the signal-time curve (green shaded
area) is integrated to determine the Integral Net output value. This value is plotted onto
the NanoFOD Response Curve. The linear slope for several plotted values is calculated
and dose conversion is performed by comparing the integrated signal from nano-FOD
system (J) to cumulative exposure (R) 2% cumulative calibration uncertainty.
3.4.7 NanoFOD dosimetry for SFRT
For accurate nanoFOD positioning, especially for peak dose and lateral beam profile
measurements under the SFRT micro-collimator, the nanoFOD is attached to a
computer-controlled positioning stage, which positions the detector tip precisely under the
micro-collimator beams. Figure 23 graphically displays the measurement setup and an
example output graph is shown in the insert. Additionally, we developed a user-friendly
automatic data collection script for easy use of the nanoFOD system, shown in Figure 23.
The script controls both detector data collection, performing automatic dose conversion
for real-time readings and background measurement subtractions, as well as the
computer-controlled positioning stage, ensuring that the data and stage are synchronized.
Data collection begins with background acquisition and is followed by dose measurement.
The GUI displays dose, dose rate, position, and speed of the detector in real time, shown
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in the graphical insert (bottom right) where we compare the performance of two different
scintillator tips. Of these two tips, one displays a 910% increase in signal sensitivity
compared to an older generation detector with small crystal (purple line).
Figure 23: The nanoFOD scintillation tip is fixed to a x-y translation stage and is translated
through the lateral direction of the SFRT beams profile. A in-house written script performs
automatic data collection, background correction, data collection and synchronization
with stage translation, signal-to-dose conversion, and displays the data in real time for
quick readout.
3.4.8 NanoFOD limitations
Several limitations have been encountered with NanoFOD dosimetry that make SFRT
dosimetry challenging.
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1. The nanoFOD scintillator is strongly energy dependent; therefore, dose measurements
in the valley region of the SFRT beams are unreliable, because scattered photons in
the valley region may have vastly different energy spectra than those photons lying
directly in the path of the beam.
2. NanoFOD measurements for SFRT are only valid when the entire scintillator tip
(active volume) is illuminated; therefore, as the solid angle between the scintillator tip
and the radiation source changes, the active volume of the scintillator becomes either
only partially illuminated at the edge of the SFRT beams or completely blocked in
the valley regions directly underneath the SFRT collimator.
3. At long exposure times nanoFOD measurements undergo upwards signal drift, and
noise amplitude rises over time due to increases in natural temperature and resistance
of the detector’s internal components; therefore, a heat exchanger should be included
in future detector setups to mitigate thermal noise and related measurement error .
3.5 SFRT Dosimetry for Small Animal Studies
3.5.1 SFRT beam profiles
Shown in Figure 24, the 300µm-sized SFRT collimator dose profile was measured using
both the EBT-3 Gafchromic film and the nanoFOD detectors, and these results were
compared. In the SFRT peak regions, the film and nanoFOD largely agreed, with less
than 2% difference in measurements for the central 7 peaks. Unsurprisingly, measurements
in the valley region did not agree. This is likely due to the nanoFOD limitations discussed
earlier, namely the strong energy dependence of the nanoFOD detector as well as changes
to the percentage area activated in the scintillator as a function of position.
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Figure 24: EBT-3 Gafchromic film and nanoFOD were both used to measure the SFRT
beam profile for a multi-slit collimator with 300µm-wide peaks. The film and nanoFOD
largely agreed in the peak with < 2% difference (after correcting for upwards signal drift
due to noise). Measurements do not agree in the valley region largely due to strong
nanoFOD detector energy dependence and variability in detector scintillated active area
as a function of position. Setup conditions included a 320kVp tube potential, 12.5mA, and
Cu0.254mm added filtration.
Additional film beam dose profile results are shown in Figure 25. A variety of different
“broad beam” or large field collimators as well as SFRT collimator measurements are
included to demonstrate the versatility of the radiotherapy treatment setup. While the
primary focus of the treatment setup was to develop a system capable of delivering
spatially fractionated radiotherapy beams, an important aspect of radiobiological studies
involves comparing the SFRT treatments against their more conventional “seamless”, or
uniform, radiotherapy counterparts. The radiotherapy beam dose profile measurements are
largely taken at 320kVp; however, two plots notably contain an additional measurement at
160kVp (Figure 25-A and G). The “TBI- Large Field” and “SFRT-TBI” curves correspond
to a total body irradiation study (TBI), where the entire mouse (with dimensions
3cm-width and approximately 8cm-length) undergoes radiotherapy treatment with SFRT.
The corresponding large TBI collimators, 4× 10cm, were dosimetrically tested at both
320kVp and 160kVp to determine at which treatment energy superior SFRT beams and
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corresponding peak-to-valley dose ratios were produced for the given TBI treatment field
size requirements.
Figure 25: The measured relative beam profiles are shown for a variety of SFRT collimators.
The large variation in fractionation scale demonstrates the flexibility of the SFRT treatment
system for potentially delivering a wide range treatments for a number of disease sites.
Calibrated EBT-3 film was used for measuring the dose profiles (largely at 320kVp, 12.5mA
with 0.254mmCu added filtration.) Additional details for each collimator are shown in
Figure 26.
Beam profile measurements are useful for determining a number of dosimetric
parameters for radiotherapy treatments. Figure 26 summarizes several of the computed
dosimetric parameters for the collimator dose beam profiles shown in Figure 25. The table
in Figure 26 includes the overall field size (or span of the SFRT beams) for each of the
collimators as well as their collimator factors, ratio of the maximum (or peak) dose to the
open-field measurements under the same measurement conditions. In addition, the table
includes several characteristic SFRT parameters such as peak-to-valley-dose-ratio
(calculated as the average dose in the “peaks” divided by the average dose in the “valleys”
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of the SFRT beams), the average SFRT peak beam width (calculated as the average
full-width-at-half-maximum of the SFRT beams), the average width of the “valley”
regions, and their corresponding peak-to-peak distances. It should be noted that not all
studies used the same treatment conditions. For example, the TBI-Large Field and
SFRT-TBI dose profile measurements are at depth d = 10mm, whereas all other dose
profile measurements are at depth d = 0mm.
Figure 26: Dosimetric results for a variety of SFRT collimators used in small animal
studies. The first 4 are uniform, seamless radiotherapy collimators, intended distinguish
the effects of SFRT treatments from more conventional therapies. The bottom 4 are all
SFRT collimators varying in shape.
3.5.2 SFRT percentage depth dose
In our small animal experiments, the radiation target or region of interest may often
be tissue, lying at or just below the surface of the skin, or a tumor up to 10mm deep.
However, the dose deposited to tissue generally decreases with increasing depth, and
for larger treatment targets the tissue exit dose deposition will differ significantly from
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deposition at the tissue entrance. This depth-dependent variable dose distribution may be
characterized as percentage depth dose (PDD), defined as the dose distribution in depth





[187]. For beam energies below 400kVp such as our own, Dmax corresponds to a depth of
d = 0; however, at higher energies, the depth ofDmax may be significantly greater, d >> 0.
Figure 27 shows the PDD film measurement results for some of the various collimators
used in our radiobiological studies
Figure 27: Some of the wide variety of SFRT collimators we used in our preclinical studies
are shown. Panel ’A’ corresponding to the ”TBI-Large Field” collimator film measurement
shows both 160kVp and 320kVp PDD calculations. The size and shape of the collimator,
photon energies, and experimental setup conditions all play a role in dose depositions
in depth. Hence, film irradiated at different energies were often examined to aid in the
experimental design of a preclinical study. Percentage Depth Dose (PDD) results for a
variety of SFRT collimators that we used in animal studies.
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PDD measurements for the different collimators were largely taken at 320kVp; however,
the TBI- Large Field plot also includes a PDD measurement at 160kVp. Note the steeper
dose fall-off for the lower energy 160kVp beam. TBI treatments should ensure near-uniform
(or as uniformly as possible) delivery of radiotherapy to the entire body. As the TBI
radiotherapy beams enter the body they become attenuated by approximately 20% at the
torso exit at 320kVp and by nearly 30% at 160kVp, which demonstrates that the 320kVp
treatment energy delivers a more uniform dose. For this reason, among others, the 320kVp
treatment energy was chosen for the TBI mouse study.
3.5.3 Integral dose calculation
Some studies require knowledge of the absorbed dose in tumor and normal tissues,
integrated over their entire volumes. The volume-averaged doses are approximated by
computing the film dose within an area of 1cm× 1cm(depth) of the scanned PDD film.
Similarly, to capture the effects of the radiation on nearby tissues that may have been
exposed, the volume-averaged tissue dose is approximated by computing the film dose
average within a 2cm × 2cm(depth) of the PDD film, as shown in Figure 28. The
Trapezoidal Riemann summation method is used to approximate the area under the
definite integral along both dimensions of the 2D film-dose response surface shown, giving











Figure 28: Integral dose was determined for specific depths in tissue from Percentage Depth
Dose (PDD) film measurement results and were computed using an in-house generated
Matlab script (Mathworks, Natick, MA) [103]. The top panel shows a 2Dimensional dose
intensity map (with x-dimension in cm, z-dimension in cm, and y-dimension displaying
the radiation intensity (Gy) of the 2D film PDD measurements for the 300µm peak width
collimator. The integral dose is calculated in depth, shown in the middle panel, and the
Riemman summation method is used to compute the definite integral for the area under
the 2Dimensional curved dose surface of the PDD film.
3.6 SFRT Delivery System
SFRT radiobiological studies are ready to begin after completing dosimetry.
Standardized protocols, located in the Appendix, were created for consistent, repeatable
treatment system setup and animal alignment and to enable reliable radiotherapy delivery.
Figure 29 shows the full SFRT treatment system setup. The external beam x-ray source
(1) produces a large radiation field that is attenuated by one of the custom Cerrobend
collimators (2). The position of the collimator with respect to the x-ray source is
determined via a built-in light field in the XRad irradiator and the dosimetry
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measurements. Once the optimal position is identified, the collimator is fixed onto the
custom-made stationary shelf. The animal stage is positioned below the stationary
collimator and shielding blocks. Both the animal and tumor (4) are aligned with the
source-collimator setup using the beam’s-eye-view PC-linked camera (3) as well as the
rotable platform and z-stage for angle and height adjustment (5). Live video feeds via a
second PC-linked endoscopic camera will be used for animal tumor alignment as well as
monitoring vitals throughout the procedure.
Figure 29: The SFRT treatment delivery system includes (1) the uncollimated
treatment source, (2) a live-video feed endoscopic camera that is angled for target
viewing and alignment, (3) a lead-alloy collimator and other shielding placed onto an
alumninum-reinforced acrylic shelf, (4) a second PC-linked endoscopic camera placed
close to the anesthetized animal for treatment monitoring, as well as (5) the height- and
angle-adjustable platform for animal positioning under the collimated radiation field.
Prior to irradiating the animal, radiochromic film is placed over the tumor/radiation
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target, directly on top of the skin. This is to verify tumor alignment with radiation field
during treatment. This film is intended as a second method to verify post-treatment
that the radiotherapy beams were aligned with and delivered to the target as intended,
though the treatment-verification film has multiple other uses. If any target motion occurs,
this may be indicated on the treatment-verification film. Treatment-verification film also
ensures that there were no off-target or otherwise unintentional exposures during the
course of treatment. These films serve as treatment documentation, for record-keeping
purposes, and may be re-examined at a later date if necessary.
3.7 SFRT Delivery System Limitations
Despite the great care and consideration taken for several possible factors that may
affect our radiation treatments and setup, there are still several important limitations. First,
there is no on-board imaging available for this treatment machine or setup. Clinically,
on-board imaging is used regularly and has proven incredibly beneficial for accurate
treatment delivery. However, delivering accurate treatments to targets such as tumors
or specific internal organs without on-board imaging is very difficult and subject to high
incidences of off-target treatments, such as the one shown in Figure 30.
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Figure 30: Several challenges were encountered during SFRT delivery system design.
Examples of some of these challenges include off-target treatment failure due to a lack
of pre-treatment imaging for precise targeting of the SFRT beams to the treatment site
and beam smearing caused by animal cardiac or respiratory motion. These challenges
were met with creative solutions for overcoming them, involving a combination of several
techniques, including developing strategies to minimize their impact such as selectively
choosing treatment sites that are distant from motion-causing organs, placing a PC-linked
endoscopic camera near the target for target viewing and alignment, and trial and error,
among others.
To overcome this limitation, we use several techniques to ensure that we have a high
probability of hitting our target. We include a 5mm margin around all gross tumor (or
other target) areas to account for variations in shape and position of the target during
treatment and decrease the probably of treatment failure. While this inevitably may
sub-optimally expose more normal tissues to high doses of radiation, we look to decades
of preclinical data that have demonstrated the preferential normal tissue sparing effect
and safety of high dose SFRT. Additionally, whenever possible, we use externally visible
anatomic markers to identify regions of interest. For example, when targeting a mouse
brain for a whole brain irradiation treatment (with rodent lying prone and viewed in the
frontal/coronal plane), the mouse cerebellum within the skull very reliably lies inferior to
ocular cavity and superior to the ear lobes, a section approximately 1cm long. Furthermore,
when viewed in the sagittal plane, the brain reliably occupies half the cranial cavity, lying
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inferior to the esophagus/oral cavity. For superficial solid tumor tissues we physically
palpate the tumors to identify tumor/normal tissue boundaries and delineate them with
permanent marker to visually define them for treatment. In addition to visual external
markers, we use a PC-linked live video feed from a small endoscopic camera with a near
beam’s-eye-viewing angle help align the target with the radiation light field. Finally,
the post-treatment verification film is used to verify that we delivered the intended dose
to the target as described earlier. However, with no access to onboard imaging, or live
video-rate CT, x-ray imaging of the treatment, or in vivo during treatment, we have no
way of knowing what the animal organs look like or where they are at any given time,
so it is nearly impossible to avoid them. Though on-board imaging would be ideal, our
error is mitigated with visual and technological tools, and when error occurs, it is reliably
identified with post-treatment verification radiochromic film.
A second limitation to our SFRT treatment setup is that all dosimetric calculations
do not consider potential effects from cardiac or respiratory motion. Shown in Figure 30,
motion blur has the unintended consequence of smearing the sub-millimeter treatment
beams and reducing the peak dose while increasing the valley dose such that the delivered
dose more closely resembles a conventional radiotherapy treatment, effectively eliminating
the potential impact of SFRT. For this reason our radiobiological studies primarily focus
on treatment targets that are distant from the source of organ motion, near the animal
pelvis or head/neck area. In addition, animals are immobilized as much as is feasible
during treatments without restricting breathing. However, even after immobilization and
controlling for disease site, there may still be some organ motion effects beneath the skin
to consider; therefore, the 5mm margin around the radiation target may also help account
for any resulting variation in target shape or position in addition to limiting the target size
to fit within this margin. Developing creative solutions to overcoming some of these design
and implementation challenges or minimizing their impact is essential for successfully
carrying out SFRT treatments.
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A third limitation in our SFRT delivery system is the limited treatment planning
techniques we have available. While we do have a treatment planning method that uses
a combination of dosimetry, modeling on matlab, visual image alignment, etc. these
methods do not allow for accurate dose delivery and do not provide dose volume histogram
information. However, we do not expect this limitation to impact any of the final study
results as these are limitations that affect all study arms throughout each of the studies
and not on any specific study arm.
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CHAPTER 4: CONVENTIONAL DOSE RATE SPATIALLY
FRACTIONATED RADIATION THERAPY TREATMENT RESPONSE
AND ITS ASSOCIATION WITH DOSIMETRIC PARAMETERS – A
PRECLINICAL STUDY IN A FISHER 344 RAT MODEL
4.1 Overview
Previously, we demonstrated the feasibility of creating a compact and low-cost spatially
fractionated radiation therapy (SFRT) delivery system for use in advancing preclinical
SFRT research. Despite deades of research shoing that SFRT has an enhanced therapeutic
ratio over conventioanl radiotherapy, SFRT remains poorly understood, which hinders its
broad clinical translation. One front to advance wide-spread clinical translation of this
approach is to identify key SFRT dosimetric parameters that have close associations with
treatment outcomes in the hopes of gaining a better understanding of SFRT.
This chapter has been submitted for publication in PLOS One and is in review at
the time of this writing2. I have included the study here in full and have additionally
incorporated several additional figures (Figures 41, 45, 46, and 36) of statistical analysis
results as well as their accompanying text throughout the Methods, Results, and Discussion
sections. These are included only to elaborate on several ideas presented throughout the
paper that was originally condensed for publication.
2This chapter has been submitted as an article in the Journal PLOS One. The original citation is as
follows: Rivera JN, Kierski TM, Kasoji SK, Abrantes AS, Dayton PA, Chang SX, Conventional dose rate
spatially-fractionated radiation therapy (SFRT) treatment response and its association with dosimetric
parameters – A preclinical study in a Fisher 344 rat model. PlosONE. 2020 [Manuscript In Review]
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4.2 Introduction
Spatially-fractionated radiation therapy (SFRT) is a nonconventional radiation
therapy that is characterized by intentionally-created high dose inhomogeneities,
ultra-high maximum doses, and single fraction treatments [70], [97]. The dose
inhomogeneity consists of many small sub-regions with alternating high and low doses
throughout the treatment volume. SFRT includes clinical GRID therapy [70], [77] and
preclinical microbeam radiation therapy (MRT) [203], each of which of has a decades-long
history demonstrating its superior therapeutic ratio compared to conventional radiation
therapy, especially in terms of normal organ sparing. Detailed summaries can be found in
two recent reviews by Billena and Khan [204] for GRID therapy and by Eling et al. [203],
[205] for MRT. Today, there are a number of modern treatment delivery technologies
available for clinical SFRT including multi-leaf collimator generated GRID [96],
LATTICE [88], [100], [206], Tomotherapy [204], and particle GRID therapy [207], [208].
For preclinical SFRT, newer technologies include “minibeams” with larger spatial
fractionation scales (on the order of millimeter instead of the tens of microns used in
classical MRT) [209], [210] and with conventional dose-rates [180], [186]. Most published
MRT research utilized brilliant x-rays generated from synchrotron accelerator facilities
with ultrahigh dose rates [203]. The conventional dose rate SFRT radiations, such as the
ones used in this study, are highly relevant to translational research for LINAC-based
SFRT clinical applications, where conventional dose rates are also used.
Despite the long history and well demonstrated therapeutic ratio advantage over
conventional uniform dose radiation therapy, SFRT remains an experimental therapy.
There are several reasons attributed to the sluggish clinical translation progress including
a lack of understanding of SFRT working mechanisms and of the association between
SFRT treatment response and dosimetry. While we have verified treatment dosimetry
and tumor control outcome correlations for conventional radiation therapy (i.e., tumor
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minimum dose and Equivalent Uniform Dose (EUD) are closely correlated with tumor
control) [211]; however, we do not yet have such understanding for SFRT, which has
significantly more complex dosimetry than that of conventional radiation therapy. Unique
SFRT dosimetric parameters that describe the dosimetry include peak dose, valley dose,
peak-to-valley-dose-ratio, peak width, valley width, and percentage tumor volume directly
irradiated. It is reasonable to assume that not all these dosimetric parameters have
the same clinical significance. To effectively advance SFRT clinical translation it is
critically important to identify which parameters have strong/weak associations with a
given treatment response.
The goal of this study is to identify key dosimetric parameters that are most closely
associated with treatment response using a preclinical animal model. We hypothesize
that while peak dose has always been used to prescribe SFRT treatment for both clinical
and preclinical applications, peak dose may not be the dosimetric parameter most closely
associated with SFRT tumor control or treatment toxicity. If it is not, which SFRT
dosimetric parameters are? Further, we ask that, for a given pattern of SFRT treatment,
what is its conventional radiation therapy equivalence for a given treatment response? The
answers to these questions are crucial to advance clinical translation of SFRT. Unfortunately,
decades of synchrotron-based MRT studies may not be able to answer these questions due
to the use of ultrahigh dose rates (1000sGy/sec) [212]. Recent research on FLASH radiation
has shown that radiation with dose-rates of 100Gy/s or higher selectively spares normal
tissue not tumor [203], [213], [214]. This new finding revealed that the ultrahigh dose-rate
alone is partially responsible for the observed high therapeutic-ratio demonstrated in the
majority of SFRT research published so far [203]. This study will help discern the impact
of radiation spatial fractionation at dose rates relevant to clinical SFRT treatments.
Today, SFRT is receiving much deserved renewed attention and enthusiasm in the
field of radiation oncology. In 2018 National Cancer Institute and Radiosurgery Society
jointly held the first workshop on Understanding High-Dose, Ultra-Dose-Rate and Spatially
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Fractionated Radiotherapy and created three standing working groups (clinical, biology,
and physics) aiming to provide guidelines on SFRT research and clinical application [215].
We hope this work will assist in this endeavor by shedding light on the clinical impact of
SFRT dosimetry parameters.
4.3 Materials and Methods
4.3.1 Study design
The secret of SFRT lays in its radiation dose spatial fractionation. Although this work
does not address the very much needed understanding of working mechanism it addresses
another important matter for SFRT application - the association of SFRT dosimetric
parameters with treatment response at conventional dose rates (dose rate ranges from 4.27
to 5.25Gy/min was used). Figure 31 shows a six-arm study design using a very large span
of radiation spatial fractionation, constructed to explore the impact of radiation spatial
fractionation. The table in Figure 32 summarizes the dosimetric parameters of each of
the six arms. To study the effect of radiation spatial fractionation under the condition
of equal volume-averaged dose we used the following four study arms: 20GyUniformRT
(entire tumor directly irradiated), 20GyHalfRT (only one-half of tumor directly irradiated),
20Gy2mmSFRT (50% of tumor directly irradiated by 2mm-wide planar beam array),
and 20GySFRT (20% of tumor directly irradiated with 0.3mm-wide planar beam array).
Note that the doses are volume-averaged doses computed for the entire tumor volume. A
50GySFRT arm (50Gy volume-averaged dose, beam width 0.31mm) is added as it has a
peak dose of 225Gy, which is within the known minibeam peak dose range showing tumor
control. To account for unavoidable variations in tumor position under the 20Gy2mmSFRT
treatment beams during animal irradiations, we computed the maximum and minimum
beam coverage positions and calculated their corresponding dosimetric specifications. The
20Gy2mmSFRT treatment arm dosimetric values reported in Table 1 correspond to the
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average at these positions for a 10mm diameter tumor. For example, a 10mm sized tumor
is irradiated by at most three 2mm-peaks and at minimum two 2mm-peaks and the average
dosimetric parameter at these two positions was calculated.
Figure 31: A very large range of radiation spatial fractionation scale was used to derive the
impact of radiation spatial fractionation. Four arms share the same 20Gy volume-average
dose. The high dose 50GySFRT arm is added because 20GySFRT is not known to have
tumor control. The dosimetric parameters studied and number of animals per study arm
are listed in 32.
Figure 32: Summary of nine SFRT dosimetric parameter specifications in the six-arm
study.
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Custom-made radiation blocks and collimators made of Cerrobend or tungsten were
used to define the 2cm× 2cm field for 20GyUniformRT arm treatment, the 2cm× 1cm
for 20GyHalfSFRT treatment, and the beamlet array 2cm × 2cm fields for both the
20Gy2mmSFRT and 20Gy/50GySFRT treatments. The 2cm field size in the direction of
the uniform dose within each of SFRT planar beams is made possible by the very large
focal spot size (8mm2) of the XRad irradiator (Precision X-ray Inc., North Branford, CT
USA). All irradiations in this study used the same irradiator.
4.3.2 Animal tumor model
This study was carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health
(NIH). The University of North Carolina- Chapel Hill Institutional Animal Care and Use
Committee (IACUC) reviewed and approved the animal protocol (IACUC ID: 15-366.0)
in accordance with NIH standards. All animal surgical, radiation, and imaging procedures
were performed under general anesthesia and all efforts were made to minimize suffering.
Forty-two eight-week-old female Fischer 344 rats from Charles River Labs and rat
fibrosarcoma tumor allografts were used [216]. The rat fibrosarcoma (FSA) allograft
model has been well characterized in several radiotherapy response studies by our and
collaborator labs [216]–[218]. Rat FSA is characterized as a local, non-metastasizing tumor
that is highly vascular and oxygen dependent [219], [220]. It is an appropriate tumor
model for our long-term study goal that investigates the association of SFRT dosimetric
parameters with treatment responses, which is reported here, and the association between
SFRT treatment response and tumor vascular change post radiation using 3D acoustic
angiography. The latter is ongoing research for future publication.
All surgical, radiation, and imaging procedures were performed under general anesthesia,
induced in the animals initially using 5% vaporized isoflurane mixed with pure oxygen as
the carrier gas and then maintained at 2.5% isoflurane mixed with pure oxygen throughout
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each procedure. Depth of anesthesia was monitored by toe pinch reflex and breathing
rate. Opthalmic ointment was placed on the animal’s eyes during anesthesia to provide
lubrication and body temperature under anesthesia was maintained via electronically
controlled heating pad. Tumors were grown in each rat by implanting freshly resected tumor
tissue (1mm3) that was harvested from tumor-bearing donor rats into the subcutaneous
space of the rodent flank using blunt dissection. Postoperative care included daily incision
surveillance, body temperature monitoring, and a water bottle containing 6mg/mL
cherry-flavored, dye-free children’s Tylenol diluted in water for a minimum of 24-hrs
post-surgery to alleviate any associated pain from the implantation procedure. Animals
were used for experiments 2-3 weeks post-implantation, when the tumors reached the
target RT treatment size of approximately 5-10mm.
In preclinical studies the pre-treatment tumor volume is known to be strongly correlated
with treatment tumor control [216]. We minimize this unwanted effect by controlling the
pre-treatment tumor volume in a randomized, matched group study design. We binned
animals according to their pre-treatment tumor volume and then randomly assigned these
matched bins of animals such that at least one animal from each bin is assigned to each
treatment group. This technique resulted in an average initial tumor volume across groups
of 566± 47mm3 on RT treatment day. Biological variability was minimized by ordering
animals from the same vendor and of the same age (6 weeks old), implanting tumor on
the same day and from the same donor animal, treating with radiation on the same day,
and housing animals in the same Vivarium location with identical husbandry conditions.
All animals (mixed caged) were provided identical standard laboratory rodent diets of
(23% > crude protein) and water ad libitum throughout the study. In addition, all animal
diets were supplemented with high-calorie, nutritionally fortified water-based gel cups to
help mitigate any potential significant weight loss and dehydration post-radiation.
The animals body weight and tumor volumes are monitored prior to radiation and
every third day thereafter for up to 30 days. Study endpoints are maximum tumor burden
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(2.5cm or larger in any dimension), weight loss in excess of 15%, body condition scores [221]
less than or equal to 2, or other signs of pain, discomfort, or moribundity as recommended
by University of North Carolina- Chapel Hill Division of Comparative Medicine veterinary
staff. Animals that met study end-point criteria will be ethically euthanized primarily via
compressed carbon dioxide gas or vaporized isoflurane overdose followed by thoracotomy
as a secondary means of physical euthanasia per the approved animal study protocol.
4.3.3 Animal radiation dosimetry
XRad Irradiator and 320kV x-rays were used in this study. Surface dose rates ranging
from 4.27 to 5.25Gy/min were used for all study arms. Figure 33 shows the treatment
setup, the radiation light field on animal seen by the camera, and treatment verification
films. Dosimetry was measured via EBT-3 film calibrated by an ADCL-calibrated ion
chamber under large field conditions.
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Figure 33: Animal irradiation setup and treatment alignment and verification. (A−B)
The treatment setup components include (1) X-ray source, (2) endoscopic camera (lens
shielded), (3) field shaping collimator for all treated arms (20GySFRT shown), (4) animal
and tumor, and the (5) 3-axial heated animal positioning stage. (C) Photo of the built-in
irradiator light shines through the 50GySFRT collimator and onto the outlined tumor
as seen from the beams-eye view camera (live feed used to position tumor within the
treatment fields.) (D) EBT-3 treatment verification films with a cutout in the tumor
region. The films were reviewed for all treated animals for treatment targeting verification.
Acrylic phantom measurement setup and beam profile and percentage depth dose
(PDD) dosimetry are shown in Figs 3 and 4. The volume-averaged tumor dose was
approximated by computing the film average dose within an area of 1cm by 1cm (depth)
of the PDD film. The differential dose volume histograms of the PDD films were used for
tumor and normal tissue EUD calculations as described by Niemierko [222] using values
of a = −10 for tumor and a = 5 for normal tissue and the resulting computed EUDs are
shown in Figure 36.
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Figure 34: EBT-3 films were calibrated by ion chamber under large field conditions. All
beam profiles and corresponding percentage depth dose were measured using two films as
shown: one is on the surface perpendicular to radiation beam (A) and one sandwiched
between two small phantom blocks parallel to radiation beam (B). The circles indicate the
film areas used for volume-average dose calculation estimates. The following assumption
was made for volume-averaged tumor dose and EUD calculations: dose value does not
vary +/− 1cm along the direction parallel to the same valleys/peaks.
94
Figure 35: (A − D) Figures display the percentage depth doses for each of the 20Gy
volume-averaged treatment arms. (E −H) Figures display the corresponding SFRT beam
profiles for each of the 20Gy volume-averaged treatment arms. Note that the 20GySFRT
and 50GySFRT arms share the same SFRT collimator and thus the same relative dosimetry.
The large non-uniformity of the peak doses in the SFRT radiation is due to the finite x-ray
target size and the nondivergence of the SFRT collimator. However, the actual peak dose
non-uniformity in the treated tumor (diameter of 10mm) is within 10%.
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Figure 36: Tumor and normal tissue Equivalent Uniform Dose, EUD, calculations are shown
for the different collimators used in each of the 5 radiotherapy treated arms. EUD dose
calculation is a relatively new technique for summarizing inhomogenous dose distributions
under the assumption that they are ”equivalent” if the induce the same radiobiological
effects. EUD was calculated using the differential dose volume histogram of the PDD
film-based dose distribution and the expected number of surviving clonogens within the
tumor as described by Niemierko [222].
EUD dose calculation is a relatively new technique for “summarizing and reporting
inhomogeneous dose distributions” developed by Niemierko [222]. It assumes that any
two non-uniform dose distributions are considered equivalent if they cause the same
radiobiological effect. For calculating EUD, we estimate that the dose distribution within
the tumor does not vary significantly along the 1cm length of the tissue in the direction of
the valley or peak dose regions This allows us to compute EUD using the differential dose
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volume histogram of the PDD film (depth) as well as the expected number of surviving
clonogens within the tumor as described by Niemierko [222].
4.3.4 Animal radiation delivery and verification
All of the RT collimators were aligned with x-ray target of the irradiator using film
dosimetry. Animals were anesthetized with vaporized isoflurane mixed with oxygen carrier
gas and positioned on an electronically controlled heating pad (Figure 33, panels A and
B). For radiation tumor targeting we used the light field and a PC-linked camera before
radiation and verified it with film dosimetry during each irradiation (Fig 2, panel C). Live
video-feed from the camera was used for animal tumor-radiation alignment and for animal
monitoring during treatment. Radiation targeting is achieved by (a) delineating the tumor
boundary on animal skin using marker pre-treatment, (b) transferring the marking onto
the verification EBT-3 film taped on skin and cutting out the tumor portion of the film,
(c) taping the film back with the tumor inside the cutout, (d) placing the animal in the
irradiator and align the tumor with the radiation, and (e) animal monitoring throughout
irradiation. The treatment verification films were reviewed post-radiation for radiation
targeting documentation (Figure 33, panel D).
4.3.5 Tumor volume imaging and body weight monitoring
Three-dimensional B-mode ultrasound imaging of the tumors was performed using a
Vevo 770 preclinical ultrasound scanner (Vevo 770, VisualSonics, Toronto, ON, Canada)
and the resulting images used to calculate tumor volume, as described in a previous
publication [216]. Imaging was performed on the day before treatment as well as every
third day post-treatment for approximately 30 days, or when maximal tumor burden
was met, at which point the animals were humanely sacrificed per IACUC-approved
animal protocol. 37 shows an illustration of the 3D ultrasound tumor imaging setup
and acquisition. Three-dimensional imaging is performed by mechanically stepping the
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ultrasound probe in the elevational dimension and acquired a two-dimensional image
at each step (100µum step size, 2cm elevational scan length). The reconstructed 3D
ultrasound images were used to calculate tumor volume. The longest orthogonal tumor
dimensions in each 3D image were measured using the digital caliper feature on the Vevo
770 imaging software and tumor volume was approximated using the volume formula for
an ellipsoid, V = 43πa× b× c, where V is the calculated tumor volume, and a, b, and c
are each the half lengths of the principal axes of the tumor [223]. A sample tumor volume
change post radiation from a 20GyHalfSFRT arm animal shows no tumor control (Figure
37, panel D). Animal body weight was measured using the same schedule.
Figure 37: Figure (A) is an illustration of the 3D ultrasound imaging setup with
anesthetized animal [216]. Two-dimensional transverse image slices (B) are acquired
along the elevational direction and are then reconstructed into 3D images [224] (C).
Tumors are visually identified on the ultrasound images. Resulting 3D images (C) are
used to measure the tumor dimensions and calculate tumor volume. Imaging data is
acquired pre-treatment (D) and every third day thereafter (E −G). In images D-G the
tumor (yellow dotted line) and corresponding tumor volume grow over time following a
20GyHalfSFRT treatment.
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4.3.6 Association between SFRT dosimetry and treatment response
We analyzed the associations between animal treatment responses and each of the
nine dosimetric parameters, listed in the table in Figure 32. The treatment responses
are time-to-euthanasia, proportion of animals surviving to Day 17, and change in animal
body weight on Day 17. We deem animal survival is a better indicator of tumor treatment
response than tumor size change in this study. When tumors reach the maximum tumor
mass, defined by the IACUC-approved animal protocol, ethical euthanasia is performed.
As a result, animal numbers in different study arms decrease at different rates, which
can introduce biases due to unbalanced sample sizes in the study. Hence, Day 17 was
chosen for the linear regression association studies because at this timepoint there is a
good compromise between the number of animals available for statistical consideration
and the magnitude of radiation effects (20GyUniformRT n = 8, 20GyHalfSFRT n = 3,
20Gy2mmSFRT n = 4, 20GySFRT n = 4, 50GySFRT n = 5, Untreated n = 0). We
also fit a more robust Cox Proportional Hazards (CoxPH) model to the full data set that
includes all animals. Animal body weight change on Day 17 is used as an indicator of
treatment toxicity. Animal body weight change is a gross assessment on treatment toxicity,
especially in this study where tumors were implanted in the rodent flank, near the lower
gastro-intestinal tract (including the rodent anus, rectum, colon, and cecum) and parts of
the upper gastro-intestinal tract (including portions of the small bowel). We speculate
that some treatment arms may induce more GI toxicity that others. We subtracted the
tumor weight from the measured body weight and regard this “net” animal body weight
change as an indication, not confirmation, of treatment toxicity. To confirm any lower
GI toxicity, additional tissue histological staining or organ function examination studies
would be necessary, both of which are beyond the scope of this work.
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4.3.7 Statistical methods
We computed Product-Limit (Kaplan-Meier) Estimator and Logrank (Mantel-Haenszel)
test for statistical significance of survival difference between each pair of treatment arms
[225]. Multiple simple linear regression models [226] were used to study the association
between dosimetric parameters with animal body weight and percentage survival within
treatment group on Day 17. R2 (square of the Pearson correlation) coefficient is computed
to estimate the proportion of variance explained in each of the linear regression models. In
general, the greater the magnitude of the test statistic (t or F), the more closely associated
the dosimetric parameter studied is with the treatment response (survival or body weight).
In addition to linear regressions, we fit Cox Proportional Hazard (CoxPH) models with
individual animal survival as the time-to-event outcome, which used data from all dates
including Day 17. This allowed us to calculate the hazard ratio associated with the impact
of dosimetric parameters on treatment response. We also used hierarchical linear regression
analysis of predictors to show the association of dosimetric parameters to body weight
change as well as a Pearson Correlation matrix to show the cross-correlation between each
pair of the dosimetric parameters. All data collected were analyzed using R (version 3.5.3)
statistical software available from R Core Team [227] .
4.4 Results
4.4.1 Overall treatment response
Figure 38 shows (A) animal survival, (B) normalized tumor volume, and (C) normalized
body weight post treatment for all 6 study arms. Figure 39 also shows the non-normalized
tumor volume in units of mm3. In this study no animal died of body condition deterioration.
All endpoints were due to ethical animal euthanasia triggered by tumors exceeding the
maximum allowable burden per IACUC-approved animal protocol limitations. Our data
shows that the 20GyUnformRT arm has the best tumor control followed by the 50GySFRT
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and 20Gy2mmSFRT arms. Note that among the four arms sharing similar volume-averaged
dose (20Gy or 18Gy) survival varies greatly, from 33% to 100% on Day 17, which is a strong
indication that volume-averaged dose is poorly associated with tumor treatment response.
The tumor volume data indicate that although 50GySFRT arm and 20Gy2mmSFRT arm
have similar survival the former has a better tumor volume reduction than the latter arm.
Only the 20GyUniformRT arm experienced weight loss post-treatment and then recovered
back to pre-treatment weight after week three. The 20GySFRT and 20Gy2mmSFRT arms
experienced similar body weight gains as the untreated arm, indicating little treatment
toxicity from the two SFRT treatments.
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Figure 38: Animal survival (A), normalized tumor volume (B), and normalized
body weight (C) are shown for all six study arms. The differences between
survival curve pairs are significant (p < 0.05) for 20GyUniformRT-50GySFRT,
20GyUniformRT-20GyHalfSFRT, 20GyUniformRT-20Gy2mmSFRT,
20GyUniformRT-Untreated, 20GyUniformRT-20GySFRT, Untreated–20GySFRT,
Untreated-20Gy2mmSFRT, Untreated-50GySFRT, and Untreated-20GySFRT,
and moderately significant (0.1 > p < 0.05) for 20GyHalfSFRT-50GySFRT,
20Gy2mmSFRT-50GySFRT, and 20GySFRT–50GySFRT.
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Figure 39: Tumor volumes for all animals within each treatment arm are averaged and
then polotted over time in units of mm3. Error bars represent one standard deviation
from the mean.
4.4.2 Association between tumor response and SFRT dosimetry
We associated eight dosimetric parameters with percentage of animals surviving to
Day 17 and with the survival curves shown in Figure 38. Figure 40 shows scatter plots
of eight tumor-related dosimetric parameters vs. percentage survival at Day 17, each
fitted with a corresponding regression line, R2 (Figure 40). In addition, Figure 41 is
the table of coefficients for the corresponding liner regression models used in Figure 40.
The table contains 8 models with single covariates, one for each dosimetric parameter
and their corresponding statistics. Tumor EUD (R2 = 0.7923, F − stat =15.26*), Valley
dose (R2 = 0.7636, F − stat =12.92*), and percentage volume directly irradiated (R2 =
0.7153, F − stat =10.05*) are the top three most statistically significant dosimetric
parameters in terms of association with the animal survival at Day 17 (see Figure 41). Peak
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dose (R2 = 0.04472, F − stat = 0.6874 (not sig.)) and AVG Dose (R2 = 0.2745, F − stat =
1.514 (not sig.)) showed little association with survival.
Figure 40: Tumor EUD (A), valley dose (B), percentage volume irradiated (C), valley
width (D), peak width (E), volume-averaged dose (F ), peak dose (G), and PVDR (H) vs
survival (%) at Day 17 are presented as well as their corresponding regression lines and
R2 values. Eight linear regression models with single covariates, one for each dosimetric
parameter, were used to calculate the R2 value and corresponding statistics.
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Figure 41: Univariate linear regression analysis of Survival on Day 17.
Analyzing data for a single timepoint (Day17) is limited by animal losses at Day 17
(ie: missing data). To validate the above finding in Fig 7 we used data from the entire
survival curves in Univariate Cox Proportional Hazards analysis, a more robust statistical
model that utilizes all of the data, and the results are shown in Table 3. The results
from the Univariate Cox Proportional Hazards analysis confirms the results from the
linear regression analysis - among the eight dosimetric parameters analyzed tumor EUD
(z − stat = −4.07 ∗ ∗∗), valley/min dose (z − stat = −4.338 ∗ ∗∗), and percentage tumor
volume directly irradiated (z − stat = −3.837 ∗ ∗∗) have the closest associations with
animal survival. Compared to the linear regression analysis (Fig 7) the improved p-values
in the CoxPH model analysis is likely due to the increased sample size. The Hazard Ratio
shows the impact of change in each of the dosimetric parameters to the hazard rate (risk
of death). For instance, when valley/min dose parameter changes by 1 Gy, the hazard
rate (risk of death) changes by 19% (95% CI, 26% − 11%) with p-value of 1.44 × 10−5.
For a 1Gy change in peak dose, the corresponding change in hazard rate is 0.2% (95% CI,
0.7% - 0.3%) with p-value of 0.432. Three additional statistical tests were used to validate
the CoxPH z-test statistics results for each model (Likelihood Ratio Test, Wald Test, and
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Logrank Test) and all three tests largely agree with the results presented in Figure 42.
Figure 42: Table of coefficients for univariate Cox Proportional Hazards analysis of survival.
4.4.3 Association between body weight change and SFRT dosimetry
Eight dosimetric parameters are associated with the body weight change on Day-17.
Note that the body weight is the measured body weight subtracted the measured tumor
weight to remove the influence of tumor size on the analysis. Figure 43 is a scatter plot
of the dosimetric parameters vs. the “net” body weight at Day 17. This time point was
chosen for both the tumor and body weight study because it is a good compromise between
data statistics and magnitude of treatment response. The table in Figure 44 is a table of
coefficients for the corresponding linear regression models used in Figure 43. In general, the
greater the magnitude of the t statistic, the greater the individual parameter association
with Body Weight (Day 17). For the F-statistic, the greater the statistic value, the more
closely associated the model is with Body Weight (Day 17). Based on the t statistics and
F-statistics, among the eight dosimetric parameters studied the Valley Dose has the greatest,
yet modest, association with Body Weight (Day 17). The order of decreasing association
with the body weight change are: valley dose (R2 = 0.3814, F − stat = 13.45 ∗ ∗), valley
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width (R2 = 0.2853, F − stat = 8.783∗), peak width (R2 = 0.2759, F − stat = 8.382∗),
percentage volume irradiated (R2 = 0.1985, F − stat = 5.448∗), PVDR (R2 = 0.1203, F −
stat = 3.009(not sig.)), volume-averaged dose (R2 = 0.03308, F − stat = 0.7526(not sig.)),
normal tissue EUD (R2 = 1.022 × 10−03, F − stat = 0.882(not sig.)), and peak dose
(R2 = 5.99× 10−06, F − stat = 1.32× 10−04(not sig.)). A strong similarity between the
peak width and valley width association with body weight is expected (see discussion
in section 4.5.3.5). Further, no significant association is observed between body weight
change post radiation and PVDR, average dose, normal tissue EUD, and peak dose.
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Figure 43: Scatter plots of each of the 8 treatment dosimetric parameters: valley dose
(A), valley width (B), peak width (C), percentage volume irradiated (D), normal tissue
EUD (E), PVDR (F ), volume-averaged dose (G), and peak dose (H) vs % Body Weight
at Day 17 and their corresponding regression lines and R2 values are shown. Eight linear
regression models with single covariates, one for each dosimetric parameter, were used to
calculate the R2 value and corresponding statistics.
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Figure 44: Table of coefficients for univariate linear regression analysis of Body Weight
(Day 17)
To determine the combined effects of multiple dosimetric parameters on treatment body
weight outcomes, we tested several different multivariate models. Results for select variables
are shown in the table in Figure 45, a coefficient table of a multivariable, hierarchical linear
regression analysis of body weight on Day 17. The table contains 4 models with 2 or 3
covariates(dosimetric parameters) each and their corresponding statistics. Included in the
table are the combinations of dosimetric parameters with highest F-statistic values from
the table in Figure 44, namely valley/min dose (12.29**), valley width (5.69*), and peak
width (5.45*). The results are that body weight change is associated with Valley Dose
combined with Peak Width (F − stat = 4.466, p < 0.01) and that Valley Dose combined
with Valley Width (F − stat = 6.348, p < 0.01). This indicates that Valley dose combined
with either Peak Width or Valley Width have a significant effect on Body Weight (Day 17);
however, since Peak Width and Valley Width are co-linear (see Discussion in section 4.5),
then the combination of the 3 dosimetric parameters together results in an insignificant
test statistic and the model lose is predictive capability.
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Figure 45: Multivariate hierarchical regression analysis of predictors of Body Weight (Day
17)
Before completing the formal statistical analysis of the data, we analyze what role
both the pre-treatment body weight and pre-treatment tumor volumes have on Survival
outcomes when analyzed together with each of the other dosimetric parameters. These
results are displayed in Figure 38, a multivariate, hierarchical CoxPH coefficient table
for each of the eight dosimetric parameters studied as well as the pre-treatment tumor
volume and the pre-treatment body weight used as controls. The table in Figure 46 shows
that the Pre-TX tumor volume is associated with treatment outcome, where the row of
pre-treatment tumor volume parameter p-values across 7 of the 8 models are statistically
significant; however, the pre-TX tumor volume does not change the results shown in models
from the tables in Figures 41, 42, and 44. The two models with highest Logrank Test
values still support that Tumor EUD and Valley Dose are most significant for predicting
individual survival outcomes, while pre-treatment body weight is not a significant predictor
of survival outcomes.
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Figure 46: Hierarchical multivariate CoxPH analysis of predictors of Survival
4.5 Discussion
4.5.1 Study limitations
There are several limitations in this study, many of which are discussed below. (i)
There was no image-guidance used in the irradiation study. Our remedy for the lack of
online imaging technology included the use of light field and video-based animal alignment,
of treatment verification film, and lastly, removal of treatment-misaligned animals from the
study. This was judged from reviewing the treatment verification film for each animal. Our
remedy worked well, resulting in a 20GyHalfRT arm % volume irradiated of 47.8.8% (±2.2)
and which is near the target value of 50% and these results are shown in Figure 47. (ii)
No CT-based treatment planning. Based on the anatomical location of the implanted
tumor (rodent flank) we believe a portion of the rodent GI tract may have been irradiated
but the actual volume irradiated is unknown. Because all animals were randomized across
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study arms such that all arms have the same average pre-treatment tumor size and similar
tumor location distribution, it is reasonable to assume that any variations in portions of
GI track irradiated do not bias any particular study arm. (iii) Only a single tumor model
used. The FSA rat tumor model does not represent tumors with low vascularity, which
may have different treatment responses. The study should be repeated using different
tumor and animal models. (iv) The dosimetric parameters have strong cross correlations
in this study, which is discussed in more detail at the end of this section.
Figure 47: (A) The post-treatment verification film for a 20GyHalfSFRT treated tumor
shows that only one-half the tumor was treated as intended. The black dashed line in
the photograph was drawn to illustrate which half of the tumor was irradiated. (B) The
verification films for all 5 animals included in the study arm were analyzed by calculating
the percentage area of the tumor irradiated.
The potential impact of spatial fractionation pattern (lines vs. dots, for instance) on
treatment response is beyond the scope of this work. However, it is a very important
question that deserves methodical investigations as some spatial fractionation patterns are
easier to achieve than others in practical application. Our data shows that valley/minimum
dose has the closest association with treatment response for tumor and body weight.
However, different spatial fractionation patterns with the same valley dose may not lead
to the same treatment response when a different endpoint is used. In our study the
20Gy2mmSFRT arm and the 20GySFRT arm have similar valley doses but dissimilar
survival fraction on Day 17. To investigate the impact of radiation spatial fractionation
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pattern alone on given treatment responses, carefully designed new studies are needed.
The exciting noncytotoxic effects of SFRT, such as induction therapy to sensitize tumor
to increase therapeutic ratio of the following therapy including anti-tumor immunotherapy,
remain largely underexplored [228]; however, they are also beyond of the scope of this
work. Our own and others’ work have demonstrated that SFRT radiation impacts tumor
microenvironment and modulates immune system very differently than uniform radiation
therapy [150], [220], [229]. We intend to conduct similar studies to identify associations
between dosimetric parameters and these indirect effects of SFRT in the future.
4.5.2 SFRT dosimetric association with treatment tumor response
4.5.2.1 Valley dose and tumor EUD
The importance of tumor minimum dose to tumor control has long been established in
conventional radiation therapy [230]. Does the same association between tumor control
and minimum/valley dose hold for SFRT? For some the answer is yes and sophisticated
techniques have been developed to “fill up” the dose valleys in an MRT beam by interlacing
the microbeams from MRT from different irradiation angles. As a result, a uniform
dose distribution inside the tumor is reached [133] while the surrounding normal tissue
out of the “cross-firing” range still receive largely MRT radiation pattern of peaks and
valleys. In a synchrotron-MRT study Ibahim et al. [231] reported that valley dose
is closely correlated with cell survival, but valley dose alone does not determine the
observed radiobiological effects. Our study shows that the tumor EUD (a = −10) and
minimum/valley tumor dose have the highest linear associations (R2 = 0.7923, F − stat =
15.26∗; R2 = 0.7636, F − stat = 12.92∗, respectively) with tumor treatment response
(Figure 40, 41, and 42). This observed association between tumor treatment response with
tumor valley/minimum dose and tumor EUD dose in this preclinical study is consistent
with their known association in tumor treatment response seen in clinical conventional
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uniform dose radiation therapy. Our data suggests that valley/minimum dose or Tumor
EUD are more appropriate than peak dose for SFRT treatment prescription. When
tumor control is the endpoint, we suggest that equal valley or minimum dose be used for
comparative study between a uniform radiation and SFRT therapy or among different
SFRT treatments.
4.5.2.2 Peak-to-valley dose ratio
Our data showed that PVDR has a consistent but not statistically significant association
with tumor treatment response (R2 = 0.7194, F − stat = 7.691) (Figure 40, 41). The
linear regression analysis on day 17 was not statistically significant. The CoxPH analysis
using the entire survival data set show a modest association with survival. Although
not statistically significant, an inverse association is observed between PVDR value and
survival fraction on Day 17 - the higher PVDR value the less survival fraction. The inverse
association is largely determined by the uniform radiation arm where PVDR value is 1.0.
If this data point is removed, the PVDR association with survival for all SFRT arms is
inconclusive (Figure 40). We believe this result of inverse association is likely biased by the
study design that has very limited PVDR values (4 values) and strong cross-correlations
between PVDR and other SFRT parameters (see more discussion later in the section). A
better understanding of PVDR’s association with a given treatment response requires a
carefully designed new study that focuses on the impact of PVDR value on treatment
response.
4.5.2.3 Percentage volume irradiated, peak width, and valley width
It seems logical that tumor treatment response is closely associated with the tumor
volume irradiated. However, this is not supported by a clinical GRID therapy study by
Neuner et al. [97] where both MLC-based and collimator-based GRID treatments showed
114
similar response rates for pain, mass effect, other patient complaints, and have similar
adverse reactions. The collimator-generated GRID had 50% of the radiation field open
while the MLC-generated GRID had only 31% open. In our study the 20GyHalfSFRT and
20Gy2mmSFRT arms have similar percentage-volume-irradiated (as well as PDD curves)
but there is a difference of 5 days in the 50% survival time (Figure 31 and Figurefig:Fig6).
Nonetheless, our data shows that percentage-volume-irradiated has the 3rd highest linear
association (R2 = 0.7153, F − stat = 10.05∗) with tumor treatment response (Figure 40
and figures 41 and 34). Since percentage-volume-irradiated is jointly determined by peak
width and valley width it is understandable to see moderate associations between tumor
treatment response and peak width (R2 = 0.4201, F − stat = 2.898 (not sig.)) and valley
width (R2 = 0.4296, F − stat = 3.012 (not sig.)). In a synchrotron microbeam brain study
using multiple beams Serduc et al. kept valley dose constant while varying peak width
and peak dose. They concluded that the latter two parameters have strong influence
therapeutic ratio [129].
4.5.2.4 Volume-averaged dose and peak dose
This study is designed to scrutinize the association of volume-averaged dose with tumor
treatment response (Figure 31). The four study arms sharing very similar volume-averaged
doses (20 or 18 Gy) exhibited very different tumor treatment responses (Figure 38 and 40)
showing the survival rate at day 17 varied from 100% to 33%. Therefore, the association
between volume-average dose and tumor treatment response is weak. We found that peak
dose has little to no association with tumor treatment response (R2 = 0.04472, F − stat =
0.6874 (not sig.)) (Fig 40, Figure 41, and Figure 42). This finding is significant because
peak dose has been used for treatment prescription in practically all SFRT treatments
[88], [96]. Although the linear regression analysis on day 17 showed a weak association
between peak dose and survival that was not statistically significant, the CoxPH analysis
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using the entire survival data set did show a modest association with survival.
4.5.3 SFRT dosimetric association with normal tissue toxicity
We did not study treatment induced normal tissue toxicity directly in this study. We
used body weight change post radiation (targeted to the flank, lower abdominal region
of the animal) as an indicator, not evidence of normal tissue toxicity. We did not see a
strong association between animal body weight change and any of the eight dosimetric
parameters studied, except a modest association with valley/minimum dose.
4.5.3.1 Valley dose
The strongest association we observed is a weak one between body weight change and
valley/min dose (R2 = 0.3814, F −stat = 13.56∗∗)( Figure 44). Note that valley/min dose
is also strongly associated with tumor treatment response (R2 = 0.7636, F−stat = 12.92∗).
Our finding is consistent with a normal mouse brain MRT study Nakayma et al. reported
that valley dose is one of the important factors to determine normal brain dose tolerance
[232]. Our data suggests that valley dose may have a close correlation with both tumor
control and toxicity, and thus is a crucial dosimetric parameter in SFRT treatment.
4.5.3.2 Valley width, peak width, percentage volume irradiated
The valley width, peak width, and percentage volume of the tumor that is irradiated
parameters were only weakly associated with animal body weight change post radiation
(R2 = 0.2853, F − stat =8.783**;R2 = 0.2759, F − stat =8.382**; and R2 = 0.1985, F −
stat =5.448*, respectively) (Figure 43 and Figure 44). Note that in this study peak width
and valley width are closely correlated (more discussion on correlations, below). Percentage
volume directly irradiated showed no statistically important association with body weight
change. Neuner et al. reported that they observed similar treatment responses from
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clinical GRID treatments of different percentages of volume directly irradiated [97].
4.5.3.3 Normal tissue EUD, peak width, percentage volume irradiated
The normal tissue EUD, PVDR, volume-averaged dose, and peak dose parameters
showed little to no association with body weight change post radiation (R2 = 1.022 ×
10−03, F − stat = 0.882 (not sig.); R2 = 0.1203, F − stat = 3.009 (not sig.); R2 =
0.03308, F−stat = .7526(notsig.); and R2 = 5.99×10−06, F−stat = 1.32×10−04(notsig.),
respectively). Our finding is consistent with a rat normal brain minibeam study by Prezado
et al. showing arms with similar volume-average-doses have drastic differences in survival
(14) and inconsistent with a MRT study on normal mouse skin by Priyadarshika et al.
concluded that integrated dose (i.e., volume-averaged dose) rather than peak or valley
dose, may dictate the acute skin toxicity [233].
4.5.3.4 2mm wide beam array SFRT
Our data indicates that the 20Gy2mmSFRT arm is not only the most relevant to
clinical application because of its millimeter scale, but it also has the potential for superior
therapeutic ratio. The 20Gy2mmSFRT arm showed similar survival with the 50GySFRT
arm but has significantly lower valley dose (6.2 Gy vs. 17 Gy). At the same time, it
showed the least, if any, body weight change compared to the untreated arm while the
50GySFRT arm with 0.31mm beam width exhibited significant body weight growth deficit
(Table 1 and Fig 6). The 20GyUniform arm has the best tumor treatment response and
the worst body weight change. Our data indicated the 2mm wide beam array is a kV
photon SFRT pattern that has the potential for high therapeutic ratio SFRT and deserves
further investigation.
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4.5.3.5 Cross-correlation in the SFRT dosimetry parameters
The dosimetric parameters studied in this work are not all independent variables and
their cross-correlations are shown in the table of Pearson Correlation coefficients (Figure
48) The larger the magnitude of the coefficient, the more co-linear and correlated the
pair of dosimetric parameters. In this study, peak width and valley width are perfectly
co-linear (correlation of 1.0) by study design. Valley/min dose, a parameter used in tumor
EUD calculation, is also highly correlated with tumor EUD (correlation of 0.99). These
strong correlations explain the similar statistical associations of these parameters with
treatment responses. These correlations also limited the study’s ability to better exam the
association between a given treatment response with each of the dosimetric parameters.
For example, in Figure 48, the multi-variate analysis of predictors of Body Weight, when
both Peak Width and Valley Width and Valley Dose are analyzed together in a three
variable model, their combined effect on Body Weight Day 17 is no longer significant due
to the co-linearity of Peak Width and Valley Width.
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Figure 48: Pearson Correlation coefficient matrix for the eight SFRT dosimetric parameters
relevant for tumor treatment response.
4.6 Summary
In this conventional dose rate small animal SFRT study we used a large range of
radiation spatial fractionation scales to study the association of dosimetric parameters with
treatment response. We concluded that valley/minimum dose, tumor EUD, and percentage
tumor irradiated have strong and proportional associations with tumor treatment response
while peak dose exhibited little association. Among the SFRT dosimetric parameters
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CHAPTER 5: MINIBEAM RADIATION IS SUPERIOR TO UNIFORM
RADIATION FOR ABSCOPAL EFFECT WITH COMBINED PD-L1
CHECKPOINT INHIBITOR IMMUNOTHERAPY
5.1 Overview
Previously, we demonstrated the feasibility of creating a compact, spatially
fractionated radiation therapy (SFRT) delivery system for use in preclinical studies and
then applied it in a dosimetric parameter study of SFRT. This chapter presents a different
avenue for advancing our understanding of SFRT, using the SFRT delivery system for
investigating the advantages of SFRT in multimodality therapy approaches such as
anti-cancer immunotherapy.
Recent evidence suggests that SFRT may have different mechanisms of tumor cell
killing than conventional radiotherapy, which may include bystander and systemic immune
activating effects such as the abscopal effect, wherein the control or elimination of distant
tumors occurs subsequent to irradiation of the primary tumor. Such effects are thought to
be immune mediated and have been shown to be enhanced by immune therapy, specifically
immune checkpoint inhibition. This chapter explores the combination of SFRT with PD-L1
checkpoint inhibition in a duo-synchronous tumor model of murine mammary carcinoma.
This chapter has been submitted for publication3 in the journal Radiation Research and is
in review at the time of this writing. I have included the study here in full, with minor
changes such as including using full-color versions for all figures.
3This chapter has been submitted as an article in the journal Radiation Research. The original citation is
as follows: Rivera JN, Laemont K, Tovmasyan A, Stryker S, Young K, Chang SX, Palmer GM. Minibeam
Radiation is Superior to Uniform Radiation for Abscopal Effect when Combined with PD-L1 Checkpoint
Inhibitor Immunotherapy. Radiation Research. 2020 [Manuscript In Review]
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5.2 Introduction
Spatially fractionated radiation therapy (SFRT) includes clinical GRID and Lattice
therapy and preclinical microbeam and minibeam radiation therapy. All forms of SFRT
can be characterized by many alternating sub-volumes receiving very high dose separated
by and volumes receiving no direct radiation in a single or a few fraction treatment
[69], [204]. Impressive treatment outcomes have been reported in GRID clinical studies
demonstrating the absence of increased treatment toxicity and benefits of palliation and
local control for patients with bulky and treatment-resistant tumors, especially when SFRT
was followed by a conventional course of chemoradiation [52], [73], [97], [206], [234]. The
preclinical research also produced fascinating results on both the lack of radiation toxicity
and tumor control [70], [120], [160], [210]. Although SFRT research and clinical use have
decades of history, it remains an unconventional treatment and with limited application.
One key reason for it is the lack of understanding of its working mechanism, which not
only impacts its wide acceptance in the field but also hinders the optimization of SFRT
treatment techniques. In 2018, partnered with the Radiosurgery Society, the National
Cancer Institute created a new international working group dedicated to investigating
SFRT and the related Flash radiotherapy [215]. The working group is tasked to develop
strategies to guide the field to advance our understanding of SFRT in biology, physics,
and clinical translation of this promising radiation therapy approach. One area of special
interest that deserves more research is abscopal effect, a systemic anti-cancer effect of
localized radiation, which may be enhanced using anti-cancer immunotherapy.
We hypothesize that compared to the uniform dose radiation therapy we use today
SFRT may have advantages in enhancing anti-cancer immunotherapy. SFRT may results
in unique effects on the tumor microenvironment that in turn may result in different
mechanisms of cell killing such as bystander effects [137], [140] and effects on stromal
cells including the tumor vasculature [128], [143], [146], [150], [235]. Of interest are
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radiation-induced immunological effects which can lead to abscopal or distant tumor
responses. These have been reported in a variety of contexts involving SFRT both with
and without immune therapies [49], [123], [173], [220], [228]. For instance, Kanagavelu et
al. reported a significant growth inhibition in distant unirradiated Lewis lung carcinoma
tumors following partial volume radiation of a primary tumor, which was correlated with a
T-cell mediated immune response [173]. Clinical data also supports the efficacy of partial
volume irradiation targeting the hypoxic tumor regions specifically to elicit an immune
mediated abscopal response [136]. The leading theory is that SFRT induces a systemic
immune response that can target distant (unirradiated) tumor sites. The combination
of SFRT with immunotherapies has also been shown to have potential synergy and may
have unique effects relative to broad beam radiation therapy [45], [49], [123], [173], [220].
The high spatial dose variability in the tumor may induce unique effects by sparing some
fraction of the resident immune population while still delivering high dose [49], to elicit
the in-situ vaccine effect that has been reported for uniform radiotherapy [236]. Several
clinical studies have indicated that “the tumor can serve as an autologous vaccine through
RT-induced immunogenic cancer cell death” [237]. That is, that the radiation itself may
act to activate or enhance the host-immune response against future metastatic tumor
cells, which may lead to better long-term prognoses in patients [237]–[243]. Despite the
tremendous promise of this treatment combination, the specific immune responses elicited
are relatively poorly understood. Therefore, the goal of this study is to characterize the
efficacy of combination radiation (SFRT or uniform radiation) with anti-PD-L1 therapy,
as well as to use flow cytometry to characterize the immune cells present in the primary




In this study we aim to investigate potential advantage of minibeam radiation therapy
(MinibeamRT) over uniform radiation therapy (UniformRT) in synergistic effect with
immune checkpoint inhibitor therapy. We hypothesize that Minibeam is more effective in
activating the host systemic immune response and thus more effectively potentiating this
immunotherapeutic effect. Hence, we compare a single fraction 50Gy (peak/max dose)
MinibeamRT treatment against a 10Gy (uniform dose) conventional seamless UniformRT
treatment (both with and without immunomodulator, anti-PD-L1 antibody) delivered
to one of two tumors in a dual tumor mouse model of adenocarcinoma. The primary
endpoint for this study is tumor growth inhibition on both the irradiated and unirradiated
tumor sites.
A 50Gy peak dose was chosen for the MinibeamRT group based on our initial dose-
determination pilot study comparing single fraction 50Gy peak dose and 100Gy peak
dose MinibeamRT against a 10Gy UniformRT treatments for abscopal tumor control in
a distant, unirradiated tumor. Results from this pilot study indicated that a the 50Gy
MinibeamRT was more effective than the 100Gy MinibeamRT at inhibiting tumor growth
in the unirradiated tumor and hence potentially enabling a more robust immune response.
The table in Figure 49 shows the 5 treatment groups designed for this study, where
both MinibeamRT and UniformRT with and without immunotherapy are tested against
Control (untreated) group. Pre-treatment tumor volumes in both flanks are also reported
in Figure 49. Initial tumor size at the time of treatment is strongly correlated with
treatment outcome. Care was taken minimize this unwanted effect using a randomized,
matched study design with respect to the pre-treatment tumor volume. This was achieved
by organizing the animals into groups of similarly sized right flank tumor volumes and
then randomly assigning animals to each treatment arm within this ordered category.
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This results in similar average pre-treatment tumor volumes and size ranges in the right
flank tumors among different treatment groups; however, we have no control over the
volumes in the left flank tumors per group. To minimize the variance among the left flank
pre-treatment tumor volumes, we set minimum and maximum acceptable pre-treatment
volume limits and excluded any tumor volumes outside of this range from consideration
in the study. The randomized, matched study design technique described above resulted
in an average pre-treatment tumor volume for all right flank tumors of approximately
124mm3 (±7% standard− error) as well as an average pre-treatment tumor volume for
all left flank tumors of 132mm3(±8% standard− error).
Figure 49: Experimental design of seamless (UniformRT) vs spatially fractionated
(MinibeamRT) radiation therapy study of the systemic immune response of mice.
5.4 Animal Model Description and Cell Culture
This study was carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health
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(NIH). The University of North Carolina- Chapel Hill Institutional Animal Care and Use
Committee (IACUC) reviewed and approved the animal protocol (IACUC ID: 19-041.0)
in accordance with NIH standards. All animal radiation procedures were performed under
general anesthesia and all efforts were made to minimize suffering.
A dual-tumor model of 6-week-old female C57BL/6 mice with murine mammary
adenocarcinoma (EO771) were used in all in vivo experiments. EO771 cells were derived
from a metastatic mammary gland adenocarcinoma in a C57BL/6 mouse [244]–[246]. This
model was chosen as it is an immune competent, clinically relevant model whose
radiotherapy-induced tumor microenvironment modulation effects have previously been
extensively studied by our group [247]. This mammary gland adenocarcinoma is
characterized as a poorly metastatic, triple negative model of breast cancer.
Tumor cells were cultured in DMEM with 10% FBS (Gibco 16140071) and 1% antibiotic-
antimycotic (Gibco 15240062). Cells were injected into the subcutaneous space of both
mouse flanks such that the right flank received 250,000 cells, and the left flank received
100,000 cells. Figure 50 shows a graphical timeline of the experiment. Following cell
injections, tumors on both flanks are grown naturally for approximately 2 weeks, until the
primary tumor reach the target radiotherapy treatment size of approximately 120mm3.
Tumors on the right flank served as the “primary” tumor and target for radiation therapy,
while tumors on the left flank served as a “secondary” tumor outside the radiation field
for the purpose of evaluating the abscopal (unirradiated tumor growth control) response.
Immediately following radiotherapy treatments, animals are injected with anti-PD-L1
monoclonal antibody (BioXCell clone 10F) or Isotype control antibody (isotype control,
IgG2a). The antibody drug dose is based on our previous studies on mice, i.e. 250 µg
for a single injection. Antibodies are administered via intraperitoneal injection every 3
days beginning on the day of radiation treatment for a total of 4 injections. At 14 days
post-radiotherapy, approximately n=5 animals from each treatment group are ethically
euthanized for immunophenotyping of spleen and the irradiated and unirradiated tumors,
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per IACUC-approved animal protocol. The spleens were homogenized using a syringe
plunger and filtered through the cell strainer (40 mm, Corning, cat#431750). The red blood
cells were lysed with the lysis buffer (15.5 mM NH4Cl, 1.2 mM NaHCO3, 0.01 M EDTA).
Tumor lymphocytes were isolated using the GentleMACS dissociator, Miltenyi Biotec, in a
soluton of 0.2mg/ml DNase I, 1 mg/ml collagenase IV and 0.1 mg/ml hyaluronidase from,
Sigma. This was incubated at 37 degrees Celsius for 1 hour and then passed through a
40µM strainer, Falcon, to get single cell suspensions. Next, the cells were stained with
anti-CD16/32 Ab (BioLegend) to block non-specific binding and LIVE/DEAD Fixable
Violet Dead Cell Stain Kit (Thermo Fisher), which enables exclusion of dead cells. The cells
were stained with antibodies against CD45, CD3, CD4, CD8, CD19, CD335, CD11b, F4/80,
Gr1 and PD-1 (BioLegend) and analyzed by multiparameter flow cytometry (FACSCanto,
BD Bioscience). Analysis of data was performed using FlowJo (Tree Star).
Figure 50: The timeline of the study is shown. A single fraction radiation is given two
weeks after tumor cell implantation. Anti-PD-L1 immune drug was given in 4 fractions
starting on day 0. On day 14 tissues are harvested from n=5 animals per treatment group
for flow cytometry immunophenotypic analysis. The remaining animals are monitored for
tumor growth and the study ends on day 20.
5.4.1 Animal monitoring and husbandry
Animals were monitored before irradiation as well as every third day thereafter until
study end-point criteria were met. Study endpoints included a maximum combined tumor
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burden of 3000mm3 (or greater than 2cm in any dimension for a single tumor), weight
loss in excess of 15%, body condition scores of ≤ 2, as well as any other signs of pain,
discomfort, or moribundity as recommended by DCM veterinary staff. Animals that met
study end-point criteria were ethically euthanized via compressed carbon dioxide gas
followed by a secondary means of physical euthanasia (thoracotomy) per the approved
animal study protocol. Animal body weights and tumor volumes were recorded prior to
radiotherapy treatments as well as every third day thereafter for up to 30 days. Tumor
dimensions were measured via digital caliper and tumor volumes were calculated using





L×W ×W , as recommended
by Faustino-Rocha et al [223]. To minimize biological variability between animals and
experimental rounds, all animals were of similar age and supplied by same vendor [Charles
River Laboratories, Inc., Wilmington, MA], had a full 2 weeks to acclimate to their
environments before the start of any treatments, were injected with cells on the same day,
and were provided identical (mixed caged) housing and husbandry in a UNC Division
of Comparative Medicine (DCM) operated vivarium facility. Further, all animals were
provided with identical standard laboratory rodent diets consisting of 23% > crude
protein and water ad libitum throughout the study. To help mitigate any potential
significant weight loss or dehydration post-radiation, all animal diets were supplemented
with high-calorie, nutritionally fortified water-based gel and hydration cups.
5.4.2 Radiotherapy dosimetry and treatments
Radiotherapy treatments were delivered using a commercially available small animal
research irradiator, XRad-320 [Precision XRay, Inc., North Branford, CT], at 320kVp
and 12.5mA. Different inhouse made collimators were used to deliver both collimated
MinibeamRT and UniformRT radiation patterns to solid tumors. Figure 51 shows (A) the
results for the beam profile and percentage depth dosimetry measurements for both the
MinibeamRT and UniformRT treatments, (B) the small animal radiotherapy treatment
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system setup, and (C) an image of an 10Gy UniformRT-treated mouse example.
Figure 51: (A) Dosimetry beam profiles and percentage depth dose (PDD) for the
UniformRT and MinibeamRT treatments by EBT-3 film. The yellow dotted rectangle
represents the approximate size of a typical tumor at the time of irradiation and the
position in the treatment field. (B) The radiation treatment setup, includes [1] an external
beam x-ray source, [2] an in-house Cerrobend MinibeamRT or UniformRT collimator, [3]
a PC-linked camera provides beam’s-eye-view of the light field on animal skin, and [4] a
6-degree freedom platform for angle and height adjustment. (C) image of an animal treated
with 10GyUniformRT, photographed approximately 3 weeks post-radiation. A demarcated
square patch of white fur is visible, corresponding to the radiation field, indicating a
localized radiation-induced epidermal and fur depigmentation disorder (vitiligo). No
abscopal effect is observed in this animal.
Radiotherapy dosimetry was measured via EBT-3 Gafchromic film [Ashland Inc.,
Covington, KY] calibrated against an ADCL-calibrated ion chamber in large-field
geometry. Thte table in Figure 52 shows the relevant dosimetric parameters for the
UniformRT and MinibeamRT treatment arms calculated from the dosimetry film (Figure
51, panel A). To determine the surface peak dose and valley dose for the MinibeamRT
treatments the individual peak/valley doses are first calculated and then averaged over
the peaks that span 10mm around the center of the overall MinibeamRT field. Surface
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dose-rates are 4.27Gy/min for MinibeamRT and 5.25Gy/min for UniformRT treatments.
The volume-Averaged dose for both radiotherapy treatment types are approximated by
computing the average dose on the 10mm (width) × 10mm (depth) area of the percentage
depth dose (PDD) dosimetry film.
Figure 52: Dosimetric parameters for both radiotherapy treatment types used in the study
Both the uniform and minibeam radiation were formed by inhouse-made collimators.
A single radiation treatment is targeted to the tumors with a 5mm margin for each
radiotherapy treatment type. Radiation targeting is achieved by (a) depilating animal
flanks to locate tumors and delineating target tumor boundaries on skin using marker, (b)
transferring the markings onto a 3cm× 3cm square of Gafchromic film placed over the
tumor (for treatment verification) as viewed from the beams-eye-view frame of reference,
(c) cutting out the tumor portion of the film and placing the film back over the tumor with
the tumor inside the cutout, (d) fixing the film in place with tape and placing the animal
in the irradiator, (e) aligning the tumor with the radiation field using the built-in light
field inside the irradiator together with a PC-linked endoscopic camera live video feed, (f)
performing tumor/animal height adjustments via a manual Z- stage and angle adjustments
via rotatable heated animal platform, and (e) monitoring animal throughout irradiation via
a second PC-linked endoscopic camera. All animals are anesthetized with isoflurane mixed
with 2% oxygen carrier gas as described above throughout the tumor-to-radiotherapy beam
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alignment and irradiation procedures to minimize both stress to the animal and off-target
error due to tumor motion during radiotherapy treatment. The treatment verification film
records the targeting accuracy of the treatment and allows for post-radiation film reviewal
and documentation.
5.4.3 Flow cytometry studies and analysis methods
At 14 days post-radiation approximately n=5 animals from each treatment group were
ethically euthanized and animal spleens and both the irradiated and unirradiated tumors
were harvested for immune profile analysis, per IACUC-approved protocol. Flow cytometry
was used to characterize the prevalence of different immune cell subtypes within these
tissues. Different cell surface markers were identified using fluorescent labeled antibodies
and cells expressing defined combinations of markers could be then categorized into their
respective types. CD45 has been shown to be an essential regulator of T-cell and B-cell
antigen receptor signaling. As such, this makes it a useful selection marker for leukocytes.
Thresholding is used to identify (count) cells high in this marker. To further categorize
the leukocyte population into the primary subtypes, three additional markers were used.
CD3 is a protein that is expressed by a high percentage of circulating peripheral T cells
which makes it a highly effective T cell marker and is useful in further categorizing the
CD45+ leukocytes. CD4 is a glycoprotein commonly found on the surface of immune cells
such as the T helper cell (Th); hence, we use it in our study as a marker for T-helper
cell presentation. Finally, we use the CD8 co-receptor as a marker in our study as it is
predominantly expressed on the surface of cytotoxic T cells (Tc) as well as natural killer
cells (NKcells). Thus cells high for both CD3 and CD4 markers were counted as helper
T cells, and cells high in both CD3 and CD8 were counted as cytotoxic T cells.
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5.5 Results
5.5.1 Irradiated tumor response
Figure 53, on the left side, shows results for normalized tumor volume growth curves
for the irradiated “primary” tumors. Ethical euthanasia was largely triggered by tumors
exceeding the maximum combined tumor burden for both tumors per IACUC- approved
protocol limitations. Our data shows that conventional UniformRT groups (10Gy surface
peak dose and 9.2Gy average dose to tumor), with or without anti-PD-L1 drug, have better
tumor growth control than the corresponding MinibeamRT arms (50Gy surface peak dose
and 11Gy average dose to tumor.) The impact of anti-PD-L1 on the radiation tumor
growth control, however, are different: it suppressed tumor growth in the MinibeamRT
arms but enhanced tumor growth in the UniformRT arms.
Figure 53: Normalized tumor volume change post radiation is shown for both the irradiated
tumor (left) and the unirradiated tumor (right) in the dual tumor animal model study.
For the unirradiated tumor, the difference between the 10GyUniformRT+anti-PD-L1 and
the 50GyMinibeamRT+anti-PD-L1 treatment groups at the end of study is statistically
significant (p=0.04948). Differences between any other two groups are not statistically
significant.
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5.5.2 Unirradiated tumor response
Figure 53, on the right side of the page(B)), shows results for normalized tumor
volume growth curves for the unirradiated tumor. In the absence of anti-PD-L1 drug the
UniformRT and MinibeamRT radiation treatment to the primary tumor have practically
no impact on the secondary, unirradiated tumor, whose growth curves are similar to those
of the control arm animals. When anti-PD-L1 is combined with radiation, MinibeamRT
radiation exhibits the strongest abscopal effect, where the growth of the unirradiated tumor
is significantly reduced, especially when compared to the UniformRT+anti-PD-L1 arm
(p=0.04948). Further, the combination of anti-PD-L1 with UniformRT radiation appears
to generate a negative abscopal effect, where the tumor growth is enhanced compared to
uniform radiation alone; however, differences between these and any other two groups are
not statistically significant.
5.5.3 Spleen lymphocyte profile
Figure 4 shows the flow cytometry immune profiling data from spleen. We analyzed
CD45+, CD3+, CD4+, CD8+, B cells, and NK cells. A few clear differences are seen.
First, the CD4+ cell population is similarly elevated for both the MinibeamRT+isotype
and UniformRT+isotype arms (p=0.01322) compared to Controls, and similarly lowered
for the anti-PD-L1 with RT-treated animals, which are very similar and not statistically
significantly different from the Control arm. A similar but inverse trend is seen for the
CD8+ cells, where the control and RT+anti-PD-L1 drug combination treated animals
retained their CD8+ cell population percentages compared to Controls (and so were
not statistically significant from Controls); however, the RT-alone (without anti-PD-L1
drug) treated animals showed statistically significantly lowered levels compared to Controls
(p=0.02685 for Uniform+isotype arm; p=0.0256 for the MinibeamRT+isotype arm.) B and
NK cells may also be slightly elevated for all the treatment groups relative to the controls,
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but no statistically significant trend is seen among the MinibeamRT and UniformRT
groups.
Figure 54: Flow cytometry immunophenotypic analysis of spleen cells that are
harvested at 14 days post-radiotherapy. Approximately five animals per study
group are harvested. When statistically compared against the Control+isotype arm,
the 10GyUniformRT+isotope arm is significantly different for CD45+ (p=0.04378),
CD4+ (p=0.01322), and CD8 (p=0.02685). In addition, for CD8 cells the
50GyMinibeamRT+isotope arm is significantly different from Control+isotype (p=0.0256).
Differences between all other arms are not statistically significant.
5.5.4 Tumor lymphocyte profiles
Figure 55 shows the flow cytometry immune profiling data from both the irradiated
and unirradiated tumors. where CD3+, CD8+, and CD4+ cell population percentages are
analyzed. For the irradiated tumor, UniformRT alone (without anti-PD-L1) appears to
cause greatest depletion of the overall T-cell population (CD3+), while the MinibeamRT
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alone arm CD3+ population remained nearly same as for the Control arm. This may
indicate that MRT is able to spare some fraction of the resident lymphocyte population.
However, anti-PD-L1 drug enhanced the resident T-cell population in both radiation
groups, especially for the UniformRT group.
Figure 55: Flow cytometry immunophenotypic analysis of tumor cells harvested from the
irradiated tumor (left) and unirradiated tumors (right) of a dual tumor mouse model of
adenocarcinoma. Tumors were harvested from approximately n=5 animals per treatment
group at 14 days. Differences between all arms are not statistically significant.
For the distant unirradiated tumor, there is not a clear difference among the immune
cell populations as a whole. However, there does appear to be a trend towards higher
CD8+ cytotoxic T cells in the MRT+anti-PD-L1 group, which would indicate greater
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anti-tumor immune activity. This is also consistent with the spleen data, where the
MRT+anti-PD-L1 had the highest CD8+ T cell population among the irradiated animals.
This would indicate a greater systemic CD8+ T cell response, which has been shown to be
a critical determinant of response in several models. These observed trends are consistent
with our hypothesis that MRT induces and enhances systemic immune response. However,
the relatively large within group variance and exploratory nature of this study does not
allow us to establish statistical significance between the groups.
5.6 Discussion and Conclusions
Our study demonstrates that when combined with anti-PD-L1 therapy minibeam
radiation is superior to uniform radiation in eliciting abscopal effect. This is indicated
primarily by the tumor growth data, in which a distant tumor showed the significant growth
inhibition in response to Minibeam radiation to a primary tumor site when combined
with anti-PD-L1 therapy. This effect was notably different than a comparable UniformRT
radiation, where a possible negative abscopal effect is observed. Note that we did not
observed negative abscopal effect from UniformRT + anti− PD− L1 in a previous pilot
study, however it also showed that MinibeamRT + anti−PD−L1 had stronger abscopal
effect than UniformRT + anti − PD − L1. This is consistent with other studies [47],
[248] showing that a single dose of seamless, uniform radiotherapy does not induce an
abscopal tumor response. However, many more studies need to be conducted to make the
case for any specific dose and fractionation schedule.
Our study indicates the potentially advantageous role of SFRT and MinibeamRT in
eliciting a systemic anti-tumor immune response. These results are supported by trends
seen in the flow cytometry characterization of immune cell infiltrates. Notably, elevated
CD8+ T cells were seen in the distant (unirradiated) tumor site, as well as the spleen,
indicating greater systemic cytotoxic immune response. In addition, the overall T cell
populations were elevated in MinibeamRT+ anti-PD-L1 treated groups which may indicate
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greater retention of resident T cell populations, in line with our hypothesis. This is
consistent with previous reports on the immune response following more conventional
radiation, where CD8+ T cell response has been reported to be elevated following combined
radiation and PD-1/PD-L1 blockade in mouse models of glioblastoma multiform [249].
Deng et al. also showed that CD8+ T cells play a critical role in the response to UniformRT
+ immune checkpoint inhibition in a breast cancer mouse model [250]. Elevated CD8+ T
cells is also a positive prognostic factor clinically [251], and immune checkpoint inhibition
in combination with radiation has been demonstrated to increase the prevalence and
activation of CD8+ T cell populations as an important mechanism of response [252]. Thus,
the fact that MinibeamRT appears to further enhance this response, may be an important
indication of this treatment’s potential role in enhancing the immune response following
combination therapy as discussed previously [49], [123], [173], [220], [228]. In this work,
we have chosen to use anti-PD-L1 as an immune therapy because it has been shown to
synergize with radiation therapy in a wide range of tumor models and is also being studied
clinically. However, there are a wide range of other potential immune therapies that have
also been shown to be synergistic in combination with radiation therapy.
One challenge in any SFRT scheme is the large parameter space over which to select and
optimize the therapeutic regimen. The spatial dose distribution clearly has a significant
role in how the immune response develops, and this dependence is likely to be dependent
on the specific microenvironmental properties of the tumor. Thus, future work is needed to
better understand how the spatial dose distribution affects immune response, and how this
can be optimally implemented clinically. Our data shows that while Minibeam radiation is
superior at initiating abscopal effect the conventional uniform radiation is better at local
irradiated tumor control. If our finding is validated, there may be a treatment strategy that
can best harvest the benefits of both SFRT and uniform radiation therapy. The treatment
strategy can be first, SFRT+anti-PD-L1 to enhance systemic anti-cancer immunotherapy
and second, conventional radiation therapy for local irradiated tumor control. Research is
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CHAPTER 6: MICROBEAM RADIATION THERAPY ENHANCED
TUMOR DELIVERY OF PEGYLATED LIPOSOMAL DOXORUBICIN
IN A TRIPLE NEGATIVE BREAST CANCER MOUSE MODEL
6.1 Overview
Previously, we showed the potential for spatially fractionated radiation therapy
(SFRT) to enhance the systemic immune response in mice when used in combination
with immunomodulatory anti-cancer drugs. In a similar vein, this chapter presents an
investigation into the potential advantages of SFRT over conventional radiotherapy in
enhancing novel anti-cancer, chemotherapeutic drug delivery.
Carrier-Mediated Agents (CMAs) are a new class of chemotherapy drugs that have
demonstrated to be much safer than typical chemotherapy drugs with significantly
less cardiotoxicty, longer circulation time, and greater tumor exposure than seen with
conventional, free doxorubicin. However, the lack of drug uptake into the tumor hinders the
clinical translation of this promising treatment approach. The purpose of this study is to
investigate the use of SFRT, a safe, experimental radiotherapy approach that preferentially
eradicates tumors while sparing normal tissues, as a potential method for enhancing CMA
anti-cancer drug delivery into tumors as compared to conventional, seamless radiotherapy
methods in a GEMM of aggressive claudin-low triple-negative breast cancer.
This chapter has been submitted for publication4 in the journal Therapeutic Advances
in Medical Oncology and is in review at the time of this writing. I have included the study
4This chapter has been submitted as an article in the journal Therapeutic Advances in Medical Oncology.
The original citation is as follows: Price LSL, Rivera JN, Madden AJ, Herity LB, Piscitelli JA, Mageau S,
Santos CM, Roques JR, Midkiff B, Feinberg N, Darr D, Chang SX, Zamboni WC. Microbeam radiation
therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple negative breast cancer
mouse model. Therapeutic Advances in Medical Oncology, 2020 [Manuscript In Review]. Authors Price
and Rivera contributed equally to this work and should be considered co-first authors. Senior coauthors,
Zamboni and Chang, contributed equally to this work.
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here in full, with minor changes, including full-color versions for all figures and changes to
formatting and terminology for consistency with previous chapters in this dissertation.
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6.2 Introduction
The theoretical advantages of carrier mediated agents (CMAs) in cancer treatment
include increased solubility, prolonged duration of exposure, selective delivery of entrapped
drug to the tumor, and an improved therapeutic index [253], [254]. The primary
types of anticancer CMAs are liposomes, nanoparticles (NPs) and conjugated agents.
PEGylated liposomal doxorubicin (Doxil®; PLD), liposomal daunorubicin (DaunoXome®)
and paclitaxel albumin-bound particles (Abraxane®) are members of this relatively new
class of drugs that are approved by the U.S. FDA for the treatment of solid tumors
[255]. However, the promise of these drugs is currently unfulfilled due to an overall low
tumor uptake [256], [257]. In theory, enhancing permeability of the tumor vasculature
allows CMAs to enter the tumor interstitial space, while suppressed lymphatic filtration
allows them to stay there. This phenomenon, termed the Enhanced Permeability and
Retention (EPR) effect, may be exploited by CMAs to deliver drugs to tumors [256], [257].
However, progress in developing effective CMAs using this approach has been hampered by
heterogeneity of EPR effect in different tumors and the lack of information on factors that
influence EPR [256]–[259]. In addition, cancer cells in tumors are surrounded by a complex
microenvironment comprised of endothelial cells of the blood and lymphatic circulation,
stromal fibroblasts, collagen, cells of the mononuclear phagocyte system (MPS) and other
immune cells that may be associated with the variability in EPR and are potential barriers
to tumor delivery of CMAs [256], [258]–[264]. Moreover, it appears that the ability of
CMAs to enter tumors by EPR or other factors is highly variable across tumor types
and thus all solid tumors may not be conducive for CMA delivery and treatment [256],
[264]–[271]. It also is unclear how these factors affect CMAs of different sizes and shapes
[267], [272], [273]. Thus, it is important to development new methods to overcome barriers
and increase the tumor delivery of several different types of CMAs in solid tumors with
different degrees of EPR effect.
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The pharmacokinetics (PK) of CMAs is dependent upon the carrier and not the
encapsulated drug it carries [263]–[266]. Drug that remains encapsulated within the carrier
has a completely different clearance and distribution compared to small molecule (SM)
drugs. In theory, the EPR effect exists in tumors and may be exploited for selective delivery
of drugs to tumor by CMAs. However, PK studies show that in reality the tumor delivery of
CMAs is low and inefficient due to tumor heterogeneity and associated barriers [259], [263],
[264], [266]. Recent publications have highlighted the relatively lower efficiency of tumor
delivery seen with CMAs compared with SMs. In addition, a workshop by the Alliance
for Nanotechnology in Cancer concluded that there are major gaps in the understanding
of factors that affect and inhibit CMA and NP tumor delivery and new fundamental
preclinical and clinical studies in this area are needed to effectively advance CMA and
NP drug delivery and efficacy in solid tumors [256], [274]. So far, the advancement of
CMA and NP treatment of cancer has been focused primarily on modifying formulations
to overcome PK, efficacy and toxicity issues. However, this approach alone may not be
adequate as biologic issues, such as barriers within the tumor microenvironment appear to
play important roles in low and inefficient tumor delivery of CMAs.
Maximizing tumor control while minimizing treatment toxicity is the holy grail of
all cancer treatments including chemotherapy, radiation therapy, and surgery, the three
standard modalities for cancer treatment. Treatment associated toxicities directly limit
the treatment “dosage” and thus hinder cancer control. Treatment toxicity is becoming
more of an issue, as more cancer patients today live longer due to better cancer treatments
and live to experience cancer reoccurrence years later.
Radiation therapy has been used as cytotoxic therapy for cancer local control since
the discovery of x-rays by Wilhelm Conrad Röntgen in 1895. Therapeutic radiation is
targeted at the tumor and causes tumor cell DNA double strand breaks, which lead
to cell death and then tumor control. Although non-direct radiation effects such as
bystander effect, abscopal effect, and radiation-induced anti-cancer immune responses
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have received increasing attention from research communities today these effects remain
poorly understood [128], [150], [212]. Microbeam radiation therapy (MRT) is a preclinical
radiotherapy with promising clinical potential. In animal studies high dose MRT has shown
an extremely high tissue-type selectivity where it eradicates tumors without damaging
or inhibiting the function of normal tissues that are exposed to the same high dose
radiation [150], [212]. The extraordinary MRT effect may be stemmed from its unique
spatial, temporal, and dosimetric characteristics, which are radically different than those
of the conventional broadbeam radiation therapy (BRT). MRT consists of many parallel
microplanar beams at peak dose levels that are 10-100 times greater than BRT [212].
Remarkably, in animal studies the ultrahigh cytotoxic MRT dose is well tolerated by
normal tissue while producing tumor control and survival comparable to conventional BRT.
The MRT normal tissue sparing effect are well accepted and include two major hypotheses:
(1) surviving stem cells in the low dose MRT, termed “valley” regions repopulate and repair
tissue damage and (2) its mature microvasculature is resistant to MRT damage. Further,
the mechanism behind MRT tumor control is still poorly understood; however, there are
two major hypotheses under active investigation: (1) cellular bystander effects, wherein
unirradiated or less-irradiated cells in the beam low-dose, “valley”, regions are exposed
to the cytotoxic factors released by nearby dying cells from the beam “peak” regions
that received massive radiation dose; and (2) immature tumor microvasculature damage
effects, where tumor microvasculature is more susceptible to damage by the high dose MRT
compared to normal tissue. In addition to these direct impacts on tumor control, MRT
may also alter the tumor microenvironment factors important to the delivery of CMAs.
Griffin et al. reported that MRT induced a transient but drastic reduction in tumor
hypoxia which might open up vessels for better drug delivery [128]. The combination
of direct anti-tumor activity and improved tumor delivery of CMAs with low off-target
toxicity makes MRT an attractive therapy for multi-modal cancer treatment.
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6.3 Methods
Animal Model All animal studies were completed under a protocol approved by the
University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee
and in accordance with all relevant animal welfare regulations. Mice were maintained in
a barrier facility on a 12-hour light/dark cycle and were provided with folate-free chow
and water ad libitum. Tumors derived from BALB/c TP53 -/- orthotopic mammary gland
transplant line (T11) were transplanted into the inguinal mammary fat pad of 12-week-old
wild-type BALB/c mice (The Jackson Laboratory; strain 000651 [271]). Mice were housed
in the UNC Lineberger Comprehensive Cancer Center’s Mouse Phase I Unit and observed
for tumors as per the standard practice [275]. Mice were randomized to treatment cohorts,
and therapy began once a tumor reached approximately 300-500 mm3.
6.3.1 Treatments
An XRAD-320 Research Irradiator (Precision X-Rays, Inc.) with customized collimators
was used to produce the BRT and MRT radiation. For both, a 2cm × 2cm irradiation
treatment area was centered over the tumor. Radiation dosimetry of the BRT and MRT
radiation was achieved via EBT3 Gafchromic film calibrated against an ion chamber under
large field conditions [194], [199]. The in-house developed MRT collimator generated
microbeams with an average beam width of 307µm and a peak-to-peak separation of
1260µm. PLD was purchased from FormuMax Scientific and diluted with 5% dextrose in
water to 1.2 mg/mL before injection.
6.3.2 Pharmacokinetic studies
Mice (n=3 per treatment per time point) were anesthetized using isoflurane and treated
with either BRT 7Gy, MRT 28Gy, or MRT 100Gy. Following completion of radiation,
mice were returned to the vivarium and monitored for signs of toxicity. Either 16 hours
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(for MRT 28Gy) or 24 hours (for BRT 7Gy and MRT 100Gy) after radiation, mice were
administered 6 mg/kg PLD IV ×1 via a tail vein. An additional group of mice with
no radiation exposure were also administered an identical dose of PLD. At predefined
time points following PLD administration (5 minutes, 24 hours, and 96 hours), mice were
anesthetized using 100 mg/kg ketamine IP ×1 and 1 mg/kg dexmedetomidine IP ×1 then
ethically euthanized via cardiac puncture for collection of blood. Tumors were excised
post-mortem and snap frozen in liquid nitrogen and stored at -80 degress Celsius until
processing. Additional animals received a second treatment of MRT 28Gy + PLD 16 hours
post-MRT one week after the initial treatment. Mice (n=3 per timepoint) were sacrificed
5 minutes and 24 hours following the second dose of PLD and blood and tissues collected
as above.
6.3.3 PLD quantification
The complete methods for sample collection, preparation and analysis of encapsulated
doxorubicin in plasma and sum total (encapsulated + released) doxorubicin in tumor after
administration of PLD have been previously described [271], [276]–[280]. Briefly, blood
samples were collected in sodium heparin tubes at 0.083, 3, 6, 24, 48, and 96 hours after
the administration of PLD. Blood was centrifuged at 1,500xg for 5 minutes to obtain
plasma. Encapsulated and released doxorubicin in plasma were separated using solid
phase separation. Upon processing, tumors were thawed, weighed, and diluted in a 1:3
ratio with phosphate buffered saline prior to homogenizing with a Precellys 24 bead mill
homogenizer (Omni International Inc, Kennesaw, GA). Samples were further processed by
addition of 800µL extraction solution (acetonitrile with 100 ng/mL Daunorubicin internal
standard) to 200µL of plasma or tumor homogenate. The samples were vortexed for 10
minutes and centrifuged at 10,000xg for 10 minutes at 4 degrees Celsius. The supernatant
was removed to a clean tube, evaporated to dryness under nitrogen, and reconstituted in
150µL of 15% acetonitrile in water plus 0.1% formic acid. The samples were then vortexed,
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transferred to autosampler vials, and analyzed by high-performance liquid chromatography
with fluorescence detection (HPLC-FL) set to excitation wavelength 490nm/emission
wavelength 590nm. The HPLC-FL technique had a quantitative range of 10 – 3,000 ng/mL
for sum total doxorubicin in tumor and 300 – 30,000 ng/mL for encapsulated doxorubicin
in plasma. Samples that returned a concentration above the quantitative limit were diluted
to fall within the quantitative range and reinjected.
6.3.4 Pharmacokinetics analysis
The PK of PLD plasma and tumor was analyzed by noncompartmental analysis using
Phoenix WinNonlin Professional Edition version 8.0 (Pharsight Corp., Cary, NC, USA).
The area under the doxorubicin concentration versus time curve (AUC) was calculated
using the linear up/log down rule for plasma and tumor from T0 to Tlast (24 or 96 hours,
depending on treatment group).
6.3.5 Tumor Staining and Immunohistochemistry
A separate group of T11 mice were randomized to either no radiation, BRT 7Gy,
MRT 28Gy, or MRT 100Gy and irradiated as above. Twenty-four hours after radiation
mice were anesthetized with ketamine and dexmedetomidine and sacrificed by cervical
dislocation. Tumors were excised post-mortem and placed into 10% formaldehyde for
paraffin embedding. Tumors were then sliced and mounted on slides for staining. Samples
were stained using Masson’s Trichrome Stain (MTS), anti-Collagen IV monoclonal antibody,
anti-F4/80 monoclonal antibody, and anti-CD31 monoclonal antibody as previously
described. Stained slides were scanned using ScanScope XT (Leica Biosystems Inc.) an
Automated High-Throughput Scanner. A quantifying algorithm employing a modified
membrane analysis was utilized to automatically quantify the stained area of viable tumor
[271]. Collagen IV, MTS, and macrophages (F4/80) in the viable tumor tissue were
quantified by standard H-score [271], [281] and microvessels (CD31) were quantified by
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microvessel density analysis (1/mm2) [271], [281].
6.4 Results and Discussion
In order to assess the impact of MRT on the tumor delivery enhancement of CMAs
we evaluated the pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in
a genetically engineered mouse model of triple negative breast cancer (T11) following
either MRT or conventional BRT. Radiation-enhanced accumulation of nanoparticles
and macromolecules in tumors has been reported in several previous studies [282], [283].
However, this is the first publication comparing the impact of conventional BRT and the
novel MRT on the tumor microenvironment and the tumor accumulation of a drug-loaded
nanoparticle. We also evaluated the impact of MRT on the tumor microenvironment
through histological examination of tumor in irradiated animals.
6.4.1 Single dose pharmacokinetics
We first evaluated the PK of PLD in tumor-bearing T11 mice following a single dose of
either PLD alone, BRT 7Gy + PLD, MRT 28Gy + PLD, or MRT 100Gy + PLD. For the
MRT 28Gy + PLD arm, radiation was administered 16h prior to PLD. In the remaining
two combination therapy arms (BRT7 Gy + PLD and MRT100 Gy + PLD), radiation
was administered 24 h prior to PLD. The encapsulated plasma and sum total tumor
doxorubicin concentration vs time profiles for all single dose treatments are presented in
Figure 56. The encapsulated plasma and sum total tumor doxorubicin AUC0−96h and
ratio of tumor to plasma AUC0−96h are presented in the table in Figure 57.
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Figure 56: Mean encapsulated doxorubicin concentration in plasma (A) and sum total
doxorubicin concentration in tumor (B) vs time profiles in female T11 mice after
administration of: 1) PLD 6 mg/kg alone, 2) BRT 7Gy + PLD, 3) MRT 28Gy + PLD
16hours post-MRT, or 4) MRT 100Gy + PLD. The encapsulated doxorubicin exposure
in plasma is similar among all groups, consistent with a lack of effect of irradiation on
plasma clearance of PLD. The tumor exposure of sum total doxorubicin is significantly
enhanced at 24 hours post-PLD for all radiation therapy groups compared to PLD alone,
with the greatest increase in tumor exposure of sum total doxorubicin after treatment
with MRT 28Gy + PLD 6 mg/kg 16 hours post-MRT.
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Figure 57: Summary of PLD Pharmacokinetics After a Single Dose of PLD Alone, BRT +
PLD, or MRT + PLD
The encapsulated plasma concentration vs time profiles and AUC0−96h did not
significantly differ between treatments. Because the irradiated area in this study was
limited to a relatively small area centered on the tumor mass, little impact was
anticipated on the primary clearance pathway of nanoparticles – the MPS. Consistent
with this hypothesis, the plasma exposure of PLD was similar across all groups (< 25%
difference in AUC0−96h), regardless of radiation type or dose, suggesting that a single dose
of BRT or MRT minimally alters the plasma clearance and disposition of PLD.
In contrast, all BRT and MRT treatment groups had significantly higher sum total
tumor doxorubicin exposure compared to PLD alone. The sum total tumor doxorubicin
AUC0−96h was 2.7-fold and 2.2-fold higher following BRT 7Gy and MRT 100Gy, respectively,
compared to PLD alone. MRT 28Gy yielded the highest PLD tumor delivery enhancement
with a tumor AUC0−96h 6.3-fold higher compared to PLD alone.
The tumor:plasma doxorubicin AUC ratio represents the relative delivery of
nanoparticles to tumor compared to the plasma. Tumor delivery results following
radiation therapy mirrored the tumor exposure due to the limited impact of radiation on
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the plasma exposure. The ratio of tumor to plasma AUC0−96h were 2.7-fold, 7.1-fold, and
2.8-fold higher following BRT 7Gy, MRT 28Gy, and MRT 100Gy, respectively, compared
to PLD alone. These results show that MRT provides comparable enhancement of tumor
nanoparticle accumulation to BRT when given at 14 times the peak dose (i.e., MRT
100Gy was similar to BRT 7Gy). Despite increased peak doses, MRT typically has
significantly lower normal tissue toxicity when compared to BRT while maintaining
anti-tumor efficacy [72], [174], [212]. The combination of independent anti-tumor activity,
low normal tissue adverse effects, and comparable tumor delivery enhancement makes
MRT an attractive modality for combination therapy in this manner.
Intriguingly, the lower peak radiation dose (MRT 28Gy) provided the most significant
enhancement of tumor delivery following a single dose, suggesting that the relationship
between radiation dose and tumor delivery enhancement may not be direct. While the
administration of BRT 7Gy + PLD enhanced the relative delivery of PLD to the tumor
2.7-fold compared to PLD alone, MRT 28Gy + PLD 16 hours post-MRT enhanced the
relative delivery of PLD a further 2.6-fold compared to BRT 7Gy + PLD. Similarly, MRT
28Gy + PLD 16 hours post-MRT enhanced relative delivery of PLD to tumor 2.5-fold
compared to MRT 100Gy + PLD, which itself provided 2.8-fold enhancement relative to
PLD alone.
Additionally, we explored the efficacy of MRT to enhance the tumor delivery of PLD at
varying levels of systemic exposure. Using the treatment with the greatest tumor delivery
enhancement after a single dose (MRT 28Gy + PLD 16 hours post-MRT), we compared
a group of animals (n=3) with higher plasma doxorubicin exposure 96 hours after PLD
administration to a group of animals (n=3) with lower plasma doxorubicin exposure. The
tumor size, encapsulated plasma doxorubicin concentration, sum total tumor concentration,
and tumor to plasma concentration ratio for these animals is presented in the table in
Figure 58.
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Figure 58: Comparison of MRT-Induced Delivery Enhancement at Low and High Plasma
Exposures After a Single Dose of MRT 28Gy + PLD 16h post-MRT
The animals with higher plasma doxorubicin exposure had smaller tumors
(75.3± 0.6mm3) while those with lower plasma doxorubicin exposure had larger tumors
(210.3± 52.8mm3). Higher plasma exposure led to higher sum total tumor doxorubicin
concentration (110, 416± 29, 753 vs 16, 780± 4, 539 ng/g) but the ratio of tumor to plasma
doxorubicin concentration did not differ between the groups (11.80± 0.60 vs 10.13± 5.88).
This suggests that the tumor delivery enhancement provided by MRT is not limited by
nanoparticle dose across an approximately 4-fold range of plasma concentrations.
6.4.2 Multiple dose pharmacokinetics
After identifying enhanced tumor delivery following a single dose of MRT 28Gy + PLD
16 hours post-MRT, the efficacy of repeated dosing was investigated. The encapsulated
plasma and sum total tumor doxorubicin concentration vs time profiles for 24 hours
following PLD administration for single dose PLD alone, single dose MRT 28Gy + PLD
16 hours post-MRT, and two dose MRT 28Gy + PLD 16 hours post-MRT weekly are
presented in Figure 59. The encapsulated plasma and sum total tumor doxorubicin
AUC0−24h and ratio of tumor to plasma AUC0−24h for these treatments are presented in
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the table in Figure 60.
Figure2
Figure 59: Mean encapsulated doxorubicin concentration in plasma (A) and sum total
doxorubicin concentration in tumor (B) vs time profiles in female T11 mice after
administration of: 1) Single Dose PLD 6 mg/kg alone, 2) Single Dose MRT 28Gy +
PLD 6 mg/kg 16 hours post-MRT, or 3) Two Dose MRT 28Gy + PLD 6 mg/kg 16 hours
post-MRT. The tumor exposure of sum total doxorubicin is significantly enhanced following
one and two doses of MRT 28Gy + PLD 16 hours post-MRT compared to PLD alone.
Tumor sum total doxorubicin exposure after the second dose of MRT 28Gy + PLD 16
hours post-MRT was increased relative to a single dose, consistent with increased plasma
encapsulated doxorubicin exposure.
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Figure 60: Summary of PLD Pharmacokinetics After a Single Dose of PLD Alone or One
or Two Treatments of MRT 28Gy + PLD Weekly.
There are slight differences in the encapsulated plasma doxorubicin exposures with
single dose MRT 28Gy + PLD 16 hours post-MRT giving an AUC0−24h approximately
24% lower relative to PLD alone and two dose MRT 28Gy + PLD, which is 31% higher
relative to PLD alone. The tumor accumulation of sum total doxorubicin is significantly
enhanced following one or two doses of MRT 28Gy + PLD 16 hours post-MRT compared
to PLD alone. The sum total tumor doxorubicin AUC0−24h are 36, 710, 156, 244, and
267, 275 hng
g
following a single dose of PLD alone, a single dose of MRT 28Gy + PLD
16 hours post-MRT, and two doses of MRT 28Gy + PLD 16 hours post-MRT weekly,
respectively. In addition, tumor sum total doxorubicin exposure is increased following a
second dose of MRT 28Gy + PLD 16 hours post-MRT relative to a single dose, consistent
with increased plasma encapsulated doxorubicin exposure. The relative tumor delivery
(given by the ratio of tumor to plasma AUC0−24h) is similar following one (18.28%) or two
(18.05%) doses of MRT 28Gy + PLD 16 hours post-MRT and higher than following a
single dose of PLD alone (3.25%). The relative tumor delivery (ratio of tumor to plasma
AUC0−24h) was approximately 5.6-fold higher following either one or two doses of MRT
28Gy + PLD 16 hours post-MRT compared to PLD alone. The relative tumor delivery
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enhancement of PLD following MRT is conserved following a second dose.
6.4.3 Tumor microenviroment profiling
The tumor microenvironment plays a pivotal role in the delivery and accumulation
of nanoparticle drugs. In particular, alterations in macrophages and vasculature have
been associated with changes in nanodrug delivery to tumors [257], [260], [263], [268]. A
separate group of T11 mice were randomized to either no radiation, BRT 7Gy, MRT 28Gy,
or MRT 100Gy and tumors were profiled via immunohistochemistry. H-scores for F4/80,
Collagen IV, and MTS and microvessel density (CD31) in viable tumor are presented in
Figure 61.
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Figure 61: Tumor microenvironment profiles 24 h after 1) no radiation, 2) BRT 7 Gy, 3)
MRT 28 Gy, or 4) MRT 100 Gy, in female T11 mice. A) F4/80 H-Scores, B) Collagen IV
H-Scores, C) MTS H-Scores, D) CD31 Microvessel Density. *p¡0.01 vs Untreated Control,
#p¡0.01 vs BRT 7 Gy. Both BRT and MRT decrease macrophages with MRT 100 Gy
yielding a larger decrease in F4/80 H-Scores in viable tumor. There are no statistically
significant (p¡0.01) changes in collagen as assessed by either Collagen IV or MTS or
microvessel density (CD31) between untreated control and any radiation therapy group.
There is a significant, dose-dependent reduction in macrophages in viable tumor, as
evidenced by decreases in F4/80 H-Scores, 24 hours after both BRT and MRT. The highest
F4/80 H-score was observed in the Untreated Control group (175.3± 12.1) followed by the
155
lower radiation doses, BRT 7Gy (98.2± 4.3) and MRT 28Gy (84.4± 20.2). The higher
peak radiation dose, MRT 100Gy, resulted in the lowest F4/80 H-score (27.5± 21.4). In
this study, radiation led to depletion of macrophages in viable tumor tissue 24 hours after
either BRT or MRT. Lower radiation doses, BRT 7Gy and MRT 28Gy, resulted in 44% and
52% reductions in macrophages, respectively, while the higher peak radiation dose of MRT
100Gy resulted in 84% reduction in macrophages. A previous BRT study associated a
relative increase in macrophages following radiation with an increase in nanodrug delivery
[284]. However, the relative timing of radiotherapy and nanodrug administration differed
between the two studies. Miller et al. administered a therapeutic polymeric cisplatin
prodrug NP (TNP) 72 hours post-irradiation and assessed macrophage presence 24 hours
post-TNP administration (96 hours post-irradiation). Macrophage assessment and PLD
administration in our study was performed 24 h post-irradiation. Furthermore, analytical
techniques differed as macrophages were assessed relative to tumor cells in a flow cytometry
assay by Miller et al. A potential explanation for these seemingly opposite findings would
be a rapid radiation-induced nadir of macrophages (within 24 hours post-irradiation)
followed by later macrophage infiltration resulting in the increased PLD tumor exposure
24-96 hours post-PLD (48-120 hours post-irradiation).
Collagen, assessed by both Collagen IV IHC and MTS, showed no significant changes
between untreated control and irradiated tumors. In addition, microvessel density, assessed
by CD31, also did not differ between untreated control and irradiated tumors. This
suggests that, at least for the first 24 hours following radiation, there is not a change in
collagen content or microvessel number driving the enhancement of nanoparticle delivery
to tumors.
In this study we evaluated the impact of conventional BRT in comparison to novel
MRT on the tumor microenvironment and ability to enhance tumor delivery of a drug
loaded nanoparticle. In a GEMM of triple negative breast cancer, both BRT and MRT
altered the microenvironment through depletion of macrophages and significantly enhanced
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the tumor delivery of PLD. Notably, High dose MRT (100Gy peak dose and valley dose
of approximately 8Gy) provided comparable PLD tumor delivery enhancement to BRT
(7Gy). But the most significant enhancement of tumor delivery occurred when a lower
peak radiation dose MRT of 28Gy was used (and valley dose of 2.26Gy). In addition, the
tumor delivery enhancement provided by pretreatment with MRT 28Gy is maintained at
both high and low plasma exposure and following repeated dosing. Further studies are
warranted to assess the efficacy of radiation-induced tumor delivery enhancement in other
tumor models and with other nanoparticles as well as the mechanism of radiation-induced
tumor delivery enhancement.
6.5 Acknowledgements
The authors thank Nana Nikolaishvili-Feinberg and Bentley R. Midkiff in the UNC
Translational Pathology Laboratory (TPL) for expert technical assistance. The UNC TPL
is supported in part by grants from the NCI (2-P30-CA016086-40), NIEHS
(2-P30ES010126-15A1), UCRF, and NCBT (2015-IDG-1007). Animal histopathology was
performed by the Animal Histopathology & Laboratory Medicine Core at UNC, which is
supported in part by an NCI Center Core Support Grant (5P30CA016086-41) to the UNC
Lineberger Comprehensive Cancer Center. The authors wish to acknowledge Certara for
providing academic access to Phoenix WinNonlin through the Center of Excellence
program.
6.6 Funding
This investigation was funded, in part, by the UNC Eshelman Institute for Innovation
(1U54CA198999-01) Carolina Center of Cancer Nanotechnology Excellence- Pilot Grant
Program.
157
CHAPTER 7: DISCUSSION AND FINAL CONCLUSIONS
7.1 The Potential Global Impact of SFRT
There are nearly 20 million new cancer cases a year, with over 70% of them arising in
the developing world [54], [285], [286]. From a public health perspective, the most rational
and cost-effective method to address this crisis is through prevention and education, but
cancer deaths are already on the rise, with nearly 10 million deaths worldwide in 2018,
and deaths are expected to increase up to 12 million this year, doubled compared to a
decade ago [285], [287].
Radiation therapy is one of the most cost-effective methods for treating cancer and
has the potential for alleviating the global cancer burden [15], [288]; however, severe
inequities exist in access to radiation therapy around the world [15], [288]. Numerous
countries have access to only a limited number of radiotherapy treatment facilities, with
most countries in Asia having only one unit available for every 1-2 million people [286],
though often less, and 29 out of 52 countries in Africa have no radiotherapy facilities at all
[289]. When a radiotherapy treatment facility is available, the barriers to implementation
of radiation therapy are numerous and diverse; high up-front costs for facilities and
equipment [15], [67], [290], the lack of training and personnel for the specialized team
of healthcare professionals needed to use and maintain the equipment [67], [291], and
widespread systemic barriers such as governmental policies or practices (or lack thereof)
make implementation exceedingly difficult [67], [68], [291].
Even after mitigating some of these barriers, increasing access to radiotherapy facilities
is just one small step towards helping meet the pressing clinical needs to effectively
implement radiotherapy treatments. Studies have shown that developing countries also
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have higher incidences of advanced disease presentation, up to 70% presenting with late
stage illness according to the World Health Organization (WHO) [292]. Advanced disease
presentation is correlated with poor prognostic outcomes, and treatments to minimize
suffering, including palliative radiation, are often the only options left available [293]–[296].
With the high number of new cancer cases yearly, and the low number of facilities in
high-need regions, the global cancer burden continues to rise. Alleviating this serious
global cancer burden is critically important and requires new strategies for improving
healthcare outcomes.
Accessible, low-cost radiotherapy and alternatives to conventional radiotherapy may
play a part in utilizing available radiotherapy facilities to reducing cancer burden. Spatially
fractionated radiation therapy is a strong candidate for helping meet some of the most
pressing clinical needs in cancer therapy. As both a therapeutically- and cost-effective
approach, SFRT may have an important role to play in improving patient outcomes in
both the definitive and palliative settings for patients in underserved communities [297].
For example, SFRT treatment has been shown to be beneficial for those patients with very
advanced, or bulky disease and for very aggressive tumors types [73], [204]. Hence, for
those 70% of patients presenting with very advanced, late stage disease, palliative SFRT
may offer a safe treatment option and dramatic pain symptom relief, especially for those
that would otherwise suffer [73]. For the five most common cancers in developing countries,
stomach, lung, liver, breast, and cervix [286], SFRT studies have reported good oncological
outcomes in each of these disease sites [49], [52], [73], [82], [84]–[87], [90], [91]. From an
economic perspective, definitive SFRT may be offered as a boost to conventional courses
of radiotherapy without significantly added time or cost, while palliative SFRT may be
offered as a single, cost-effective treatment, something that would be extremely beneficial
for patients that have to travel long distances to an radiotherapy-equipped facility [287].
SFRT may also be easily implemented in existing radiotherapy units with very low added
costs, since SFRT utilizing a relatively inexpensive, reusable GRID compensator (see
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Chapter 2.4.1 on GRID Therapy) does not require use of the highly advanced, state-of-the
art radiation therapy treatment technologies, which are largely limited to highly developed
industrialized nations.
7.2 New Horizons in SFRT
Despite its very high therapeutic ratio and long history, SFRT remains largely an
experimental treatment and there are still many unanswered questions behind the promising
radiotherapy approach. In the past decade, SFRT has recently gained traction, becoming
a very active area of investigation, and its application in combination treatment strategies
has made studying SFRT an interesting and valuable research endeavor. In fact, in
2018 the National Cancer Institute together with the Radiosurgery Society created a
new, international working group dedicated to investigating SFRT, and the related Flash
radiotherapy, with the goal of advancing our understanding of SFRT biology, physics, and
clinical translation. The new working group consists of a researchers from around the
country and the world, including many leaders in the field of SFRT and MRT technology
research and development, as well as physicians and other stakeholders that have a special
interest in the clinical translation of this promising treatment modality. In just the last
two years, several clinical trials using SFRT have been developed specifically for targeting
patients with massive, bulky tumors, patients with radioresistant tumors such as squamous
cell carcinomas of the head and neck, as well as patients with pediatric osterosarcomas
of the extremities [298]. Current, active clinical trials using SFRT include, but are not
limited to:
1. GRID Therapy as Palliative Radiation for Patients with Advanced and Symptomatic
Tumors (NCT02333110)
2. Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity
(NCT03139318)
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3. Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and
Interstitial Pressure to Increase Translation of Solid Tumor Therapy (NCT01967927)
4. Lattice Stereotactic Body Radiation Therapy (LATTICE SBRT) for Localized
Unresectable or Metastatic Conventional Type Chondrosarcoma (NCT04098887)
5. Palliative Lattice Stereotactic Body Radiotherapy (SBRT) (NCT041333415)
6. MRI-Guided Lattice Extreme Ablative Dose Radiotherapy for Prostate Cancer
(NCT01411319)
7. Randomized MRI-Guided Prostate Boosts via Initial Lattice Stereotactic vs Daily
Moderately Hypofractionated Radiotherapy (BLaStM) (NCT02307058) [299]
8. Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk
Soft-Tissue Sarcoma (NEXIS) (NCT03116529)
Additionally, moves have been made at the European Synchrotron Facility (ESRF)
in Grenoble, France to establish a modern SFRT, micro-collimated beamline for use in
clinical patient trials [203]. The marked, growing interest in this promising treatment
approach is readily apparent and is very encouraging for the future of the field of SFRT
research as well as the future of cancer therapy.
In addition to the new clinical trials, it is very important to continue improving our
understanding of the working mechanisms behind SFRT through preclinical studies. One
avenue for potential SFRT advancement is by using larger animals as pre-clinical models
[174]. Nolan et al noted the remarkable similarities in pet dog cancer outcomes and
radiobiology when compared to humans and that modern veterinary radiation oncology
utilizes the same treatment technologies as those used for human patients [300], including:
• MV energy LINACs capable of stereotactic radiosurgery [301]–[303] (see Section
1.4.3 SBRT in Chapter 1), as well as IMRT [304] (see Chapter 1.4.2 on IMRT),
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• Modern dosimetry technology and protocols [301], [302], and
• Advanced treatment planning techniques [302].
• In addition, in one of our own studies, we implemented veterinary SFRT on a pet
canine model of spontaneous soft-tissue sarcomas [305] while other studies have also
applied SFRT on weanling pigs [115].
These advances in veterinary medicine may enable the use of large animals in pre-clinical
SFRT studies as large animals have the potential for serving as acceptable surrogates for
human clinical trials with similar clinical endpoints, but without the exceedingly high
cost-barriers.
7.3 Conclusions
Clearly, a tremendous amount of work still needs to be completed to expand our
knowledge of SFRT, its radiobiological effects, and what advantages it has to offer. This
body of work attempts to shed light on some of the unanswered questions in SFRT in the
hopes of advancing the broad clinical translation of this promising treatment technology,
especially for those currently underserved patients that may benefit most. In particular,
the fascinating observation that SFRT may modify the tumor microenvironment differently
than conventional radiation has inspired us to formulate creative, innovative research ideas,
aimed to not only understand this unique form of radiation, but also to develop its relevant
technology and dosimetry and identify new applications for it. One such interesting
application explored in this dissertation involves using SFRT multi-modality approaches
for potentially enhancing the therapeutic ratio of anti-cancer drug therapies. Chapter 5
investigated the potential for SFRT to enhance the systemic immune response in mice
when used in combination with anti-cancer immunomodulatory drugs. Results indicated
that SFRT with immunomodulatory drugs significantly enhanced the abscopal effect,
where distant unirradiated tumors exhibited control response, and results also showed
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greater immune cell infiltration as compared to the corresponding conventional, uniform
radiotherapy treatment. In addition, Chapter 6 investigated the potential for SFRT to
enhance the delivery of novel, nanoparticle anticancer agents to tumors. Pharmacokinetic
results indicated that low dose SFRT safely and effectively enhanced tumor delivery of
the nanoparticle drugs compared to conventional radiotherapy and drug alone. These
studies together help provide a deeper understanding of how the unique radiobiological
effects induced by SFRT may be exploited for potentially enhancing treatment outcomes
in combination therapy treatments.
One additional front for advancing the clinical translation of SFRT is a better
understanding of the correlation between dosimetric parameters and treatment outcomes.
In Chapter 4, we identified key SFRT dosimetric parameters and their association
with treatment outcomes using a range of spatial-fractionation patterns at conventional
dose-rates in a preclinical model. Results indicated that although peak dose is often
used to prescribe clinical and pre-clinical SFRT treatments, among the various dosimetric
parameters studied, peak dose was most weakly associated with treatment response, while
the valley dose and tumor EUD were most closely associated with treatment response.
This indicates that clinicians and researchers may need to more carefully consider the
valley dose and tumor EUD, in addition the peak dose, when prescribing SFRT treatments
and that more research examining the effects of dosimetric treatment parameters on
treatment outcomes is warranted. Finally, Chapter 3 discusses the development of a novel,
non-synchrotron-based, low-cost preclinical SFRT delivery system for use in small animal
research, a system that may allow other SFRT researchers to more readily expand upon
these findings and also explore uncharted horizons in our understanding of SFRT and its
uses.
These studies may provide a deeper understanding of the underlying radiobiology of
SFRT and may also reveal new additional pathways for increasing the therapeutic ratio
in patients via combination therapy approaches. Most importantly, these studies may
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allow us to proceed one step closer to the eventual clinical translation of these promising
alternative treatments, with the hope that these cancer therapies may one day become a
“saving grace” to those patients for whom conventional treatments are not an option.
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[106] E. Bräuer-Krisch, H. Requardt, P. Régnard, S. Corde, E. Siegbahn, G. LeDuc,
H. Blattmann, J. Laissue, and A. Bravin, “Exploiting geometrical irradiation
possibilities in MRT application,” en, Nuclear Instruments and Methods in Physics
Research Section A: Accelerators, Spectrometers, Detectors and Associated
Equipment, vol. 548, no. 1-2, pp. 69–71, Aug. 2005, issn: 01689002. doi:
10.1016/j.nima.2005.03.068.
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[132] E. Schültke, B. H. Juurlink, K. Ataelmannan, J. Laissue, H. Blattmann,
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